Conditions: Immunoglobulin A Nephropathy
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 7
Healthy volunteers: no

Brief summary:
The primary safety objective of this study is to evaluate the safety and tolerability of CCX168 in subjects with IgAN on background supportive therapy with a maximally tolerated dose of RAAS blockade. The primary efficacy objective is to evaluate the efficacy of CCX168 based on an improvement in proteinuria.

Detailed description:
Study acquired by Amgen and all disclosures were done by previous sponsor ChemoCentryx.

Arms:
arm 1: CCX168 (Avacopan) plus stable dose of RAAS blocker

Interventions: intervention 1: CCX168
Intervention descriptions: intervention 1: CCX168 30 mg, twice daily (b.i.d.) orally for 84 days (12 weeks). The CCX168 dose was taken in the morning, optimally within one hour after breakfast, and in the evening, optimally within one hour after dinner.

Protocol document:
Prot_000.pdf: 
ChemoCentryx, Inc. 
CONFIDENTIAL 
Protocol CL005_168 
CCX168 
 
Amendment 3.0  
                                                                    Page 1 of 72                                            17 July 2015 
 
PROTOCOL 
Protocol Amendment 3.0 
TITLE PAGE 
Study Title: An Open-Label Phase 2 Study to Evaluate the Safety and Efficacy 
of CCX168 in Subjects with IgA Nephropathy on Stable RAAS 
Blockade 
Protocol Number: CL005_168 
Investigational Product: Complement 5a Receptor Antagonist CCX168 
Indication: IgA nephropathy 
Sponsor: ChemoCentryx, Inc. 
Development Phase: 2 
IND number 
EUDRACT number 
123187 
2014-003402-33 
Sponsor's Responsible 
Medical Officer: 
Pirow Bekker, MD, PhD 
ChemoCentryx, Inc. 
Mountain View, California 94043, USA 
Sponsor Signatory: Pirow Bekker, MD, PhD 
Approval Date: 8 September 2014—FINAL 
5 November 2014—Protocol Amendment 1.0 
13 May 2015—Protocol Amendment 2.0 
17 July 2015—Protocol Amendment 3.0  
 
 
 
Confidential 
The information contained herein is the property of the Sponsor and may not be reproduced, 
published, or disclosed to others without written authorization of the Sponsor. 
This study will be conducted according to the principles of Good Clinical Practice as described 
in International Conference on Harmonization guidelines, including the archiving of essential 
documents. 


ChemoCentryx, Inc. 
CONFIDENTIAL 
Protocol CL005_168 
CCX168 
 
Amendment 3.0  
                                                                    Page 2 of 72                                            17 July 2015 
 
INVESTIGATOR SIGNATORY PAGE 
Protocol Number: CL005_168 
Protocol Title: An Open-Label Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in 
Subjects with IgA Nephropathy on Stable RAAS Blockade 
I agree: 
• to assume responsibility for the proper conduct of the study at this site. 
• to conduct the study in compliance with this protocol, any future amendments, and with 
any other study conduct procedures provided by ChemoCentryx, Inc. 
• not to implement any deviations from or changes to the protocol without agreement from 
the sponsor and prior review and written approval from the Institutional Review Board 
(IRB)/Ethics Committee (EC), except where necessary to eliminate an immediate hazard 
to the subjects, or for administrative aspects of the study (where permitted by all 
applicable regulatory requirements). 
• that I am thoroughly familiar with the appropriate use of the investigational drug(s), as 
described in this protocol, and any other information provided by the sponsor including, 
but not limited to the following: the current version of the Clinical Investigator’s 
Brochure prepared by ChemoCentryx, Inc. and approved product label, if applicable. 
• that I am aware of and will comply with current ICH/FDA good clinical practices 
guidelines (GCP) and all regulatory requirements. 
• to ensure that all persons assisting me with the study are adequately informed about the 
investigational drug(s) and their study-related duties and function as described in the 
protocol. 
__________________________________      
 
 ___________________ 
Principal Investigator  
 
 
 
 
 
 
 
Date 
 
__________________________________ 
Printed Name 
Address*_____________________________________________________________ 
____________________________________________________________________ 
Phone Number* ___________________________________________ 
* If the address or phone number needs to be changed during the course of the study, this will be 
done by the Investigator, with written notification to the Sponsor, and will not require (a) 
protocol amendment(s). 


ChemoCentryx, Inc. 
CONFIDENTIAL 
Protocol CL005_168 
CCX168 
 
Amendment 3.0  
                                                                    Page 3 of 72                                            17 July 2015 
 
SPONSOR CONTACT INFORMATION 
Protocol Number: CL005_168 
Protocol Title: An Open-Label Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in 
Subjects with IgA Nephropathy on Stable RAAS Blockade 
 
Medical Officer 
 
Pirow Bekker, MD, PhD 
Chief Medical Officer 
ChemoCentryx, Inc. 
Mountain View, CA 94043, USA 
Office telephone number:   650-210-2924 
Fax number:  650-210-2910 
Email:  pbekker@chemocentryx.com  
 
Clinical  
 
 
 
Antonia Potarca, MSc 
Operations  
 
 
Clinical Operations Manager  
Managers  
 
 
ChemoCentryx, Inc. 
Mountain View, CA 94043, USA 
Mobile telephone number:  +31 6 30892290 
Fax number:  +1-650-210-2910 
Email:  apotarca@chemocentryx.com 
 
and 
 
Janet Diehl, BS 
Clinical Operations Manager 
ChemoCentryx, Inc. 
Mountain View, CA 94043, USA 
Telephone number 650-210-2923 
Email: jdiehl@chemocentryx.com 
 


ChemoCentryx, Inc. 
CONFIDENTIAL 
Protocol CL005_168 
CCX168 
 
Amendment 3.0  
                                                                    Page 4 of 72                                            17 July 2015 
 
SPONSOR SIGNATURE FOR APPROVAL 
Protocol Number: CL005_168 
Protocol Title:  An Open-Label Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 
in Subjects with IgA Nephropathy on Stable RAAS Blockade 
  
 
 
 
____________________________________ 
 
______________________ 
Pirow Bekker, MD, PhD  
 
 
 
 
 
 
Date 
Chief Medical Officer 
 


ChemoCentryx, Inc. 
CONFIDENTIAL 
Protocol CL005_168 
CCX168 
 
Amendment 3.0  
                                                                    Page 5 of 72                                            17 July 2015 
 
PROTOCOL AMENDMENT 3.0: SUMMARY OF CHANGES 
In compliance with a recommendation from FDA, the following changes were made to the 
protocol: 
1. Stopping rules for individual subjects, based on white blood cell, neutrophil, and 
lymphocyte counts, as well as hepatic aminotransferase or bilirubin elevations were 
added to section 7.2.4 of the protocol. The statement regarding potential re-challenging 
of subjects with hepatic aminotransferase or bilirubin elevations was removed. FDA’s 
rationale is that, in general, IgA nephropathy is a slowly progressive disease and, at this 
time, FDA does not believe the potential benefits of re-exposing a subject who develops 
a significant aminotransferase elevation would outweigh the risk. Hence, these subjects 
should not be rechallenged. 
2. The stopping rule for the study based on hepatic aminotransferase or bilirubin 
elevation in section 7.2.4 was modified to indicate that the Sponsor will consider 
stopping the study if at least one subject develops severe liver injury believed to be 
caused by CCX168. FDA’s rationale is that patients with IgAN are relatively healthy, 
and even one case of severe liver injury caused by CCX168 would be a concern. 


ChemoCentryx, Inc. 
CONFIDENTIAL 
Protocol CL005_168 
CCX168 
 
Amendment 3.0  
                                                                    Page 6 of 72                                            17 July 2015 
 
TABLE OF CONTENTS 
INVESTIGATOR SIGNATORY PAGE .........................................................................................2 
SPONSOR CONTACT INFORMATION .......................................................................................3 
SPONSOR SIGNATURE FOR APPROVAL .................................................................................4 
PROTOCOL AMENDMENT 3.0: SUMMARY OF CHANGES ...................................................5 
TABLE OF CONTENTS .................................................................................................................6 
LIST OF TABLES ...........................................................................................................................9 
STUDY SYNOPSIS ......................................................................................................................10 
STUDY SCHEMA.........................................................................................................................20 
TIME AND EVENTS TABLE ......................................................................................................21 
LIST OF ABBREVIATIONS AND ACRONYMS ......................................................................23 
1. 
INTRODUCTION ......................................................................................................25 
1.1. 
Background .................................................................................................................25 
1.2. 
Study Drug Development ...........................................................................................26 
1.2.1. 
Non-Clinical Pharmacology .......................................................................................26 
1.2.1.1. 
In-Vitro Efficacy and Selectivity for C5aR ................................................................26 
1.2.1.2. 
Efficacy Models ..........................................................................................................27 
1.2.2. 
Non-Clinical Safety and Toxicology ..........................................................................28 
1.2.3. 
Non-Clinical ADME ...................................................................................................31 
1.3. 
Prior Human Experience .............................................................................................33 
1.4. 
Rationale for the Study ...............................................................................................35 
2. 
OBJECTIVES .............................................................................................................36 
2.1. 
Primary Objective .......................................................................................................36 
2.2. 
Secondary Objectives .................................................................................................36 
3. 
STUDY DESIGN .......................................................................................................36 
4. 
STUDY POPULATION .............................................................................................38 
4.1. 
Size of the Population .................................................................................................38 
4.2. 
Inclusion Criteria ........................................................................................................38 
4.3. 
Exclusion Criteria .......................................................................................................39 
4.4. 
Removal of Subjects from Therapy or Assessment ....................................................40 


ChemoCentryx, Inc. 
CONFIDENTIAL 
Protocol CL005_168 
CCX168 
 
Amendment 3.0  
                                                                    Page 7 of 72                                            17 July 2015 
 
5. 
STUDY MEDICATION/TREATMENT ...................................................................41 
5.1. 
Product Characteristics ...............................................................................................41 
5.2. 
Randomization and Method of Treatment Assignment ..............................................41 
5.3. 
Doses and Regimens ...................................................................................................41 
5.4. 
Rationale for Dose Selection ......................................................................................42 
5.5. 
Drug Supply ................................................................................................................42 
5.5.1. 
Packaging and Labeling ..............................................................................................42 
5.5.2. 
Storage ........................................................................................................................42 
5.6. 
Blinding ......................................................................................................................42 
5.7. 
Drug Accountability ...................................................................................................42 
5.8. 
Treatment Compliance ................................................................................................43 
5.9. 
Concomitant Medications and Restrictions ................................................................43 
6. 
STUDY PROCEDURES ............................................................................................43 
6.1. 
Screening and Enrollment ...........................................................................................43 
6.2. 
Titration Period ...........................................................................................................44 
6.3. 
Run-In Period ..............................................................................................................45 
6.3.1. 
Study Day -63 .............................................................................................................45 
6.3.2. 
Study Day -35 .............................................................................................................45 
6.3.3. 
Study Day -7 to -2 Window ........................................................................................45 
6.4. 
Study Day 1 ................................................................................................................46 
6.5. 
Study Day 8 ................................................................................................................47 
6.6. 
Study Day 15 ..............................................................................................................48 
6.7. 
Study Day 29 ..............................................................................................................49 
6.8. 
Study Day 43 ..............................................................................................................50 
6.9. 
Study Day 57 ..............................................................................................................51 
6.10. 
Study Day 85/Early Termination Prior to Day 85 ......................................................52 
6.11. 
Study Day 113 ............................................................................................................53 
6.12. 
Study Day 141 ............................................................................................................53 
6.13. 
Study Day 169/Early Termination Prior to Day 169 ..................................................54 
7. 
STUDY ASSESSMENTS ..........................................................................................55 
7.1. 
Efficacy Assessments .................................................................................................55 


ChemoCentryx, Inc. 
CONFIDENTIAL 
Protocol CL005_168 
CCX168 
 
Amendment 3.0  
                                                                    Page 8 of 72                                            17 July 2015 
 
7.1.1. 
Urinary Protein:Creatinine and Albumin:Creatinine ..................................................55 
7.1.2. 
Estimated Glomerular Filtration Rate .........................................................................55 
7.1.3. 
Other Urinary Assessments ........................................................................................55 
7.1.4. 
Serum IgA and Plasma C3 ..........................................................................................56 
7.1.5. 
Plasma and Urinary Pharmacodynamic Markers .......................................................56 
7.2. 
Safety Assessments .....................................................................................................56 
7.2.1. 
Physical Examinations and Vital Signs ......................................................................56 
7.2.2. 
Clinical Safety Laboratory Assessments ....................................................................56 
7.2.3. 
Reporting of Adverse Events ......................................................................................57 
7.2.4. 
Stopping Criteria .........................................................................................................58 
7.2.5. 
Reporting of Serious Adverse Events .........................................................................59 
7.3. 
Pharmacokinetic Assessments ....................................................................................59 
7.4. 
Study Completion and Withdrawal ............................................................................59 
7.5. 
Statistical Methods ......................................................................................................60 
7.6. 
Subject Populations ....................................................................................................60 
7.7. 
Safety Endpoints .........................................................................................................60 
7.8. 
Efficacy Endpoints ......................................................................................................60 
7.9. 
Pharmacokinetic Endpoints ........................................................................................61 
7.10. 
Statistical Analysis Methodology ...............................................................................61 
7.10.1. 
Titration and Run-In Period ........................................................................................61 
7.10.2. 
Baseline Characteristics and Subject Disposition .......................................................61 
7.10.3. 
Safety Analyses ..........................................................................................................62 
7.10.4. 
Efficacy Analyses .......................................................................................................62 
7.10.5. 
Pharmacokinetic Analysis ..........................................................................................63 
7.11. 
Sample Size Justification ............................................................................................63 
7.12. 
Protocol Deviations ....................................................................................................64 
8. 
STUDY COMPLETION AND TERMINATION ......................................................64 
8.1. 
Study Completion .......................................................................................................64 
8.2. 
Study Termination ......................................................................................................64 
9. 
REGULATORY AND ADMINISTRATIVE REQUIREMENTS ............................64 
9.1. 
Investigator Responsibilities .......................................................................................64 


ChemoCentryx, Inc. 
CONFIDENTIAL 
Protocol CL005_168 
CCX168 
 
Amendment 3.0  
                                                                    Page 9 of 72                                            17 July 2015 
 
9.2. 
Institutional Review Board or Ethics Committee .......................................................64 
9.3. 
Informed Consent .......................................................................................................65 
9.4. 
Protocol Modifications ...............................................................................................65 
9.5. 
Regulatory Documentation .........................................................................................65 
9.6. 
Subject Identification Register ...................................................................................66 
9.7. 
Record Retention ........................................................................................................66 
9.8. 
Case Report Form Completion ...................................................................................66 
9.9. 
Monitoring ..................................................................................................................66 
9.10. 
On-site Audits .............................................................................................................66 
9.11. 
Use of Information and Publication ............................................................................67 
10. 
REFERENCES ...........................................................................................................68 
11. 
APPENDICES ............................................................................................................69 
11.1. 
Statement of Obligations of Sponsor, Monitor, and Clinical Investigator .................69 
11.2. 
Informed Consent Form ..............................................................................................72 
 
LIST OF TABLES 
Table 1: 
Overview of Toxicology Studies Performed with CCX168 .......................................29 
Table 2: 
Overview of Safety Pharmacology Studies Performed with CCX168 .......................30 
Table 3: 
Pharmacokinetic Parameters of CCX168 in CD-1 Mice, Sprague-Dawley 
Rats, Beagle Dogs, and Cynomolgus Monkeys after Administration of a 
Single Oral Gavage or an Intravenous Dose of CCX168 ...........................................32 


ChemoCentryx, Inc. 
CONFIDENTIAL 
Protocol CL005_168 
CCX168 
 
Amendment 3.0   
                                                                   Page 10 of 72                                       17 July 2015 
 
STUDY SYNOPSIS 
Name of Sponsor 
ChemoCentryx, Inc. 
Name of Active Ingredient 
CCX168 
Study number:  
CL005_168 
Title 
An Open-Label Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects with 
IgA Nephropathy on Stable RAAS Blockade 
Investigators 
Several 
Study centers 
Multi-center 
Study period 
24 months 
Phase of development 
Phase 2 
Aim 
The aim of this study is to evaluate the treatment to induce remission of proteinuria in patients 
with IgA nephropathy (IgAN) and persistent proteinuria despite supportive therapy with a 
maximally tolerated dose of renin-angiotensin-aldosterone system (RAAS) blockade 
(angiotensin converting enzyme inhibitor [ACE-I], angiotensin II receptor blocker [ARB], or 
aldosterone blocker). The intent is to reduce proteinuria to normal levels without the use of high 
dose glucocorticoids.  
Objectives 
The primary safety objective of this study is to evaluate the safety and tolerability of CCX168 
in subjects with IgAN on background supportive therapy with a maximally tolerated dose of 
RAAS blockade. 
The primary efficacy objective is to evaluate the efficacy of CCX168 based on an improvement 
in proteinuria. 
The secondary objectives of this study include assessment of: 
1. Change in albuminuria with CCX168 treatment;  
2. Change in renal function based on estimated glomerular filtration rate (eGFR) with CCX168 
treatment; 
3. Change in hematuria with CCX168 treatment; 
4. Change in renal inflammatory activity based on urinary monocyte chemoattractant protein-1 
(MCP-1):creatinine ratio and urinary epidermal growth factor (EGF):MCP-1 ratio with 


ChemoCentryx, Inc. 
CONFIDENTIAL 
Protocol CL005_168 
CCX168 
 
Amendment 3.0   
                                                                   Page 11 of 72                                       17 July 2015 
 
CCX168 treatment; 
5. Change in serum IgA:plasma C3 ratio with CCX168 treatment;  
6. Changes in pharmacodynamic markers in plasma and urine with CCX168 treatment, e.g., 
C3a, C5a, properdin, and sC5b-9; 
7. Evaluation of the pharmacokinetic profile of CCX168 in subjects with IgAN. 
Rationale 
IgAN is reported as the most common glomerulonephritis worldwide. It is associated with a 
wide spectrum of disease severity and rate of progression of renal failure. The best well 
established risk factor of progressive loss of renal function from IgAN is the persistent presence 
of proteinuria > 1 g/day, with some studies suggesting that the persistence of even lower levels 
of proteinuria (> 500 mg/day) may be associated with worse prognosis. Other clinical and 
histologic factors have also been associated with a faster decline in renal function, although 
these are not as well documented.   
Despite the relative high prevalence of disease worldwide, there is a paucity of evidence-based 
therapy available for the treatment of IgAN. Current guidelines include initiating therapy of 
patients with hypertension and persistent proteinuria > 1 g/day with RAAS blockade with an 
ACE inhibitor or ARB to attain a level of proteinuria below that threshold.   
For patients who fail to attain a reduction of proteinuria to < 1 g/day, it is currently “suggested” 
that patients be treated with a course of glucocorticoids (KDIGO Clinical Practice Guideline for 
Glomerulonephritis, 2012). However this “suggestion” carries an evidence-based grade of 2C, 
given the “weakness” of the data supporting the efficacy of such therapy in altering long term 
outcomes of patients. In addition, the use of glucocorticoids for several months (e.g., 6 months 
in the “Pozzi” protocol; Pozzi et al., 1999) is associated with significant risk of adverse effects 
especially in the adult population. 
Therefore, patients with relatively modest degree of proteinuria and well preserved eGFR (or 
stable eGFR if the decline is attributable to a cause other than IgAN) represent a large pool of 
patients with a perceived increased risk of GFR decline, but no established, safe and effective 
treatment.   
This patient population is ideal for a pilot study of CCX168. Phase 2 study data in patients with 
ANCA-associated vasculitis suggest a significant anti-proteinuric effect of CCX168 in the 
majority of treated patients (mean decrease of approximately 60% in urinary ACR over 12 
weeks of treatment with CCX168). This treatment effect was observed in patients receiving 
CCX168 plus glucocorticoids, but also in patients receiving CCX168 with no glucocorticoids.   
For patients with IgAN who have already demonstrated a decline in eGFR, more aggressive 
therapy with corticosteroids is warranted, and a delay in such treatment for the duration of the 
pilot study with a medication of unproven efficacy would be inappropriate at this early stage of 
clinical development. 


ChemoCentryx, Inc. 
CONFIDENTIAL 
Protocol CL005_168 
CCX168 
 
Amendment 3.0   
                                                                   Page 12 of 72                                       17 July 2015 
 
Methodology 
This is a pilot study to test the safety, tolerability, and efficacy of CCX168 in reducing 
proteinuria in patients with IgAN and persistent proteinuria despite supportive therapy with a 
maximally tolerated RAAS blocker. 
Patients will be screened for enrolment based on biopsy proven IgAN, and documentation of 
proteinuria > 1 g/g creatinine (by first morning urinary protein:creatinine). The screening period 
will be up to 14 days. Screening procedures will include demographics, medical history, 
medication history, physical examination and vital signs, serum pregnancy test for women of 
childbearing potential, serum chemistry, hematology, urinalysis, viral screening, and estimated 
glomerular filtration rate (eGFR) assessment. If a patient did not have a renal biopsy in the past 
3 years to confirm the diagnosis of IgAN, a renal biopsy needs to be done for eligibility 
assessment. Patients meeting inclusion and exclusion criteria will be enrolled for blood 
pressure/RAAS blockade titration and run-in period. 
At screening, patients should ideally be on one or two RAAS blocker(s) and have BP <140/90 
mmHg. Patients not on an RAAS blocker can be started, and have the medication dose adjusted 
to a maximally tolerated dose (MTD) within a period not to exceed 4 weeks. 
MTD for RAAS blockade is defined as: 
• a dose attaining a target blood pressure less than 125/75 mmHg, or  
• the maximum recommended dose (according to the label of the RAAS blocker), or  
• the maximum dose tolerated by the subject from a safety/tolerability perspective. 
  
If the blood pressure target of <125/75 mmHg is not achieved during the titration period, 
additional anti-hypertension medication (non-ACE-I or ARBs) should be considered to achieve 
this blood pressure goal. All patients must participate in an 8-week run-in period during which 
they must be on a stable, MTD of an RAAS blocker before starting treatment with CCX168 on 
Day 1. If a patient is on two RAAS blockers, e.g., an ACE inhibitor and an ARB at the time of 
screening, the patient must remain on stable doses of these medications throughout the 8-week 
run-in period. Titration to an MTD for both RAAS blockers is not needed in this case, if the 
blood pressure goal has been achieved. 
After the 8-week run-in period has been completed, two back-to-back first morning urine 
collections need to be obtained for protein and creatinine measurements. The geometric mean of 
the two urinary PCR measurements must be > 1 g/g creatinine for eligibility for further study 
participation.  
On Day 1, patients meeting inclusion criteria will start CCX168 treatment. Patients will take 
CCX168 30 mg orally twice daily for 12 weeks (84 days). The CCX168 dose will be taken in 
the morning optimally within one hour after breakfast and in the evening optimally within one 
hour after dinner. After the 84-day treatment period, patients will be followed for 12 weeks (84 
days) while continuing to take their RAAS blocker treatment at a stable dose. 
At post-Day 1 study visits, blood and urine samples will be collected for safety, efficacy, and 
pharmacokinetic measurements. A serum pregnancy test for women of childbearing potential 


ChemoCentryx, Inc. 
CONFIDENTIAL 
Protocol CL005_168 
CCX168 
 
Amendment 3.0   
                                                                   Page 13 of 72                                       17 July 2015 
 
will be done on Days 29, 43, 57, 85, 113, and 169. Physical examinations and vital signs 
assessments will be performed throughout the study. Concomitant medication and adverse event 
assessments will be made at every study visit. An optional renal biopsy could be performed 
after the 12-week treatment period to assess the effect of CCX168 treatment on kidney 
histology. 
During the 12-week treatment period and the 12-week follow-up period, the dose(s) of RAAS 
blocker(s) must remain unchanged. No new RAAS blocker or non-dihydropyridine calcium 
channel blocker or diuretic may be added during the study period (active treatment period or 
follow up).   
During the treatment period with study medication and the 12 weeks of follow up thereafter, no 
new immunomodulatory medication may be started including, but not limited to cyclosporine, 
tacrolimus, mycophenolate mofetil, azathioprine, cyclophosphamide, or glucocorticoids (e.g. 
prednisone).   
Concomitant use of omega-3 fatty acid supplements (e.g., fish oil) is permitted IF the 
medication is started at the time of, or before screening, and is maintained at a stable dose 
during the rest of the study until the end of the follow-up period (Day 169).  
Patients will visit the study center on Days 1, 8, 15, 29, 43, 57, 85, 113, 141, and 169 for the 
treatment and follow-up period. 
Duration of treatment with study medicine: 84 days 
Duration of follow up after end of treatment with study medicine: 84 days 
Subjects who experience a decrease from baseline in eGFR > 10 ml/min/1.73 m2 or > 20%, 
(confirmed by repeat after 2 weeks) which is otherwise not explained (e.g., dehydration, new 
medication), or an increase in proteinuria of > 3 g/g creatinine from baseline or to a level > 8 
g/g (confirmed by repeat after 2 weeks) during the 12-week treatment period, will exit the 
treatment phase of the study and be treated at the discretion of their primary nephrologist. They 
will remain in the study for follow up and outcome recording. 
Subjects will be discharged from the study when all the Study Day 169 visit procedures have 
been completed. The subject’s condition will be evaluated by the Investigator at the end of the 
clinical trial (Day 169) and appropriate standard of care medical treatment will be provided to 
all subjects as needed. 
Number of Subjects 
Up to approximately 20 male or female subjects with IgAN will be enrolled in this study. 
Subjects who started the CCX168 treatment period and drop out prematurely will not be 
replaced. However, subjects who drop out during the titration and run-in periods may be 
replaced. 
Main Criteria for Inclusion 
1. 
Biopsy-proven IgAN performed for clinical purposes within 3 years prior to screening; 
2. 
eGFR >60 mL/min/1.73 m2 (by MDRD equation) OR eGFR >45 mL/min/1.73 m2 if 
eGFR has not declined > 10 mL/min/1.73 m2 over the previous 24 weeks; 


ChemoCentryx, Inc. 
CONFIDENTIAL 
Protocol CL005_168 
CCX168 
 
Amendment 3.0   
                                                                   Page 14 of 72                                       17 July 2015 
 
3. 
Proteinuria, defined as first morning urinary PCR > 1 g/g creatinine; 
4. 
Male or female subjects, aged at least 18 years; Where allowed by local regulations, 
female subjects of childbearing potential may participate if adequate contraception is used 
during, and for at least the three months after study completion; Male subjects with 
partners of childbearing potential may participate in the study if they had a vasectomy at 
least 6 months prior to randomization or if adequate contraception is used during, and for 
at least the three months after study completion; Adequate contraception is defined as 
resulting in a failure rate of less than 1% per year (combined estrogen and progestogen 
[oral, intravaginal, or transdermal], or progestogen-only hormonal contraception (oral, 
injectable, or implantable), intra-uterine device, intra-uterine hormone releasing system, 
bilateral tubal occlusion, vasectomized partner, or sexual abstinence); 
5. 
Willing and able to give written Informed Consent and to comply with the requirements of 
the study protocol; and 
6. 
Judged to be otherwise healthy by the Investigator, based on medical history, physical 
examination, and clinical laboratory assessments. Subjects with clinical laboratory values 
that are outside of normal limits (other than those specified in the Exclusion Criteria) 
and/or with other abnormal clinical findings that are judged by the Investigator not to be 
of clinical significance, may be entered into the study.     
Main Criteria for Exclusion 
1. 
Severe renal disease as determined by rapid decline in eGFR (defined as >10 
mL/min/1.73 m2 over 24 weeks prior to screening, not otherwise explained);  
2. 
Pregnant or nursing; 
3. 
Proteinuria > 8 g/day (or >8 g/g creatinine); 
4. 
Patients with systemic manifestations of Henoch-Schönlein purpura within the last 2 years 
prior to screening; 
5. 
Patients with IgAN deemed secondary to underlying disease: e.g., diabetes, liver disease, 
cirrhosis, celiac disease, HIV, inflammatory bowel disease, lymphoma, or associated with 
any other multi-system autoimmune disease; 
6. 
Biopsy report demonstrating severe crescentic IgAN (>25% crescents), OR >50% 
interstitial fibrosis and/or tubular atrophy (“T2”) (Cattran et al. 2009), OR a high 
likelihood of rapid decline in eGFR based on an MEST (“Oxford”) classification (M = 
mesangial hypercellularity; E = endocapillary proliferation; S = segmental 
glomerulosclerosis/adhesion; T = tubular atrophy/interstitial fibrosis) score of M1, E0, T1, 
or M0/1, E1, T1 (Cattran et al. 2009); 
7. 
History of treatment with glucocorticoids, cyclophosphamide, azathioprine,  
mycophenolate mofetil, or any biologic immunomodulatory agent within the 24 weeks 
prior to screening;  
8. 
Symptomatic congestive heart failure requiring prescription medication, clinically evident 
peripheral edema of cardiac origin, poorly-controlled hypertension (systolic blood 


ChemoCentryx, Inc. 
CONFIDENTIAL 
Protocol CL005_168 
CCX168 
 
Amendment 3.0   
                                                                   Page 15 of 72                                       17 July 2015 
 
pressure >160 or diastolic blood pressure >95), history of unstable angina, myocardial 
infarction or stroke within 6 months prior to screening; 
9. 
History or presence of any form of cancer within the 5 years prior to screening, with the 
exception of excised basal cell or squamous cell carcinoma of the skin, or cervical 
carcinoma in situ or breast carcinoma in situ that has been excised or resected completely 
and is without evidence of local recurrence or metastasis; 
10. Positive HBV, HCV, or HIV viral screening test; 
11. History of tuberculosis; 
12. Any infection requiring antibiotic treatment that has not cleared prior to starting CCX168 
treatment on Day 1; 
13. WBC count less than 4000/L, or neutrophil count less than 2000/L, or lymphocyte 
count less than 1000/L; 
14. Hemoglobin less than 9 g/dL (or 5.56 mmol/L) at screening; 
15. Evidence of hepatic disease; AST, ALT, alkaline phosphatase, or bilirubin > 3 x the upper 
limit of normal; 
16. Participated in any clinical study of an investigational product within 30 days prior to 
screening or within 5 half-lives after taking the last dose; and 
17. History or presence of any medical condition or disease which, in the opinion of the 
Investigator, may place the subject at unacceptable risk for study participation. 
Test Product 
CCX168 will be administered via hard gelatin capsules containing 10 mg CCX168. The 
CCX168 capsules will be supplied to the study centers in plastic bottles containing 30 capsules.  
Subjects will receive two bottles of CCX168 capsules on Day 1 and Day 8, respectively, four 
bottles on Days 15, 29, and 43, respectively, and six bottles on Day 57. 
Subjects will be asked to take 3 capsules every morning and 3 capsules every evening, 
approximately 12 hours after the morning dose, as instructed. Study medication should be taken 
optimally within 1 hour after breakfast in the morning and optimally within 1 hour after dinner 
in the evening for 84 days continuously. Capsules will be taken with water, preferably with 50 
mL (~one fifth of a cup), but not to exceed 100 mL (~one half cup).     


ChemoCentryx, Inc. 
CONFIDENTIAL 
Protocol CL005_168 
CCX168 
 
Amendment 3.0   
                                                                   Page 16 of 72                                       17 July 2015 
 
Duration of Treatment and Observation  
Subjects will be screened within a period not to exceed 14 days prior to the RAAS titration and 
run-in period. The RAAS blocker titration period could be up to 4 weeks. All subjects must take 
a stable dose of a RAAS blocker at the maximally tolerated dose (MTD) for 8 weeks before 
they could start the 12-week CCX168 treatment period. Alternatively, subjects who take two 
RAAS blockers must take a stable dose of each (not necessarily at the MTD) for 8 weeks before 
starting the CCX168 treatment period. The CCX168 treatment period is 12 weeks (84 days) and 
all subjects will be followed for 12 weeks (84 days) after the dosing period.  
To the extent possible, any adverse events that are deemed study drug-related and are ongoing 
at discharge will be followed-up to resolution or until a determination is made that the 
unresolved event is stable. The subject’s condition will be evaluated by the Investigator at the 
end of the clinical trial and appropriate standard of care medical treatment will be provided to 
all subjects as needed. 
Safety Assessments 
Safety assessments include adverse events, physical examination abnormalities, vital signs, and 
clinical laboratory tests (including blood chemistry, hematology, and urinalysis). 
Efficacy Assessments 
Efficacy assessments include: 
1. First morning urinary PCR and ACR; 
2. eGFR by Modification of Diet in Renal Disease (MDRD) formula based on serum 
creatinine; 
3. Hematuria based on microscopic urinary RBC count; 
4. Urinary MCP-1:creatinine ratio; 
5. Serum IgA:C3 ratio; 
6. Urinary EGF:MCP-1 ratio, and 
7. Plasma and urine pharmacodynamic markers, e.g., C3a, C5a, properdin, and sC5b-9. 
Pharmacokinetic Assessments 
Concentrations of CCX168 and possible metabolites will be determined in plasma from 4-mL 
blood samples collected in EDTA tubes on Days 1, 8, 15, 29, 43, 57, and 85. On Day 1, samples 
will be taken at pre-dose, 0.5, 1, 2, 3, 4, and 6 hours after dosing. 
Pharmacodynamic Markers 
A plasma sample will be collected on Days 1, 8, 15, 29, 57, 85, 113, 141, and 169 for 
pharmacodynamic marker measurements, including for example galactose-deficient IgA1, 
complement factor H, cystatin C, complement fragments, and inflammatory cytokine and 
chemokine levels. The plasma samples may also be used to determine CCX168 (and relevant 


ChemoCentryx, Inc. 
CONFIDENTIAL 
Protocol CL005_168 
CCX168 
 
Amendment 3.0   
                                                                   Page 17 of 72                                       17 July 2015 
 
metabolite) concentrations. 
Urine samples will also be collected on Days 1, 8, 15, 29, 57, 85, 113, 141, and 169 for 
biomarker assessments including for example complement fragments, inflammatory chemokine 
and cytokine levels. 
Statistical Methods   
Demographics and Baseline Characteristics 
All subject baseline characteristics and demographic data (age, sex, race, ethnicity, weight, 
height, body mass index, smoking status, viral test results, IgAN disease duration (from time of 
first diagnosis based on renal biopsy), eGFR, proteinuria (PCR and ACR), urinary MCP-
1:creatinine ratio, physical examination abnormalities, medical history, previous (within 6 
months of screening) and concomitant medications (including RAAS blockers) at study entry 
will be listed by study center and subject number, and will also be summarized.  
Safety Analysis 
The primary safety endpoint is the subject incidence of adverse events. 
Other safety endpoints include: 
1. Change from baseline in all safety laboratory parameters; 
2. Change from baseline in vital signs; 
All subjects who are enrolled and received at least one dose of study medication will be 
included in the safety population.  
All clinical safety and tolerability data will be listed by subject and will be summarized. 
Treatment-emergent adverse events will be listed and summarized by System Organ Class, by 
relatedness and by maximum severity. Serious adverse events and adverse events leading to 
withdrawal will be listed and summarized. Individual vital signs and change from baseline in 
vital signs will be listed by subject, and study visit, and summarized descriptively. Laboratory 
data (actual values and change from baseline) will be listed by subject and study visit. 
Abnormal laboratory values will be flagged. 
Efficacy Analysis 
The primary efficacy endpoint is the change in slope of first morning urinary PCR from the 8-
week RAAS blocker run-in period to the 12-week CCX168 treatment period. 
Other efficacy endpoints include: 
1. The proportion of subjects achieving renal response, defined as an improvement in 
proteinuria based on a decrease from baseline to Day 85 in proteinuria to a level < 300 mg/g 
creatinine and maintaining estimated glomerular filtration rate (eGFR) within 15% of 
baseline; 
2. The proportion of subjects achieving a partial renal response, defined as an improvement in 
proteinuria based on a decrease from baseline to Day 85 in proteinuria to a level < 1 g/g 
creatinine and maintaining estimated glomerular filtration rate (eGFR) within 15% of 


ChemoCentryx, Inc. 
CONFIDENTIAL 
Protocol CL005_168 
CCX168 
 
Amendment 3.0   
                                                                   Page 18 of 72                                       17 July 2015 
 
baseline; 
3. Change in slope from the run-in period to the treatment period for urinary ACR, eGFR, 
urinary MCP-1:creatinine, urinary EGF:MCP-1, and urinary microscopic RBC counts; 
4. The percent change from baseline to Day 85 in urinary PCR and ACR; 
5. The change from baseline to Day 85 in eGFR; 
6. In patients with hematuria at baseline, the percent change from baseline in urinary RBC 
count; 
7. The percent change from baseline to Day 85 in urinary MCP-1:creatinine ratio; 
8. The percent change from baseline to Day 85 in serum IgA:plasma C3 ratio; 
9. The percent change from baseline to Day 85 in urinary EGF:MCP-1 ratio; 
10. The percent change from baseline in plasma and urinary biomarkers, e.g., C3a, C5a, 
properdin, and sC5b-9.  
Changes from baseline in all efficacy measurements at time points other than Day 85 will also 
be assessed. The 84-day follow-up period results for the endpoints listed above will also be 
summarized. Summary statistics will be calculated for each of the efficacy endpoints. For 
categorical endpoints, numbers and percentages will be calculated. For continuous variables, 
numbers, means, medians, ranges, and standard deviations will be calculated. Geometric means 
will be calculated for urinary PCR, ACR, and MCP-1:creatinine, and other measurements that 
are not normally distributed. 
The slope of the urinary PCR, urinary ACR, eGFR, urinary MCP-1:creatinine, urinary 
EGF:MCP-1, and urinary microscopic RBC count during the 8-week run-in period, the initial 4-
week, as well as the full 12-week treatment period will be calculated for each subject. The mean 
slope for the 8-week run-in period will be compared to the mean slope for the initial 4-week, as 
well as the full 12-week treatment period to evaluate the treatment effect of CCX168. If the 
slope for the first 4 weeks of the run-in period is steeper than the slope of the last 4 weeks of the 
run-in period, indicating that steady state has not been achieved over the first 4 weeks, the slope 
of the last 4 weeks of the run-in period may be used as the baseline slope, instead of the slope 
over the 8 weeks of the run-in period. 
The sample size for the study is based on the slope of the urinary ACR observed in a study in 
patients with ANCA-associated vasculitis while receiving CCX168. The mean slope was -1.32, 
with a standard deviation of 1.67 over 12 weeks, and -4.62, with a standard deviation of 4.77 
over the initial 4-week treatment period with CCX168 in ANCA-associated vasculitis. 
Assuming a mean difference in pre-treatment and on-treatment slopes of 4.6, a sample size of 
15 subjects will provide approximately 80% power and 20 subjects approximately 90% power 
to detect a difference in slopes.  
Pharmacokinetic analysis 
Plasma samples will be collected at Baseline (Day 1) and Days 8, 15, 29, 43, 57, and 85 to 
determine the PK profile of CCX168 (and metabolites). Individual plasma concentrations of 


ChemoCentryx, Inc. 
CONFIDENTIAL 
Protocol CL005_168 
CCX168 
 
Amendment 3.0   
                                                                   Page 19 of 72                                       17 July 2015 
 
CCX168 (and metabolites) will be listed, plotted, and summarized descriptively and 
graphically. The following parameters will be determined, where possible: 
Cmax 
Maximum plasma concentration 
tmax 
Time of maximum plasma concentration  
AUC0-6 
Area under the plasma concentration-time curve from Time 0 to Hour 6 on 
Day 1 
Cmin 
Trough level plasma concentrations at post-Day 1 visits       
The relationship between PK parameters and renal function based on eGFR will be evaluated. 
The data may also be used to evaluate the PK/PD relationship of CCX168 treatment. To this 
end, the change and/or percent change from baseline in urinary ACR, PCR, eGFR, urinary 
MCP-1:creatinine ratio, and other biomarkers may be used as PD markers.  


ChemoCentryx, Inc. 
CONFIDENTIAL 
Protocol CL005_168 
CCX168 
 
Amendment 3.0   
                                                                   Page 20 of 72                                       17 July 2015 
 
STUDY SCHEMA 
 
 
Screening period
RAAS titration 
and run-in period
CCX168 30 mg b.i.d. plus 
stable dose of RAAS blocker
Stable dose of 
RAAS blocker
≤14 days
84 days
84 days
Treatment Period
Visits: Days 1, 8, 15,  
29, 43, 57, 71, and 85
Visits: Days 113, 
141, and 169
N = up to 20 subjects
Up to 12 weeks;
On stable, maximally tolerated
dose (MTD) of RAAS blocker 
for 8 weeks
Eligibility confirmation
(urinary PCR and eGFR)
Follow-up Period
RAAS blocker
dose titration period: 
Up to 4 weeks;
Once on MTD of 
RAAS blocker, visits
on Day -63 and 
on Day -35 for U-PCR
and eGFR measurements 
Two visits in the Day -7 to 
-2 window for U-PCR and
eGFR measurements
Duration:
≤ 7 days
Study visits:


ChemoCentryx, Inc.                                                            CONFIDENTIAL                                                           Protocol CL005_168 
CCX168 
 
                                                                                  Amendment 3.0 
 
                                                                  Page 21 of 72                                                                      17 July 2015 
TIME AND EVENTS TABLE 
 
 
 
Study Day1 
 Screening2 
Titrat-
ion 
Run-in 
Treatment 
Follow-up 
 
≤ 14 days 
≤ 28 
days 
-63 
-35 
-7 to -23 
14 
8 
15 29 43 57  85 
113 141 169 
Informed consent 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Demographics, medical history, prior 
medications 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Physical examination5 
X 
 
 
 
 
X6 
 
 
X 
X 
X 
X 
X 
 
X 
Blood pressure7 
X 
X 
X 
X 
X, X 
X6 
X 
X 
X 
X 
X 
X 
X 
X 
X 
RAAS blocker dose titration8 
 
(X) 
 
 
 
 
 
 
 
 
 
 
 
 
 
RAAS blocker stable dosing at MTD 
 
 
X→ 
→ 
→ 
→ → → → → → 
→ 
→ 
→ 
→ 
Other vital signs9 
X 
 
 
 
 
X6 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Serum pregnancy test for women of 
childbearing potential 
X 
 
 
 
X 
 
 
 
X 
X 
X 
X 
X 
 
X 
HIV, HBV, HCV testing 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Serum chemistry10, hematology 
X 
 
 
 
 
X6 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Serum creatinine (not full chemistry) 
 
 
X 
X 
X 
 
 
 
 
 
 
 
 
 
 
Urinalysis11 
X 
 
 
 
 
X6 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Urine protein and creatinine assays 
X 
 
X 
X 
X, X 
X6 
X 
X 
X 
 
X 
X 
X 
X 
X 
Renal biopsy12 
X 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
Urine albumin, MCP-1, EGF, and 
microscopic RBC count 
 
 
X 
X 
X  
X6 
X 
X 
X 
 
X 
X 
X 
X 
X 
Serum IgA and plasma C3 samples 
 
 
 
 
 
X6 
 
 
X 
 
X 
X 
X 
X 
X 
CCX168 dispensing  
 
 
 
 
 
X6 
X 
X 
X 
X 
X 
 
 
 
 
CCX168 dosing 30 mg b.i.d. 
 
 
 
 
 
X
→ 
→ → → → → →X 
 
 
 


ChemoCentryx, Inc.                                                            CONFIDENTIAL                                                           Protocol CL005_168 
CCX168 
 
                                                                                  Amendment 3.0 
 
                                                                  Page 22 of 72                                                                      17 July 2015 
 
 
 
Study Day1 
 Screening2 
Titrat-
ion 
Run-in 
Treatment 
Follow-up 
 
≤ 14 days 
≤ 28 
days 
-63 
-35 
-7 to -23 
14 
8 
15 29 43 57  85 
113 141 169 
CCX168 accountability 
 
 
 
 
 
 
X 
X 
X 
X 
X 
X 
 
 
 
PD plasma sample collection13 
 
 
 
 
 
X6 
X 
X 
X 
 
X 
X 
X 
X 
X 
PD urine sample collection 
 
 
 
 
 
X6 
X 
X 
X 
 
X 
X 
X 
X 
X 
PK plasma sample collection14 
 
 
 
 
 
X 
X 
X 
X 
X 
X 
X 
 
 
 
Concomitant medications 
X 
X 
X 
X 
X, X  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Adverse event assessment 
 
X 
X 
X 
X, X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
1 Visit Days 1, 8, and 15 must occur on the scheduled study days. Visit Days 29, 43, 57, and 85 may occur within a +/- 2-day window of the scheduled visit. 
Visit Days 113, 141, and 169 may occur within a +/- 4-day window of the scheduled visit. 
2 Screening must occur within a period not to exceed 14 days. 
3 See Section 6.3.3 for the list of procedures identified for only the first, or for both of the back-to-back study days. 
4 Start of dosing with CCX168. 
5 Physical examination will include body weight measurement; Height will only be measured at Screening. Physical examination will include a neurological 
examination including speech, consciousness level, mood, cranial nerves, motor, coordination and gait, reflexes, and sensory systems. 
6 These procedures must be done BEFORE taking the first dose of study medication. 
7 Blood pressure needs to be measured in the supine position after 3 minutes of rest. 
8 Four-week dose titration period only needed for patients who are not on a maximum tolerated dose of a RAAS blocker, or stable dose of two RAAS blockers. 
9 Assessment of heart rate and body temperature 
10 Serum chemistry including creatinine measurements 
11 Subjects will be asked to void their bladders completely, and a representative clean catch, midstream urine sample will be collected. Urinalysis includes pH, 
specific gravity, glucose, nitrite, ketones, bilirubin, urobilinogen, RBCs, and WBCs. 
12 Renal biopsy is an optional procedure for this study, except if necessary for eligibility assessment. 
13 Blood samples will be put in wet ice immediately after collection, centrifuged in a refrigerated centrifuge and plasma put at -70 °C.  
14 PK blood sample (4 mL) will be collected prior to the morning dose on Day 1 and at 0.5, 1, 2, 3, 4, and 6 hours following dosing. 
 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 23 of 72                                            17 July 2015 
LIST OF ABBREVIATIONS AND ACRONYMS 
AAV  
anti-neutrophil cytoplasmic antibody associated vasculitis  
ACE-I  
angiotensin converting enzyme inhibitor 
ACR  
albumin:creatinine ratio 
AE  
 
adverse event 
ALT 
 
alanine aminotransferase (also called SGPT) 
ANCA  
anti-neutrophil cytoplasmic antibodies 
API 
 
active pharmaceutical ingredient 
ARB  
angiotensin II receptor blocker 
AST 
 
aspartate aminotransferase (also called SGOT) 
b.i.d.  
twice daily 
BUN  
blood urea nitrogen 
BVAS  
Birmingham Vasculitis Activity Score version 3 
C3  
 
complement 3 
C3a 
 
complement 3a 
C4a 
 
complement 4a 
C5a 
 
complement 5a 
C5aR  
complement 5a receptor 
C5b-9  
complement 5b-9 
CA  
 
competent authority 
cGMP  
current good clinical practice 
Cmax 
 
maximum (plasma) concentration 
CPK 
 
creatinine phosphokinase 
CRA  
Clinical Research Associate (also known as the Study Monitor) 
CRF 
 
case report form 
CTCAE 
Common Terminology Criteria for Adverse Events 
EC  
 
ethics committee 
ECG  
electrocardiogram 
EDC  
electronic data capture 
EGF 
 
epidermal growth factor 
eGFR  
estimated glomerular filtration rate 
FDA  
Food and Drug Administration 
g  
 
gram 
GCP 
 
good clinical practice 
GGT  
gamma-glutamyl transpeptidase 
GPA  
granulomatosis with polyangiitis (Wegener’s) 
GPCR  
G protein-coupled receptor 
HEENT 
head, eyes, ears, nose, throat 
HIV 
 
human immunodeficiency virus 
hpf  
 
high power field 
IC50 
 
concentration to inhibit 50% 
ICH 
 
International Conference on Harmonisation 
IgAN  
IgA nephropathy 
IRB 
 
Institutional Review Board 
KDIGO 
Kidney Disease: Improving Global Outcomes 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 24 of 72                                            17 July 2015 
kg  
 
kilogram 
LDH  
lactate dehydrogenase 
MAC  
membrane attack complex 
MCH  
mean cell hemoglobin 
MCHC 
mean cell hemoglobin concentration 
MCP-1 
monocyte chemoattractant protein-1 
MDRD 
Modification of Diet in Renal Disease 
MedDRA Medical Dictionary for Drug Regulatory Affairs 
mg  
 
milligram 
mL  
 
milliliter 
MPA  
microscopic polyangiitis 
MPO  
myeloperoxidase 
MTD  
maximum tolerated dose 
N  
 
number 
NOAEL 
No observed adverse effect level 
PCR 
 
protein:creatinine ratio 
PD  
 
pharmacodynamic(s) 
PK  
 
pharmacokinetic(s) 
q.d. 
 
once daily 
RAAS  
renin-angiotensin-aldosterone system 
RBC  
red blood cell 
SAE 
 
serious adverse event 
sC5b-9  
soluble C5b-9 fragment 
SGPT  
serum glutamic pyruvic transaminase (also called ALT) 
SGOT  
serum glutamic oxaloacetic transaminase (also called as AST) 
SLE 
 
systemic lupus erythematosus 
SOC 
 
standard of care 
SOP 
 
standard operating procedure 
SUSAR 
suspected unexpected serious adverse reaction 
Tmax 
 
time of maximum (plasma) concentration 
WBC  
white blood cell 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 25 of 72                                            17 July 2015 
1. 
INTRODUCTION 
1.1. 
Background 
The activation of the complement pathway generates biologically active fragments of 
complement proteins, e.g. C3a, C4a and C5a anaphylatoxins and C5b-9 membrane attack 
complexes (MAC), all of which mediate inflammatory responses by inducing leukocyte 
chemotaxis, activating macrophages, neutrophils, platelets, mast cells and endothelial cells and 
by increasing vascular permeability, cytolysis and tissue injury. 
C5a is one of the most potent pro-inflammatory mediators of the complement system, being at 
least 100 times more potent than C3a. This 8 kD polypeptide, along with a C5b fragment, is 
produced by enzymatic cleavage of a C5 precursor during activation of any of the 3 complement 
pathways. C5a induces expression of adhesion molecules and chemotactic migration of 
neutrophils, eosinophils, basophils and monocytes. It also mediates inflammatory reactions by 
causing smooth muscle contraction, increasing vascular permeability, inducing basophil and 
mast cell degranulation and inducing release of lysosomal proteases and oxidative free radicals. 
The anaphylactic and chemotactic effects of C5a are mediated through its interaction with the 
C5a receptor (C5aR), a G protein-coupled receptor (GPCR) expressed on human neutrophils, 
monocytes, basophils, eosinophils, renal glomerular tissues, and lung smooth muscle and 
endothelial cells. 
IgA nephropathy (IgAN) is a form of glomerulonephritis characterized by deposition of IgA in 
the glomeruli. Complement fragment C5a and C3a presence have been shown in the glomerular 
deposits, and C5aR and C3aR expression increased with increasing grades of renal pathology in 
patients with IgAN (Liu et al., 2013). Glomerular IgA deposits are insufficient to cause renal 
injury, since 16.1% of healthy allographs shows IgA deposition (Suzuki et al., 2003). However, 
mild mesangial proliferative changes are associated with C3 deposition as well as IgA deposition 
(Suzuki et al., 2003). This indicates that complement activation is associated with renal injury in 
these patients. Furthermore, a major susceptibility locus within the CFH gene cluster was found 
in a genome wide association study (Gharavi et al., 2011). Properdin, C5b-9 (Stangou et al., 
2008; Rauterberg et al., 1987), C4d, mannose-binding lectin, ficolin (Roos et al., 2006), and C4-
binding protein (Miyazaki et al., 1984) have been described in renal biopsy samples from 
patients with IgAN. All of these findings support an important role for complement activation in 
the pathology of IgAN. 
In a clinical trial (CL002_168) with CCX168 in patients with ANCA-associated vasculitis 
(AAV), CCX168 showed promise based on effect on renal disease parameters, including 
estimated glomerular filtration rate (eGFR), hematuria, albuminuria, monocyte chemoattractant 
protein-1 (MCP-1):creatinine ratio (a marker of renal inflammation), and the Birmingham 
Vasculitis Activity Score (BVAS). In particular, first morning urinary albumin:creatinine ratio 
(ACR) decreased approximately 60% from baseline in patients receiving CCX168 plus 
cyclophosphamide with or without corticosteroids compared to approximately 9% in the control 
group receiving cyclophosphamide plus full-dose corticosteroids.  
Several reports have also shown that anti-neutrophil cytoplasmic antibody (ANCA)-induced 
glomerulonephritis in mice (a model that closely recapitulates the histological features of human 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 26 of 72                                            17 July 2015 
pauci-immune necrotizing crescentic glomerulonephritis in granulomatosis with polyangiitis 
[GPA; Wegener’s] and microscopic polyangiitis [MPA]) is substantially ameliorated by genetic 
deletion of either C5 or C5aR (Schreiber et al., 2009).  
CCX168 was shown to be effective in human C5aR transgenic knock-in mouse model of MPO-
induced glomerulonephritis. CCX168 markedly reduced the percentage of glomeruli with 
crescents or necrosis, as well as the degree of proteinuria, hematuria, and leukocyturia (Xiao et 
al., 2014). 
The development of systemic lupus erythematosus (SLE) is associated with the deposition of 
IgG-containing immune complexes in various tissues/organs, with the ensuing activation of the 
complement cascade and production of inflammatory stimuli such as C5a. Glomerular 
expression of C5aR mRNA and protein was shown to correlate positively with the degree of 
mesangial hypercellularity and level of serum creatinine in mesangial glomerulonephritis, 
including lupus nephritis (Abe et al., 2001). Recent studies showed that C5aR-deficient mice and 
mice treated with a small peptidic anti-C5aR antagonist are protected from tissue injury induced 
by immune complex formation. In addition, use of a C5 mAb in a spontaneous mouse model of 
lupus-like autoimmune disease resulted in significant amelioration of the course of 
glomerulonephritis and in markedly increased survival. A genetic version of the disease (MRLlpr 
mice) is also attenuated significantly when the C5aR is deleted from that genetic background. 
This further supports a role for C5aR blockade in renal inflammatory conditions.  
A therapeutic indication being pursued for CCX168, a potent and selective C5aR antagonist, is in 
the treatment of patients with IgAN.  
IgAN currently is treated with angiotensin converting enzyme inhibitors (ACE-I) or angiotensin 
II receptor blockers (ARB), fish oil, glucocorticosteroids and/or immunosuppressive drugs in 
severe cases. 
1.2. 
Study Drug Development 
1.2.1. 
Non-Clinical Pharmacology 
1.2.1.1. 
In-Vitro Efficacy and Selectivity for C5aR  
CCX168 is a potent antagonist of the human C5a receptor (hC5aR). As measured in vitro with a 
myeloid human cell line, CCX168 functionally inhibits C5a-mediated chemotaxis with a potency 
(IC50) of 0.92 nM. Additionally, CCX168 displaces 125I-C5a from hC5aR with a potency (IC50) 
of 0.65 nM. When tested on freshly isolated human neutrophils, CCX168 inhibits the C5a-
mediated increase in cytoplasmic calcium levels with a potency (IC50) of 0.2 nM.  
CCX168 has been evaluated for its ability to inhibit the C5a-mediated chemotaxis of neutrophils 
in freshly isolated human whole blood. CCX168 produced 50% inhibition (IC50) of C5a-
mediation neutrophil migration in this assay at a concentration of 1.7 nM; 90% inhibition (A10 
value) was determined in human whole blood at a CCX168 concentration of 15.4 nM. CCX168 
also inhibits C5aR in cynomolgus monkeys and hamsters with potencies similar to that observed 
with human whole blood. However, CCX168 possesses moderate potency for rabbit C5aR (IC50 
~ 1.4 µM) and lacks affinity for mouse, rat or dog C5aR (IC50 > 10 µM). 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 27 of 72                                            17 July 2015 
One major metabolite (CCX168-M1) has been identified in human plasma in Phase 1 study 
CL001_168. This compound, also referred to a C0335273, has been shown to be equivalent to 
CCX168 in its potency towards hC5aR, having a potency (IC50) of 3 nM for inhibition of C5a-
mediated whole blood neutrophil chemotaxis and a potency of 7 nM for inhibition of C5a-
mediated neutrophil CD11b upregulation assay in whole blood. Like CCX168, the metabolite 
CCX168-M1 has a comparable high potency for cynomolgus monkey, hamster, and human 
C5aR, moderate potency against rabbit C5aR (IC50 ~ 1.4 µM), but lacks affinity for mouse, rat or 
dog C5aR (IC50 > 10 µM). 
CCX168 displays greater than 10,000-fold selectivity for hC5aR relative to other chemotactic 
receptors, including CCR1, CCR2, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CCR12, 
CXCR1, CXCR2, CXCR3, CXCR4, CXCR6, CXCR7, C5L2, C3aR, ChemR23, GPR1 and 
FPRL1. CCX168 has been further evaluated against a panel of 55 unrelated receptors and 
membrane-associated proteins. Weak levels of activity (>1,000-fold selectivity relative to 
hC5aR) were noted against the site 2 sodium channel (59% inhibition with 10 µM CCX168). 
CCX168-M1 was tested against a panel of 17 related chemotactic receptors and a panel of 55 
unrelated receptors and membrane-associate proteins. The only activity detected was weak 
(>1,000-fold selectivity relative to hC5aR) against CB1 (53% inhibition with 10 µM CCX168-
M1), the site 2 sodium channel (64% inhibition with 10 µM CCX168-M1) and the GABA-gated 
chlorine channel (51% inhibition with 10 µM CCX168-M1). 
1.2.1.2. 
Efficacy Models  
CCX168 has been evaluated in vivo utilizing models that are relevant to the intended therapeutic 
use in humans. When C5a is generated locally in the bloodstream, C5aR-bearing leukocytes in 
the vicinity immediately upregulate adhesion molecules and adhere to the inner face of the blood 
vessel. If C5a is introduced systemically by intravenous injection, leukocyte adherence occurs 
immediately throughout the vasculature and, as a result, the number of leukocytes still flowing in 
the bloodstream drops transiently by a substantial amount. In general, evaluation of C5aR 
antagonists in animal models poses a challenge because C5aR antagonists that are potent for 
human C5aR, including CCX168, are less potent for C5aR orthologs in most other model species 
(such as mice, rats and rabbits). For this reason, CCX168 has been evaluated in C5a-induced 
leukopenia models using transgenic mice in which the mouse C5aR gene has been replaced with 
the human C5aR gene and non-human primates. 
ChemoCentryx generated a human C5aR knock-in (hC5aR KI) mouse strain in which the mouse 
C5aR gene has been replaced with the human C5aR gene. The innate immune cells of these mice 
respond normally to C5a, in a manner highly sensitive to CCX168. In vitro, CCX168 blocks 
hC5a-mediated chemotaxis of leukocytes freshly isolated from these hC5aR KI mice with high 
potency (IC50 = 0.5 nM in 100% mouse plasma). This value is nearly identical to the potency 
(1.7 nM) exhibited by CCX168 in its inhibition of neutrophil migration to hC5a in whole human 
blood, indicating that the hC5aR KI mice are suitable for pharmacodynamic evaluation of 
CCX168. In the human C5aR knock-in mice, an intravenous dose of 20 µg/kg hC5a robustly 
induces this leukopenia within one minute after injection. Pretreatment of the mice with an oral 
dose of 0.3 mg/kg CCX168, which resulted in a plasma concentration of approximately 75 nM at 
60 min. post-dose, almost completely blocked the C5a-induced leukopenia. A dose of 0.03 
mg/kg CCX168, producing a plasma concentration of 15 nM, resulted in a 50% reduction in the 
C5a-induced leukopenic response. 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 28 of 72                                            17 July 2015 
In cynomolgus monkeys, it was determined that an intravenous hC5a dose of 10 µg/kg robustly 
induces a drop in neutrophils (neutropenia) within one minute. Pre-treatment of the cynomolgus 
monkeys with a 30 mg/kg oral dose of CCX168 completely blocked the C5a-induced 
neutropenia. This dose of CCX168 resulted in a plasma concentration of approximately 230 nM 
at the time of hC5a administration. A dose of 3 mg/kg resulted in greater than 50% reduction of 
the hC5a response, an effect that was associated with a CCX168 plasma concentration of 
approximately 38 nM. 
The efficacy of CCX168 in a mouse model of ANCA-associated glomerulonephritis was 
evaluated in order to assess the clinical potential of CCX168 in the treatment of ANCA-
associated vasculitis. In these studies, intravenous injection of mouse anti-myeloperoxidase (anti-
MPO) IgG into the human C5aR knock-in mice caused glomerulonephritis in a manner 
mimicking ANCA disease in humans. At daily oral doses of 30 mg/kg CCX168, a marked 
inhibition of anti-MPO induced glomerulonephritis was documented histologically, as assessed 
by the number of necrotic (8.2% with vehicle, 1.1% with CCX168; p<0.0001) and crescent-
containing glomeruli (30.5% with vehicle, 3.3% with CCX168; p<0.0001). These results were 
consistent with reduced protein, leukocytes and RBC levels in the urine and reduced serum BUN 
and creatinine in mice receiving CCX168. Some therapeutic benefit (30% reduction in the 
number of glomeruli with crescents) was noted at CCX168 doses as low as 0.1 mg/kg/day. 
Administration of 4 mg/kg CCX168 twice daily was identified as the lowest dosing regimen that 
produced a near-maximal therapeutic benefit. At this dose, plasma levels ranged from 35 ng/mL 
(Cmin) to 200 ng/mL (Cmax) throughout the day. The same blood biomarker of C5aR blockade 
used in Phase 1 clinical trial CL001_168 in healthy volunteers was also used with the hC5aR KI 
mice; CCX168 had similar C5aR antagonist potency on human and hC5aR KI mouse neutrophils 
(inhibition of C5a-induced CD11b upregulation in blood, IC50 4 nM). The extent of functional 
C5aR blockade on blood neutrophils associated with the plasma levels of 4 mg/kg CCX168 
twice daily was determined to range from 99% (at Cmax) to 95% (at Cmin), with a time-averaged 
level of receptor blockade of 97%. 
These mechanism-based pharmacology studies, taken together, support our estimate that 
maintaining human plasma CCX168 concentrations sufficiently high to provide ≥ 95% receptor 
coverage will provide significant clinical benefit in inflammatory conditions associated with 
C5aR activation. 
1.2.2. 
Non-Clinical Safety and Toxicology 
The toxicology program was designed to support this Phase 2 study to assess the safety, 
tolerability, and efficacy of CCX168 in subjects with IgAN. In this regard, a comprehensive 
safety pharmacology and toxicology program has been conducted in accordance with current 
ICH nonclinical toxicology guidance (including M3(R2) Nonclinical Safety Studies for the 
Conduct of Human Clinical trials for Pharmaceuticals; S2(R1) Genotoxicity Testing and Data 
Interpretation for Pharmaceuticals Intended for Human Use, S7A Safety Pharmacology Studies 
for Human Pharmaceuticals, S7B Non-Clinical Evaluation of the Potential for Delayed 
Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals, and S8 
Immunotoxicity Studies for Human Pharmaceuticals. The species selected for these studies (rats 
and monkeys) are well established models accepted by regulatory authorities for toxicology 
studies and were selected based upon metabolic, pharmacokinetic, and pharmacological 
properties of CCX168 in these species; information gained with these species was expected to be 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 29 of 72                                            17 July 2015 
of predictive clinical utility. CCX168-M1, presumed to be the only major human metabolite, was 
appropriately qualified in both the rat and the cynomolgus monkey; no additional major human 
metabolites are anticipated based on existing extensive in vitro and in vivo data. Additionally, 
CCX168 and CCX168-M1 are highly active in the cynomolgus monkey which indicated the 
latter species should be predictive of any toxicity related to C5aR inhibition. 
The toxicology studies (oral administration) conducted to date include a single-dose acute study 
in rats, dose-range finding studies in rats and cynomolgus monkeys, and GLP 28-day and 13/20-
week studies in rats and cynomolgus monkeys, respectively. The definitive 28-day and 13/20-
week studies involved the administration of CCX168 at daily doses up to 100 mg/kg/day in rats 
and up to 50 mg/kg/day in cynomolgus monkeys and included comprehensive clinical and  
ophthalmological evaluations, clinical pathology and the microscopic assessment of a full list of 
tissues. The definitive cynomolgus studies included electrocardiographic measurements. 
Toxicokinetic data were also collected in the multiple-dose rat and cynomolgus studies. The 
highest doses used in the definitive 13/20-week studies (up to 100 and 30 mg/kg/day, in rats and 
cynomolgus monkeys, respectively) represented Human Equivalent Doses (HED’s) of 15.6 and 
11.1 mg/kg/day, respectively.  
The effects of CCX168 upon the central nervous, respiratory, renal, and cardiovascular systems 
were also assessed in single-dose stand-alone safety pharmacology experiments in rats and 
cynomolgus monkeys. In vitro studies to assess the potential effects of CCX168 and CCX168-
M1 upon hERG channel ionic conductance was also conducted. An assessment of CCX168 
potential effects upon T-cell dependent humoral responses was performed in the rat. With regard 
to genotoxicity, in vitro bacterial (reverse mutation in histidine-requiring strains of S. 
typhimurium and tryptophan-requiring strains of E. coli) and mammalian (mutation at the 
thymidine kinase locus of mouse lymphoma L5178Y cells) mutagenicity tests were performed. 
Additionally, an in vivo rat bone marrow micronucleus test was also performed. 
All toxicology studies and safety pharmacology studies with the exception of dose analyses 
performed in support of the acute rat toxicology and CCX168-M1 hERG studies were conducted 
in accordance with GLP regulations. A summary of the nonclinical toxicology, genotoxicology, 
and safety pharmacology studies performed in support of CCX168 are described in Table 1 and 
Table 2. 
Table 1: 
Overview of Toxicology Studies Performed with CCX168 
Study Type 
Method of 
Administration/Dosing 
Schedule 
Species 
Doses 
Acute 
Oral /Single-Dose 
Rat 
0, 5, 25, 100 mg/kg 
Repeat Dose 
Oral / 7-Day 
Rat 
0, 30, 100 mg/kg 
 
Oral / 4 / (2) -day  
Cynomolgus monkey 
3, 50, 65, (80), (120) 
mg/kg 
 
Oral/28-Day   
Rat 
0, 5, 25, 100 mg/kg 
 
Oral/28-Day 
Cynomolgus monkey 
0, 5, 15,  50 mg/kg 
 
Oral/13-Week 
Rat 
0, 3, 15, 100 mg/kg 
 
Oral/20-Week 
Cynomolgus monkey 
0, 5, 15, 30 mg/kg 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 30 of 72                                            17 July 2015 
Study Type 
Method of 
Administration/Dosing 
Schedule 
Species 
Doses 
Genotoxicity 
 
 
 
Ames 
NA 
S. typhimurium and 
tryptophan-requiring 
strains of E. coli 
Up to 5000 µg/plate 
Mouse 
Lymphoma 
NA 
Mouse lymphoma 
cells 
Up to 500 µg/mL 
Rat Bone 
Marrow 
Micronucleus 
NA 
Rat 
0, 500, 1000 and 2000 
mg/kg 
Immunotoxicity 
Oral/28-Day 
Rat 
0, 3, 15, 100 mg/kg 
Table 2: 
Overview of Safety Pharmacology Studies Performed with CCX168 
Study Type 
Method of 
Administration/Dosing 
Schedule 
Species 
Doses 
Central Nervous 
System 
Oral/Single-Dose 
Rat 
0, 5, 25, 100 mg/kg 
Respiratory 
Oral/Single-Dose 
Rat 
0, 5, 25, 100 mg/kg 
Renal 
Oral/Single-Dose 
Rat 
0, 5, 25, 100 mg/kg 
Cardiovascular – 
In vivo 
Oral/Single-Dose 
Cynomolgus monkey 
0, 5, 15, 50 mg/kg 
Cardiovascular – 
In vitro (hERG 
with CCX168) 
In vitro 
Human cells 
transfected with 
human K-channel 
gene 
0.6, 1.2, 2.3 and 6.9 µM 
Cardiovascular – 
In vitro (hERG 
with CCX168-
M1) 
In vitro 
Human cells 
transfected with 
human K-channel 
gene 
1, 3, 10, and 15.8 µM 
There were no remarkable central nervous or respiratory system effects in rats following nominal 
single oral doses up to 100 mg/kg (actual dose of 73 mg/kg confirmed by dose solution analysis), 
or renal effects in rats following single oral doses up to 100 mg/kg, or effects on cardiovascular 
parameters in cynomolgus monkeys following single oral doses of up to 50 mg/kg. Additionally, 
no evidence of electrocardiographic abnormalities was seen in vivo in the 28-day and 20-week 
multiple dose studies in cynomolgus monkeys. In the in vitro cardiovascular safety studies, the 
IC50 values for hERG inhibition for CCX168 and CCX168-M1 were determined to be > 2.3 µM  
and 3 µM (the respective limits of solubility), further indicating CCX168 is unlikely to cause 
arrhythmias in vivo. Protein binding, red blood cell partitioning, hepatocyte metabolism, 
cytochrome P450 inhibition and induction, effects of CCX168 on cyclophosphamide metabolic 
activation and prednisone metabolism, Caco-2 permeability and genotoxicity studies, including 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 31 of 72                                            17 July 2015 
in vitro bacterial mutagenicity (Ames test), in vitro mammalian cell mutagenicity (mouse 
lymphoma) studies, and in vivo rat bone marrow micronucleus test were also conducted and did 
not identify any safety concerns or indicate a significant risk for drug-drug interactions with 
other concurrent medications in the intended patient population. In an acute toxicology study, 
single doses of CCX168 up to 100 mg/kg in rats produced no remarkable effects. In a 28-day 
immunotoxicity study in rats, CCX168 administered orally at doses up to 100 mg/kg/day, did not 
affect T-cell dependent antibody responses induced by KLH. 
CCX168 was well tolerated in 28-day studies up to doses of 100 mg/kg in rats and 50 mg/kg in 
cynomolgus monkeys. There were no significant toxicological findings of concern in these 
studies. At selected time points, minor but statistically significant differences existed in selected 
clinical pathology parameters between control and CCX168 treated rats. These included an 
increase in reticulocytes in 100 mg/kg/day recovery-phase females, an increase in prothrombin 
time in males given doses > 25 mg/kg/day and a minimal increase in ALT levels on Day 30 in 
females administered 100 mg/kg/day. These differences were not clearly test article-related and 
not considered to be of toxicological importance because of their small magnitude, mean and/or 
individual values falling within the range of normal variability and/or reversibility of the finding 
following a 2-week treatment-free period. 
CCX168 was also well tolerated in a 13-week study in rats up to doses of 100 mg/kg/day and in 
a 20-week study in cynomolgus monkeys up to 30 mg/kg/day. There were no significant 
toxicological findings of concern in these studies. The only CCX168-related clinical observation 
in the rat study was infrequent salivation, which was noted in the mid and high dose groups. 
There were no CCX168 related changes in body weights, food consumption, ophthalmic 
examinations, hematology, coagulation, gross observations, organ weights, and microscopic 
evaluation. There were no CCX168-related effects on clinical chemistry at termination or 
recovery. Serum AST, ALT, and sorbitol dehydrogenase were mildly increased in two females at 
100 mg/kg/day at termination. Given the magnitude and low incidence of these findings, they 
were considered incidental. In the monkey study, CCX168 was well tolerated at doses up to 30 
mg/kg/day. There were no CCX168-related changes in clinical observations, body weights, 
ophthalmic examinations, electrocardiographic examinations, blood pressure, and respiratory 
examinations, clinical pathology, gross observations, organ weights, and microscopic evaluation. 
Given the lack of significant safety concerns in the toxicology studies and the Phase 1 study in 
healthy volunteers, and the safety results from clinical trial CL002_168 in patients with AAV, 
the risk for serious or unanticipated untoward events to occur in this clinical trial is considered 
low. 
1.2.3. 
Non-Clinical ADME 
The pharmacokinetic behavior of CCX168 has been assessed in female CD-1 mice, male 
Sprague-Dawley rats, male beagle dogs, and male cynomolgus monkeys through intravenous 
(i.v.) and/or oral (p.o.) dosing and the data are summarized in Table 3. Following intravenous 
dosing, the compound has a moderate to medium total body clearance in mice, rats, and dogs 
(30 - 50% of liver blood flow). The terminal elimination half-life is moderate to long, at ca. 2 h 
in mice and rats, and 14.2 h in dogs, while the volume of distribution is moderate (1.5, 2.5, and 
4.7 L/kg for mice, rats and dogs, respectively). Following oral dosing in mice and rats, CCX168 
is readily absorbed, showing moderate bioavailability for the aqueous hydroxypropyl 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 32 of 72                                            17 July 2015 
methylcellulose (HPMC) suspension and high bioavailability for the PEG-400/Solutol HS-15 
solution.   
Table 3: Pharmacokinetic Parameters of CCX168 in CD-1 Mice, Sprague-Dawley Rats, 
Beagle Dogs, and Cynomolgus Monkeys after Administration of a Single Oral Gavage or 
an Intravenous Dose of CCX168 
a. Intravenous dosing 
Parameter 
Mouse 
Rat 
Dog 
dose (mg/kg) 
0.5 
0.5 
0.5 
Formulation 
Ethanol / N,N-
dimethylacetamide / 
propylene glycol / 
0.9% saline 
(10:10:30:75)  
N,N-
dimethylacetamide / 
ethanol / propylene 
glycol (31.6:36.8:31.6) 
propylene glycol / 
N,N-
dimethylacetamide / 
water (31.6/31.6/36.8) 
N = 
9 a 
2 
3 
CL [mL/min/kg] 
26.6 
21.2 
11.9 
t1/2 [h] 
1.8 
1.9 
14.2 
Vdss [L/kg] 
1.5 
1.8 
4.7 
a Non-serial blood sampling was used and a composite PK profile was obtained using the mean 
concentration at each time point 
b. Oral dosing 
Parameter 
Mouse 
Rat 
Monkey 
p.o. dose (mg/kg) 
2 
30 
2 
30 
100 
Formulation 
1% HPMC 
(suspension) 
PEG-
400/solutol 
HS-15 
(70:30) 
(solution) 
1% HPMC 
(suspension) 
PEG-
400/Solutol 
HS-15 
(70:30) 
(solution) 
PEG-400 / 
solutol HS-
15 (70:30) 
(solution) 
N = 
9 a 
9 a 
2 
3 
3 
Cmax [ng/mL] 
75 
4630 
152 
2530 
3500 
AUC [ng•h/mL] 
240 
18600 
464 
24600 
33300 
t1/2 [h] 
  
5.6 
2.3 
4.6 
6.0 
tmax [h] 
1.0 
1.0 
1.0 
1.5 
4.0 
F [%] 
17 
87 
27 
104 
- 
CCX168 displays moderate in vitro metabolic turnover in cryo-preserved mouse, rat, and dog 
hepatocytes and low to moderate turnover in human hepatocytes. This result generally correlates 
well with the observed in vivo clearance in mice, rats, and dogs and predicts a low to moderate 
clearance in humans. In vitro metabolism of CCX168 is primarily through monohydroxylation in 
a Non-serial blood sampling was used and a composite PK 
profile was obtained using the mean concentration at each 
time point. 
CL = total body clearance 
t½ = terminal half-life 
Vdss = volume of distribution at steady state 
i.v. = intravenous 
Tmax = time of peak concentration 
p.o. = oral 
F = bioavailability 
Cmax = maximum concentration 
AUC = area under the concentration-vs.-time curve 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 33 of 72                                            17 July 2015 
monkey and human hepatocytes and through monohydroxylation, dealkylation, and 
glucuronidation in rat and dog hepatocytes. A Phase I monohydroxylation metabolite, CCX168-
M1, was found to be a significant circulating metabolite in human volunteers in the Phase 1 
study. Its exposure was adequately covered in rats and cynomolgus monkeys in the toxicology 
studies that support the current Phase 2 clinical trial.    
The excretion pathways of CCX168 in animals were investigated in bile-duct cannulated 
Sprague-Dawley rats and intact cynomolgus monkeys. Neither CCX168 nor the metabolite 
CCX168-M1 is significantly excreted into urine or bile in rats or urine in cynomolgus monkeys.  
The compound is very highly protein bound in mouse, rat, dog, and human plasma, at 
approximately 99% or higher, with corresponding unbound fractions at approximately 1% or 
lower. CCX168 has a low metabolism-mediated drug-drug interaction potential as a perpetrator, 
as its inhibition against major human cytochrome P450 isoforms is minimal (negligible for 
CYP1A2, 2C9, 2C19, and 2D6, and CYP3A4) and it shows no CYP3A4 and CYP2B6 induction 
potential at 10 μM in a human hepatocyte cytochrome P450 assay. 
The ability of CCX168 or CCX168-M1 to inhibit the steroid-metabolizing enzymes 11β-HSD1 
and 11β-HSD2 was evaluated using suitable in vitro systems and both compounds were found to 
be inactive against these enzymes. CCX168 was also found to have no impact on the unbound 
concentration of prednisone and prednisolone in human plasma.  
Furthermore, neither CCX168 nor CCX168-M1 interferes with the antiproliferative effects of 
cyclophosphamide, which is known to require CYP-mediated conversion to an active metabolite. 
Therefore, CCX168 has low potential for interfering with the biological effects of either 
cyclophosphamide or corticosteroids. 
1.3. 
Prior Human Experience 
A Phase 1 study in 48 healthy volunteers has been completed. This is a randomized, double-
blind, placebo-controlled, two-period study in which subjects received either CCX168 or placebo 
(3:1 ratio) as a single dose in Period 1 and as multiple once daily or twice daily doses in Period 
2. Single doses of 1, 3, 10, 30, and 100 mg CCX168 were studied, 6 subjects in each dose cohort 
received CCX168 and 2 received placebo, except in cohort 1 in which 5 subjects received 
CCX168 and 3 received placebo. In Period 2, CCX168 doses of 1, 3, and 10 mg once daily for 7 
days, and 30 and 50 mg twice daily for 7 days, were studied.  
CCX168 appeared to be well tolerated by study subjects in this study. No serious adverse events 
or withdrawals due to adverse events have been observed. A summary of all the treatment-
emergent adverse events observed in the single-dose period and the multi-dose period of the 
study is provided in the Investigator’s Brochure. 
All adverse events in the single-dose period were mild except for one AE of injection site 
phlebitis in the 3 mg CCX168 group and one of WBC count decrease in the 1 mg group that 
were considered moderate in intensity. 
The most common AE reported in subjects receiving CCX168 in the multi-dose period was 
headache, reported in 21% of subjects receiving CCX168 compared to 18% in the placebo group. 
Diarrhoea (7% vs. 9% in placebo), dizziness (7% vs. 0% in placebo), lower abdominal pain (7% 
vs. 0% in placebo), nausea (7% vs. 0% in placebo), and oropharyngeal pain (7% vs. 9% in 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 34 of 72                                            17 July 2015 
placebo) were the other more commonly observed AEs. No clinically significant changes in 
laboratory parameters, vital signs, or ECG parameters were observed. In the multi-dose period of 
the study, a slight decrease in mean WBC and neutrophil count was observed in subjects 
receiving CCX168 compared to placebo. These WBC and neutrophil counts most often remained 
within the reference range, decreases were observed within 1 to 2 days after start of dosing, 
appeared to be most pronounced in subjects with baseline WBC and neutrophil counts at the 
higher end of the normal range, and did not appear to progressively worsen over the 7-day 
dosing period. These slight changes in WBC and neutrophil counts may be related to the 
pharmacology of CCX168 as a C5aR blocker.  
No clinically significant changes in laboratory parameters, vital signs, or ECG parameters were 
observed. Key pharmacokinetic results (mean, SD) from the single-dose period and the multiple 
dose period of clinical trial CL001_168 are provided in the Investigator’s Brochure.  
Following a single dose of 1-100 mg, mean exposures as measured by AUC0-inf ranged from 6.14 
to 2030 ng•hr/mL while Cmax ranged from 1.84 to 197 ng/mL. The apparent mean terminal half-
life ranged from 1.92 to 71.8 hr, while clearance ranged from 51.7 to 195 L/hr. 
Following administration at 1 to 10 mg CCX168 q.d. for 7 days, mean exposures as measured by 
AUC0-tau ranged from 8.72 to 104 ng•hr/mL on Day 1 and from 11.2 to 178 ng•hr/mL on Day 7, 
while Cmax ranged from 2.59 to 19.2 ng/mL on Day 1 and 2.86 to 31.4 ng/mL on Day 7.    
Following b.i.d. administration at 30 to 50 mg, mean exposures as measured by AUC0-tau ranged 
from 380 to 1400 ng•hr/mL on Day 1 and from 880 to 2340 ng•hr/mL on Day 7, while Cmax 
ranged from 97.2 to 423 ng/mL on Day 1 and 161 to 425 ng/mL on Day 7.  
CCX168 levels declined in a biphasic exponential manner, with a rapid distribution phase and an 
apparent mean plasma terminal t1/2 ranging from 12.2 to 162 hr following once daily 
administration.  
Repeat administration for seven days of CCX168 resulted in moderate accumulation (at 1 and 3 
mg q.d.) or high accumulation (10 mg q.d. or 30 – 50 mg b.i.d.) of CCX168, consistent with the 
observed terminal half-life in these dosing groups. After q.d. dosing, the exposure of CCX168 as 
measured by Cmax and AUC is approximately dose proportional in the 1 – 10 mg dose range. 
After b.i.d. dosing, the exposure increase of CCX168 statistically appears to be linearly 
proportional for 30 mg and 50 mg doses. Based on the measured trough concentrations, in 
general, CCX168 appeared to reach steady state after 3-4 days of dosing. 
Food effect was also investigated by comparing the Day 7 0-12h (fasted) and 12-24h (fed) 
parameters. No significant effects were seen in either dose group. 
CCX168-M1, a monohydroxylation metabolite of CCX168, was found to be a significant 
circulating metabolite in humans. Following 7 days of oral administration of CCX168 at 30 mg 
and 50 mg b.i.d., the AUC0-24 for CCX168-M1 was 1600 and 2340 ng•hr/mL, respectively. 
These values represent 85% and 52%, respectively, of the levels of CCX168 measured at those 
doses. Its exposure was adequately covered in rats and cynomolgus monkeys in the toxicology 
studies that support this Phase 2 clinical trial. 
In study CL001_168, pharmacodynamics assays indicated that a dose of 30 mg CCX168 twice 
daily was highly effective in blocking C5a-mediated upregulation of CD11b on circulating 
leukocytes obtained from these subjects.  


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 35 of 72                                            17 July 2015 
Clinical trial CL002_168 in patients with AAV is ongoing. This is a randomized, double-blind, 
placebo-controlled clinical trial being conducted in three sequential steps. A total of 26 subjects 
have been enrolled in the first two steps of this clinical trial. A summary of the safety and 
efficacy results, as well as the PK results from the first two steps are provided in the 
Investigator’s Brochure. 
Clinical trial CL003_168 in patients with AAV is being initiated in 2014. This is a randomized, 
double-blind, placebo-controlled trial in up to approximately 45 subjects.  
1.4. 
Rationale for the Study 
IgAN is reported as the most common glomerulonephritis worldwide. It is associated with a wide 
spectrum of disease severity and rate of progression of renal failure. The best well established 
risk factor of progressive loss of renal function from IgAN is the persistent presence of 
proteinuria > 1 g/day, with some studies suggesting that the persistence of even lower levels of 
proteinuria (> 500 mg/day) may be associated with worse prognosis. Other clinical and 
histologic factors have also been associated with a faster decline in renal function, although these 
are not as well documented.   
Despite the relative high prevalence of disease worldwide, there is a paucity of evidence-based 
therapy available for the treatment of IgAN. Current guidelines include initiating therapy of 
patients with hypertension and persistent proteinuria > 1 g/day with renin-angiotensin-
aldosterone system (RAAS) blockade with an ACE inhibitor or ARB to attain a level of 
proteinuria below that threshold.   
For patients who fail to attain a reduction of proteinuria to < 1 g/day, it is currently “suggested” 
that patients be treated with a course of glucocorticoids (KDIGO Clinical Practice Guideline for 
Glomerulonephritis, 2012). However this “suggestion” carries an evidence-based grade of 2C, 
given the “weakness” of the data supporting the efficacy of such therapy in altering long term 
outcomes of patients. In addition, the use of glucocorticoids for several months (e.g., 6 months in 
the “Pozzi” protocol; Pozzi et al., 1999) is associated with significant risk of adverse effects 
especially in the adult population. 
Therefore, patients with relatively modest degree of proteinuria and well preserved eGFR (or 
stable eGFR if the decline is attributable to other cause than IgAN) represent a large pool of 
patients with a perceived increased risk of GFR decline, but no established, safe and effective 
treatment.   
This patient population is ideal for a pilot study of CCX168. Phase 2 study data in patients with 
ANCA-associated vasculitis suggest a significant anti-proteinuric effect of CCX168 in the 
majority of treated patients (mean decrease of approximately 60% in urinary ACR over 12 weeks 
of treatment with CCX168). This treatment effect was observed in patients receiving CCX168 
plus glucocorticoids, but also in patients receiving CCX168 with no glucocorticoids.   
For patients with IgAN who have already demonstrated a decline in eGFR, more aggressive 
therapy with corticosteroids is warranted, and a delay in such treatment for the duration of the 
pilot study with a medication of unproven efficacy would be inappropriate at this early stage of 
clinical development. 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 36 of 72                                            17 July 2015 
A dose regimen of 30 mg CCX168 given twice daily is being tested in study CL002_168 in 
AAV and showed promising efficacy and a good safety profile. This dose regimen has been 
selected for this clinical trial in patients with IgAN. 
2. 
OBJECTIVES 
2.1. 
Primary Objective 
The primary safety objective of this study is to evaluate the safety and tolerability of CCX168 in 
subjects with IgAN on background supportive therapy with a maximally tolerated dose of RAAS 
blockade.  
The primary efficacy objective is to evaluate the efficacy of CCX168 based on an improvement 
in proteinuria. 
2.2. 
Secondary Objectives 
The secondary objectives of this study include assessment of: 
1. Change in albuminuria with CCX168 treatment;  
2. Change in renal function based on eGFR with CCX168 treatment; 
3. Change in hematuria with CCX168 treatment; 
4. Change in renal inflammatory activity based on urinary monocyte chemoattractant protein-1 
(MCP 1):creatinine ratio and urinary epidermal growth factor (EGF):MCP-1 ratio with 
CCX168 treatment; 
5. Change in serum IgA:plasma C3 ratio with CCX168 treatment;  
6. Changes in pharmacodynamic markers in plasma and urine with CCX168 treatment, e.g., 
C3a, C5a, properdin, and sC5b-9; 
7. Evaluation of the pharmacokinetic profile of CCX168 in subjects with IgAN. 
3. 
STUDY DESIGN 
This is a pilot study to test the safety, tolerability, and efficacy of CCX168 in reducing 
proteinuria in patients with IgAN and persistent proteinuria despite supportive therapy with a 
maximally tolerated RAAS blocker. 
Patients will be screened for enrolment based on biopsy proven IgAN, and documentation of 
proteinuria > 1 g/g creatinine (by first morning urinary protein:creatinine). The screening period 
will be up to 14 days. Screening procedures will include demographics, medical history, 
medication history, physical examination and vital signs, serum pregnancy test for women of 
childbearing potential, serum chemistry, hematology, urinalysis, viral screening, and estimated 
glomerular filtration rate (eGFR) assessment. To be eligible for study participation, a patient 
must have had a renal biopsy in the past 3 years confirming the diagnosis of IgAN. If not done, a 
renal biopsy needs to be done for eligibility assessment. Patients meeting inclusion and exclusion 
criteria will be enrolled for blood pressure/RAAS blockade titration and run-in period. 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 37 of 72                                            17 July 2015 
At screening, patients should ideally be on one or two RAAS blocker(s) and have BP <140/90 
mmHg. Patients not on an RAAS blocker can be started, and have the medication dose adjusted 
to a maximally tolerated dose (MTD) within a period not to exceed 4 weeks.  
MTD for RAAS blockade is defined as: 
• a dose attaining a target blood pressure less than 125/75 mmHg, or  
• the maximum recommended dose (according to the label of the RAAS blocker), or  
• the maximum dose tolerated by the subject from a safety/tolerability perspective. 
If the blood pressure target of <125/75 mmHg is not achieved during the titration period, 
additional anti-hypertension medication (non-ACE-I or ARBs) should be considered to achieve 
this blood pressure goal. All patients must participate in an 8-week run-in period during which 
they must be on a stable, MTD of an RAAS blocker before starting treatment with CCX168 on 
Day 1. If a patient is on two RAAS blockers (any combination of ACE inhibitor, ARB, and 
aldosterone blocker) at the time of screening, the patient must remain on stable doses of these 
medications throughout the 8-week run-in period. Titration to an MTD for both RAAS blockers 
is not needed in this case if the blood pressure goal has been achieved. 
After the 8-week run-in period has been completed, two back-to-back first morning urine 
collections need to be obtained for protein and creatinine measurements. The geometric mean of 
the two urinary PCR measurements must be > 1 g/g creatinine for eligibility for further study 
participation.  
On Day 1, patients meeting inclusion criteria will start CCX168 treatment. Patients will take 
CCX168 30 mg orally twice daily for 12 weeks (84 days). The CCX168 dose will be taken in the 
morning optimally within one hour after breakfast and in the evening optimally within one hour 
after dinner. After the 84-day treatment period, patients will be followed for 12 weeks (84 days) 
while continuing to take their RAAS blocker treatment at a stable dose. 
At post-Day 1 study visits, blood and urine samples will be collected for safety, efficacy, and 
pharmacokinetic measurements. A serum pregnancy test for women of childbearing potential 
will be done on Days 29, 43, 57, 85, 113, and 169. Physical examinations and vital signs 
assessments will be performed throughout the study. Concomitant medication and adverse event 
assessments will be made at every study visit. An optional renal biopsy could be performed after 
the 12-week treatment period to assess the effect of CCX168 treatment on kidney histology. 
During the 12-week treatment period and the 12-week follow-up period, the dose(s) of RAAS 
blocker(s) must remain unchanged. No new RAAS blocker or non-dihydropyridine calcium 
channel blocker or diuretic may be added during the study period (active treatment period or 
follow up).   
During the treatment period with study medication and the 12 weeks of follow up thereafter, no 
new immunomodulatory medication may be started including, but not limited to cyclosporine, 
tacrolimus, mycophenolate mofetil, azathioprine, cyclophosphamide, or glucocorticoids (e.g. 
prednisone).   
Concomitant use of omega-3 fatty acid supplements (e.g., fish oil) is permitted IF the medication 
is started at the time of, or before screening, and is maintained at a stable dose during the rest of 
the study until the end of the follow-up period (Day 169).  


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 38 of 72                                            17 July 2015 
Patients will visit the study center on Days 1, 8, 15, 29, 43, 57, 85, 113, 141, and 169 for the 
treatment and follow-up period. 
Duration of treatment with study medicine: 84 days 
Duration of follow up after end of treatment with study medicine: 84 days 
Subjects who experience a decrease in eGFR from baseline of > 10 mL/min/1.73 m2 or > 20% 
(confirmed by repeat after 2 weeks), which is otherwise not explained (e.g., dehydration, new 
medication), or an increase in proteinuria by > 3 g/g creatinine from baseline or to a level > 8 g/g 
(confirmed by repeat after 2 weeks) during the 12-week treatment period, will exit the treatment 
phase of the study and be treated at the discretion of their primary nephrologist. They will remain 
in the study for follow up and outcome recording. 
The cumulative safety data from the study will be reviewed in near real time by the Sponsor’s 
Medical Monitor.   
Subjects will be discharged from the study when all the Study Day 169 visit procedures have 
been completed. The subject’s condition will be evaluated by the Investigator at the end of the 
clinical trial (Day 169). Appropriate standard of care medical treatment will be implemented to 
all subjects as determined by their primary nephrologist. 
To the extent possible, any adverse events that are deemed study drug-related and are ongoing at 
discharge will be followed-up to resolution or until a determination is made that the unresolved 
event is stable. 
4. 
STUDY POPULATION 
4.1. 
Size of the Population 
Up to approximately 20 male or female subjects with IgAN will be enrolled in this study. 
Subjects who started the CCX168 treatment period and drop out prematurely will not be 
replaced. However, subjects who drop out during the titration and run-in periods may be 
replaced. 
4.2. 
Inclusion Criteria 
Subjects must meet all of the following inclusion criteria in order to enter the study: 
1. Biopsy-proven IgAN performed for clinical purposes within 3 years prior to screening; 
2. eGFR >60 mL/min/1.73 m2 (by MDRD equation) OR eGFR >45 mL/min/1.73 m2 if eGFR 
has not declined > 10 mL/min/1.73 m2 over the previous 24 weeks; 
3. Proteinuria, defined as first morning urinary PCR > 1 g/g creatinine; 
4. Male or female subjects, aged at least 18 years; Where allowed by local regulations, female 
subjects of childbearing potential may participate if adequate contraception is used during, 
and for at least the three months after study completion; Male subjects with partners of 
childbearing potential may participate in the study if they had a vasectomy at least 6 months 
prior to randomization or if adequate contraception is used during, and for at least the three 
months after study completion; Adequate contraception is defined as resulting in a failure 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 39 of 72                                            17 July 2015 
rate of less than 1% per year (combined estrogen and progestogen [oral, intravaginal, or 
transdermal], or progestogen-only hormonal contraception (oral, injectable, or implantable), 
intra-uterine device, intra-uterine hormone releasing system, bilateral tubal occlusion, 
vasectomized partner, or sexual abstinence); 
5. Willing and able to give written Informed Consent and to comply with the requirements of 
the study protocol; and 
6. Judged to be otherwise healthy by the Investigator, based on medical history, physical 
examination, and clinical laboratory assessments. Subjects with clinical laboratory values 
that are outside of normal limits (other than those specified in the Exclusion Criteria) and/or 
with other abnormal clinical findings that are judged by the Investigator not to be of clinical 
significance, may be entered into the study. 
4.3. 
Exclusion Criteria 
1. Severe renal disease as determined by rapid decline in eGFR (defined as >10 mL/min/1.73 
m2 over 24 weeks prior to screening, not otherwise explained);  
2. Pregnant or nursing; 
3. Proteinuria > 8 g/day (or >8 g/g creatinine); 
4. Patients with systemic manifestations of Henoch-Schönlein purpura within the last 2 years 
prior to screening; 
5. Patients with IgAN deemed secondary to underlying disease: e.g., diabetes, liver disease, 
cirrhosis, celiac disease, HIV, inflammatory bowel disease, lymphoma, or associated with 
any other multi-system autoimmune disease; 
6. Biopsy report demonstrating severe crescentic IgAN (>25% crescents), OR >50% interstitial 
fibrosis and/or tubular atrophy ("T2") (Cattran et al. 2009), OR a high likelihood of rapid 
decline in eGFR based on an MEST ("Oxford") classification (M = mesangial 
hypercellularity; E = endocapillary proliferation; S = segmental glomerulosclerosis/adhesion; 
T = tubular atrophy/interstitial fibrosis) score of M1, E0, T1, or M0/1, E1, T1 (Cattran et al. 
2009); 
7. History of treatment with glucocorticoids, cyclophosphamide, azathioprine,  mycophenolate 
mofetil, or any biologic immunomodulatory agent within the 24 weeks prior to screening;  
8. Symptomatic congestive heart failure requiring prescription medication, clinically evident 
peripheral edema of cardiac origin, poorly-controlled hypertension (systolic blood pressure 
>160 or diastolic blood pressure >95), history of unstable angina, myocardial infarction or 
stroke within 6 months prior to screening; 
9. History or presence of any form of cancer within the 5 years prior to screening, with the 
exception of excised basal cell or squamous cell carcinoma of the skin, or cervical carcinoma 
in situ or breast carcinoma in situ that has been excised or resected completely and is without 
evidence of local recurrence or metastasis; 
10. Positive HBV, HCV, or HIV viral screening test; 
11. History of tuberculosis; 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 40 of 72                                            17 July 2015 
12. Any infection requiring antibiotic treatment that has not cleared prior to starting CCX168 
treatment on Day 1; 
13. WBC count less than 4000/μL, or neutrophil count less than 2000/μL, or lymphocyte count 
less than 1000/μL; 
14. Hemoglobin less than 9 g/dL (or 5.56 mmol/L) at screening; 
15. Evidence of hepatic disease; AST, ALT, alkaline phosphatase, or bilirubin > 3 x the upper 
limit of normal; 
16. Participated in any clinical study of an investigational product within 30 days prior to 
screening or within 5 half-lives after taking the last dose; and 
17. History or presence of any medical condition or disease which, in the opinion of the 
Investigator, may place the subject at unacceptable risk for study participation. 
4.4. 
Removal of Subjects from Therapy or Assessment 
Subjects may be terminated early from the study for any of the following reasons: 
1. Subject request:  Subjects may withdraw their consent to participate in the study at any time 
without prejudice.   
2. Investigator request:  The Investigator may withdraw a subject if, in his/her clinical 
judgment, it is in the best interest of the subject or if the subject cannot comply with the 
protocol.   
3. Sponsor request. 
In the event of withdrawal from the study prior to the Day 85 visit, the tests and evaluations 
listed for Study Day 85 should be carried out as part of the Early Termination visit, whenever 
possible. For subjects who withdraw after Day 85, the Day 169 study procedures should be 
performed. The Sponsor should be notified of all study withdrawals in a timely manner. 
Subjects who experience a decrease from baseline in eGFR > 10 mL/min/1.73 m2 or > 20%, 
(confirmed by repeat after 2 weeks) which is otherwise not explained (e.g., dehydration, new 
medication), or an increase in proteinuria of > 3 g/g creatinine from baseline or to a level > 8 g/g 
(confirmed by repeat after 2 weeks) during the 12-week treatment period, will exit the treatment 
phase of the study and be treated at the discretion of their primary nephrologist. They will remain 
in the study for follow up and outcome recording. 
In the event of treatment failure where rescue treatment such as corticosteroid therapy is needed, 
the study drug (CCX168) will be discontinued, and appropriate SOC measures will be taken. 
However, the subject will be asked to remain in the study and complete all remaining study 
visits. If this is not possible, an attempt will be made to complete all procedures scheduled for 
the Day 85 visit (if the rescue event occurred prior to the Day 85 visit) and Day 169 (if the rescue 
event occurred after the Day 85 visit). 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 41 of 72                                            17 July 2015 
5. 
STUDY MEDICATION/TREATMENT 
5.1. 
Product Characteristics 
CCX168 will be administered as hard gelatin capsules containing 10 mg CCX168. The capsules 
are manufactured under cGMP. All doses of study medication will be administered orally. The 
CCX168 capsules will be supplied to the study centers in plastic bottles containing 30 capsules.  
5.2. 
Randomization and Method of Treatment Assignment 
Eligible subjects will all receive CCX168 30 mg twice daily for 84 days. There will not be any 
randomization or stratification.   
5.3. 
Doses and Regimens 
After the screening period, eligible subjects will fall into two categories: 
1. Those who are already on a maximum tolerated dose (MTD) of a RAAS blocker such as an 
ACE-I or an ARB, or on a stable dose of two RAAS blockers must complete an 8-week run-
in period. During this run-in period, subjects must continue to take their RAAS blocker(s) at 
a stable dose(s) before entering the 12-week CCX168 treatment period. 
2. Those who are NOT already on a RAAS blocker, or who are not on a MTD of a RAAS 
blocker must complete a dose-titration period not to exceed 4 weeks, during which time the 
dose of the RAAS blocker will be titrated up to the MTD. After this titration period, all 
subjects must complete an 8-week run-in period. During this run-in period, subjects must 
continue to take their RAAS blocker at a stable MTD before entering the 12-week CCX168 
treatment period. 
MTD for RAAS blockade is defined as: 
• a dose attaining a target blood pressure less than 125/75 mmHg, or  
• the maximum recommended dose (according to the label of the RAAS blocker), or  
• the maximum dose tolerated by the subject from a safety/tolerability perspective. 
The blood pressure goal is <125/75 mmHg. If this target is not achieved during the titration 
period, additional anti-hypertension medication (non-ACE-I or ARBs) should be considered to 
achieve this blood pressure goal. After the 8-week run-in period, all eligible subjects (based on 
urinary PCR) will receive CCX168 30 mg twice daily for 84 days. 
All subjects will take study medication as instructed on the days of visits to the study center. For 
the other study days, study medication will be taken at home as instructed. Following the 84-day 
dosing period, there will be an 84-day follow-up period.   
Subjects will receive two bottles of CCX168 capsules on Day 1 and Day 8, respectively, four 
bottles on Days 15, 29, and 43, respectively, and six bottles on Day 57. 
Subjects will be asked to take 3 capsules every morning and 3 capsules every evening, 
approximately 12 hours after the morning dose, as instructed. Study medication should be taken 
optimally within 1 hour after breakfast in the morning and optimally within 1 hour after dinner in 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 42 of 72                                            17 July 2015 
the evening for 84 days continuously. Capsules will be taken with water, preferably with 50 mL 
(~one fifth of a cup), but not to exceed 100 mL (~one half cup). 
5.4. 
Rationale for Dose Selection 
Single doses of 1 mg up to 100 mg CCX168 were studied in a Phase 1 study (CL001_168) in 48 
healthy volunteers, and multiple once daily doses of 1, 3, and 10 mg CCX168 and multiple twice 
daily doses of 30 mg and 50 mg for up to 7 days were studied in the multiple dose period of the 
study. All doses up to 100 mg (single dose) and 50 mg twice daily for 7 days were well tolerated 
with no significant safety concerns. A dose of 30 mg CCX168 twice daily has been tested in 
study CL002_168 in patients with AAV and showed promising efficacy, particularly with 
regards to albuminuria. Therefore, this dose regimen has been selected for this Phase 2 study in 
patients with IgAN. At steady state, this dose regimen is anticipated to provide at least 90% 
C5aR coverage on circulating leukocytes continuously throughout the day. It is anticipated that 
this CCX168 dose regimen would be well tolerated in patients with IgAN.   
Based on the good safety profile observed in the toxicology studies, and the safety and 
tolerability results from the Phase 1 clinical trial CL001_168 and Phase 2 clinical trial 
CL002_168, the risk for serious or unanticipated untoward events associated with CCX168 
occurring in this clinical trial is considered low. 
5.5. 
Drug Supply 
5.5.1. 
Packaging and Labeling 
CCX168 capsules containing 10 mg CCX168 will be packaged in high density polyethylene 
(HDPE) bottles with child-resistant screw caps and provided to the study sites. Each bottle will 
contain 30 capsules. All bottles will be labeled appropriately to indicate, at a minimum, protocol 
number, the bottle number, the study drug, the contents, storage conditions, cautionary statement 
to keep out of reach of children, and the expiry date. 
5.5.2. 
Storage 
CCX168 capsules will be stored according to label instructions. Access should be restricted to 
pharmacy staff or to the designated responsible member of the Investigator’s staff, and to the 
study monitor. The Investigator agrees that neither s/he nor any of the study staff will supply 
study medication to any persons other than those enrolled in the study.   
5.6. 
Blinding 
This is an open-label study.   
5.7. 
Drug Accountability 
The study pharmacist and investigator must maintain accurate records of dates and quantities of 
product(s) received, to whom dispensed (subject-by-subject accounting), and accounts of any 
product accidentally or deliberately destroyed. The Investigator must retain all unused and/or 
expired study supplies until the study monitor has confirmed the accountability data.  


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 43 of 72                                            17 July 2015 
5.8. 
Treatment Compliance 
The CCX168 capsules will be self-administered by participating study subjects. The morning 
dose of study drug on Day 1 will be taken in the presence of study site personnel. Subjects will 
be provided with dosing instructions at the start of the study, and will be encouraged by study 
site personnel to take the study medication according to the instructions for the duration of the 
study. Subjects will be instructed to bring the assigned bottles of study medication to the site 
staff at each study visit, whether empty or not. The study drug dispensed will be checked for any 
unused study drug, and a dose unit count will be done of any remaining CCX168 capsules. This 
information will be recorded in the EDC.  
Any events of non-compliance to the protocol will be documented in the study records. 
5.9. 
Concomitant Medications and Restrictions 
Use of any drug other than protocol-specified CCX168 and RAAS blocker(s) for treatment of 
IgAN is prohibited over the course of the 84-day treatment period. This includes use of 
glucocorticoids, cyclophosphamide, azathioprine, mycophenolate mofetil, or any biologic 
immunomodulatory agent. Concomitant use of omega-3 fatty acid supplements (e.g., fish oil) is 
permitted IF the medication is started at the time of, or before screening, and is maintained at a 
stable dose during the rest of the study until the end of the follow-up period (Day 169). 
Subjects will also be encouraged to remain on stable doses of all other concomitant medication 
over the course of the study, including diuretics and other anti-hypertension treatment. 
All concomitant medications taken during the course of the study must be recorded on the 
concomitant medication pages of the CRF. 
Subjects will also be advised to maintain their usual dietary and exercise patterns over the course 
of the clinical trial. 
6. 
STUDY PROCEDURES  
6.1. 
Screening and Enrollment 
Informed Consent must be obtained prior to performance of any study-specific tests or 
evaluations. Within a period not to exceed 14 days prior to randomization, subjects will undergo 
the following evaluations to determine their eligibility for study participation:  
• Ensure that subject has a biopsy report showing IgA nephropathy from a renal biopsy 
conducted within the prior 3 years; If a patient does not have a renal biopsy in the past 3 
years to confirm the diagnosis of IgAN, a renal biopsy needs to be done for eligibility 
assessment; 
• Demographics, medical history, and prior (within 6 months) and concomitant medication 
usage; 
• A physical examination (excluding genitourinary, ophthalmic, and female breast 
assessments) will be performed; body weight, height, and body mass index will be 
determined; 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 44 of 72                                            17 July 2015 
• Vital signs (temperature, blood pressure, heart rate) will be measured supine after at least 
3 minutes of rest; 
• Serum pregnancy test for women of childbearing potential; 
• Virology screening, including HIV, HBV, and HCV screening; 
• Blood chemistry and hematology; An eGFR will be calculated for eligibility assessment 
based on the following Modification of Diet in Renal Disease (MDRD) study equation: 
− eGFR (mL/min/1.73 m2) = 175 x (serum creatinine in mg/dL)-1.154 x (Age)-0.203 x 
(0.742 if female) x (1.212 if African-American/Black); 
• Urinalysis, including pH, specific gravity, glucose, nitrite, ketones, bilirubin, 
urobilinogen, RBCs, and WBCs;  
• Urinary protein and creatinine measurement on a first morning urine sample collection; 
• After all screening procedures have been completed, and the subject satisfies all 
eligibility criteria, the study schedule will be discussed with the subject and the schedule 
will be provided to the subject to ensure compliance with the study visits. 
6.2. 
Titration Period 
There are three categories of potentially eligible subjects at the end of the screening period: 
1. Subjects who are currently receiving a RAAS blocker, such as an ACE-I or ARB, but not at 
the MTD; these subjects need to participate in this titration period.  
2. Subjects who are not currently receiving any RAAS blocker; these subjects need to 
participate in this titration period. 
3. Subjects who are currently receiving a single RAAS blocker at the MTD, or subjects who are 
currently receiving two RAAS blockers, not necessarily at the MTD; these subjects do not 
need to participate in the titration period. 
MTD for RAAS blockade is defined as: 
• a dose attaining a target blood pressure less than 125/75 mmHg, or  
• the maximum recommended dose (according to the label of the RAAS blocker), or  
• the maximum dose tolerated by the subject from a safety/tolerability perspective. 
The titration period can last up to 4 weeks. During this period, the dose of the RAAS blocker will 
be titrated up to the MTD. The blood pressure treatment target for eligible subjects (with urinary 
PCR >1 g/g during the screening period) is less than 125/75 mmHg (KDIGO Clinical Practice 
Guideline for Glomerulonephritis, 2012). As soon as the MTD is reached, subjects will be 
eligible to enter the run-in period. If this target is not achieved during the titration period, 
additional anti-hypertension medication (non-ACE-I or ARBs) should be considered to achieve 
this blood pressure goal.   


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 45 of 72                                            17 July 2015 
6.3. 
Run-In Period 
After the titration period, all subjects will enter the run-in period. During thus 8-week period, all 
subjects will remain on a stable MTD (if they are on a single RAAS blocker), or stable doses (if 
they are on two RAAS blockers). The following study visits and procedures will be performed 
during the 8-week run-in period. 
6.3.1. 
Study Day -63 
The following study procedures will be performed on Day -63: 
• Blood pressure in the supine position after at least 3 minutes of rest; 
• Serum creatinine for an eGFR calculation; 
• First morning urinary protein and creatinine measurements for a PCR calculation; 
• First morning urinary albumin, MCP-1, EGF, and microscopic RBC count for ACR, 
MCP-1:creatinine, EGF:MCP-1 ratio, and hematuria assessment; 
• Recording of changes in concomitant medication; 
• Recording of all adverse events;  
• The subjects will be reminded to stay on a stable dose(s) or their RAAS blocker(s), and to 
come back to the study center for their Study Day -35 visit. 
6.3.2. 
Study Day -35 
This visit may occur within a +/- 7 day window, relative to Study Day -63. The following 
procedures will be performed on Day -35: 
• Blood pressure in the supine position after at least 3 minutes of rest; 
• Serum creatinine for an eGFR calculation; 
• First morning urinary protein and creatinine measurements for a PCR calculation; 
• First morning urinary albumin, MCP-1, EGF, and microscopic RBC count for ACR, 
MCP-1:creatinine, EGF:MCP-1 ratio, and hematuria assessment; 
• Recording of changes in concomitant medication; 
• Recording of all adverse events; 
• The subjects will be reminded to stay on a stable dose(s) or their RAAS blocker(s), and to 
come back to the study center for two back-to-back study visits in the Day -7 to -2 
window. 
6.3.3. 
Study Day -7 to -2 Window 
Two back-to-back study visits will occur within the Study Day -7 to -2 window, relative to Study 
Day -63. The following procedures will be performed on these two study days: 
• Blood pressure in the supine position after at least 3 minutes of rest (on both days); 
• Serum pregnancy test for women of child-bearing potential (on the first of the two days); 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 46 of 72                                            17 July 2015 
• Serum creatinine for an eGFR calculation (on the first of the two days); 
• First morning urinary protein and creatinine measurements for a PCR calculation (on 
both days); 
• First morning urinary albumin, MCP-1, EGF, and microscopic RBC count for ACR, 
MCP-1:creatinine, EGF:MCP-1 ratio, and hematuria assessment (on the first of the two 
days); 
• Recording of changes in concomitant medication; 
• Recording of all adverse events; 
• If the subject is still eligible for study continuation, i.e.: 
− If the geometric mean of the two first morning urinary PCR levels is still > 1 g/g 
creatinine but ≤ 8 g/g creatinine,  
− If the subject’s eGFR has not deteriorated >10 mL/min/1.73 m2 over the prior 8-week 
run-in period, 
the subject will come for their Study Day 1 visit. The subjects will be reminded to stay on 
a stable dose(s) or their RAAS blocker(s). If a subject is not eligible at this stage, the 
subject will be discontinued from study. 
6.4. 
Study Day 1 
If eligible for continuation in the study, the subject will visit the study center on Day 1 for the 
following procedures: 
• A physical examination (excluding genitourinary, ophthalmic, and female breast 
assessments); body weight assessment will be performed; 
• Vital signs (temperature, blood pressure, heart rate) will be measured supine after at least 
3 minutes of rest; 
• Serum chemistry and hematology; an eGFR will be calculated based on MDRD equation; 
• Urinalysis, including pH, specific gravity, glucose, nitrite, ketones, bilirubin, 
urobilinogen, RBCs, and WBCs on a first morning urine sample collection;  
• Urinary protein, creatinine, albumin, MCP-1, EGF, and microscopic RBC count on a first 
morning urine sample collection;  
• Serum IgA and plasma C3 measurement; 
• A plasma sample will be collected for baseline PD marker and PK measurement; 
• A urine sample will collected for PD marker assessment; 
• Any changes in concomitant medication use will be recorded; 
Note that the above listed procedures must be performed prior to taking study medication. 
• Two bottles of CCX168 study medication will be dispensed to the subject, with dosing 
instructions; 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 47 of 72                                            17 July 2015 
• The subject will be asked to take the first dose of study medication, 3 x 10 mg CCX168 
capsules, while at the study center; the time of dosing will be recorded;  
• Blood samples will be collected at 0.5, 1, 2, 3, 4, and 6 hours following CCX168 dosing 
for plasma CCX168 concentration measurements; the actual time of each blood sample 
collection will be recorded; 
• Any post-dosing adverse events will be recorded;  
• After all study procedures have been completed, the subject will be reminded to: 
− Come to the study center for the Day 8 study visit with their first morning urine 
sample; 
− Store the study medications in a cool and dry place according to label instructions for 
the duration of the study;  
− Take the CCX168 medication every morning and in the evening approximately 12 
hours after the morning dose;  
− Not to take CCX168 medication on the morning of Day 8, unless the visit is 
scheduled in the afternoon, in which case CCX168 medication should be taken the 
morning of Day 8;  
− To bring all study medication bottles, whether empty or not, when s/he comes back 
for the next study visit, and 
− Continue taking their RAAS blocker(s) at a stable dose, and all their other 
concomitant medications as usual. 
6.5. 
Study Day 8 
The Study Day 8 visit must occur on the scheduled date. The subject will visit the study center 
on Day 8 for the following procedures: 
• Vital signs (temperature, blood pressure, heart rate) will be measured supine after at least 
3 minutes of rest; 
• Serum chemistry and hematology; an eGFR will be calculated; 
• Urinalysis, including pH, specific gravity, glucose, nitrite, ketones, bilirubin, 
urobilinogen, RBCs, and WBCs on a first morning urine sample collection;  
• Urinary protein, creatinine, albumin, MCP-1, EGF, and microscopic RBC count on a first 
morning urine sample collection;  
• Plasma samples will be collected for PD marker and PK assessment; the time of sample 
collection as well as the date and time of the last dose of CCX168 prior to sample 
collection will be recorded; 
• A urine sample will collected for PD marker assessment; 
• Any changes in concomitant medication use will be recorded; 
• Study drug accountability will be performed on all returned study medication; 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 48 of 72                                            17 July 2015 
• Two bottles of CCX168 study medication will be dispensed to the subject, with dosing 
instructions; 
• The subject will be asked to take the dose of study medication, 3 x 10 mg CCX168 
capsules, while at the study center, unless the medication has already been taken that 
morning; the time of dosing will be recorded;  
• All adverse events will be recorded;  
• After all study procedures have been completed, the subject will be reminded to: 
− Come to the study center for the Day 15 study visit with their first morning urine 
sample; 
− Store the study medications in a cool and dry place according to label instructions for 
the duration of the study;  
− Take the CCX168 medication every morning and evening, approximately 12 hours 
after the morning dose;  
− Not to take CCX168 medication on the morning of Day 15, unless the visit is 
scheduled in the afternoon, in which case CCX168 medication should be taken the 
morning of Day 15; and 
− Continue taking their RAAS blocker(s) at a stable dose, and all their other 
concomitant medications as usual. 
6.6. 
Study Day 15 
The Study Day 15 visit must occur on the scheduled date. During this visit, the following study 
procedures will be performed: 
• Vital signs (temperature, blood pressure, heart rate) will be measured supine after at least 
3 minutes of rest; 
• Serum chemistry and hematology; an eGFR will be calculated; 
• Urinalysis, including pH, specific gravity, glucose, nitrite, ketones, bilirubin, 
urobilinogen, RBCs, and WBCs on a first morning urine sample collection;  
• Urinary protein, creatinine, albumin, MCP-1, EGF, and microscopic RBC count on a first 
morning urine sample collection;  
• Plasma samples will be collected for PD marker and PK assessment; the time of sample 
collection as well as the date and time of the last dose of CCX168 prior to sample 
collection will be recorded; 
• A urine sample will collected for PD marker assessment; 
• Any changes in concomitant medication use will be recorded; 
• Study drug accountability will be performed on all returned study medication; 
• Four bottles of CCX168 study medication will be dispensed to the subject, with dosing 
instructions; 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 49 of 72                                            17 July 2015 
• The subject will be asked to take the dose of study medication, 3 x 10 mg CCX168 
capsules, while at the study center, unless the medication has already been taken that 
morning; the time of dosing will be recorded;  
• All adverse events will be recorded;  
• After all study procedures have been completed, the subject will be reminded to: 
− Come to the study center for the Day 29 study visit with their first morning urine 
sample; 
− Store the study medications in a cool and dry place according to label instructions for 
the duration of the study;  
− Take the CCX168 medication every morning and evening, approximately 12 hours 
after the morning dose;  
− Not to take CCX168 medication on the morning of Day 29, unless the visit is 
scheduled in the afternoon, in which case CCX168 medication should be taken the 
morning of Day 29; and 
− Continue taking their RAAS blocker(s) at a stable dose, and all their other 
concomitant medications as usual. 
6.7. 
Study Day 29 
The Study Day 29 visit may occur within ± a 2-day window of the scheduled date. During this 
visit, the following study procedures will be performed: 
• A physical examination (excluding genitourinary, ophthalmic, and female breast 
assessments) will be performed; body weight and body mass index will be determined; 
• Vital signs (temperature, blood pressure, heart rate) will be measured supine after at least 
3 minutes of rest; 
• Serum pregnancy test for women of childbearing potential; 
• Serum chemistry and hematology; an eGFR will be calculated; 
• Urinalysis, including pH, specific gravity, glucose, nitrite, ketones, bilirubin, 
urobilinogen, RBCs, and WBCs on a first morning urine sample collection;  
• Urinary protein, creatinine, albumin, MCP-1, EGF, and microscopic RBC count on a first 
morning urine sample collection;  
• A blood sample will be collected for IgA and C3 measurements; 
• Plasma samples will be collected for PD marker and PK assessment; the time of sample 
collection as well as the date and time of the last dose of CCX168 prior to sample 
collection will be recorded; 
• A urine sample will collected for PD marker assessment; 
• Any changes in concomitant medication use will be recorded; 
• Study drug accountability will be performed on all returned study medication; 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 50 of 72                                            17 July 2015 
• Four bottles of CCX168 study medication will be dispensed to the subject, with dosing 
instructions; 
• The subject will be asked to take the dose of study medication, 3 x 10 mg CCX168 
capsules, while at the study center, unless the medication has already been taken that 
morning; the time of dosing will be recorded; 
• All adverse events will be recorded;  
• After all study procedures have been completed, the subject will be reminded to: 
− Store the study medications in a cool and dry place according to label instructions for 
the duration of the study;  
− Take the CCX168 medication every morning and evening, approximately 12 hours 
after the morning dose;  
− Not to take CCX168 medication on the morning of Day 43, unless the visit is 
scheduled in the afternoon, in which case CCX168 medication should be taken the 
morning of Day 43; and 
− Continue taking their RAAS blocker(s) at a stable dose, and all their other 
concomitant medications as usual. 
6.8. 
Study Day 43 
The Study Day 43 visit may occur within ± a 2-day window of the scheduled date. During this 
visit, the following study procedures will be performed: 
• A physical examination (excluding genitourinary, ophthalmic, and female breast 
assessments) will be performed; body weight and body mass index will be determined; 
• Vital signs (temperature, blood pressure, heart rate) will be measured supine after at least 
3 minutes of rest; 
• Serum pregnancy test for women of childbearing potential; 
• Serum chemistry and hematology; an eGFR will be calculated; 
• Urinalysis, including pH, specific gravity, glucose, nitrite, ketones, bilirubin, 
urobilinogen, RBCs, and WBCs on a first morning urine sample collection;  
• A plasma sample will be collected for PK assessment; the time of sample collection as 
well as the date and time of the last dose of CCX168 prior to sample collection will be 
recorded; 
• Any changes in concomitant medication use will be recorded; 
• Study drug accountability will be performed on all returned study medication; 
• Four bottles of CCX168 study medication will be dispensed to the subject, with dosing 
instructions; 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 51 of 72                                            17 July 2015 
• The subject will be asked to take the dose of study medication, 3 x 10 mg CCX168 
capsules, while at the study center, unless the medication has already been taken that 
morning; the time of dosing will be recorded; 
• All adverse events will be recorded;  
• After all study procedures have been completed, the subject will be reminded to: 
− Come to the study center for the Day 57 study visit with their first morning urine 
sample; 
− Store the study medications in a cool and dry place according to label instructions for 
the duration of the study;  
− Take the CCX168 medication every morning and evening, approximately 12 hours 
after the morning dose;  
− Not to take CCX168 medication on the morning of Day 57, unless the visit is 
scheduled in the afternoon, in which case CCX168 medication should be taken the 
morning of Day 57; and 
− Continue taking their RAAS blocker(s) at a stable dose, and all their other 
concomitant medications as usual. 
6.9. 
Study Day 57 
The Study Day 57 visit may occur within ± a 2-day window of the scheduled date. During this 
visit, the following study procedures will be performed: 
• A physical examination (excluding genitourinary, ophthalmic, and female breast 
assessments) will be performed; body weight and body mass index will be determined; 
• Vital signs (temperature, blood pressure, heart rate) will be measured supine after at least 
3 minutes of rest; 
• Serum pregnancy test for women of childbearing potential; 
• Serum chemistry and hematology; an eGFR will be calculated; 
• Urinalysis, including pH, specific gravity, glucose, nitrite, ketones, bilirubin, 
urobilinogen, RBCs, and WBCs on a first morning urine sample collection;  
• Urinary protein, creatinine, albumin, MCP-1, EGF, and microscopic RBC count on a first 
morning urine sample collection;  
• A blood sample will be collected for IgA and C3 measurements; 
• Plasma samples will be collected for PD marker and PK assessment; the time of sample 
collection as well as the date and time of the last dose of CCX168 prior to sample 
collection will be recorded; 
• A urine sample will collected for PD marker assessment; 
• Any changes in concomitant medication use will be recorded; 
• Study drug accountability will be performed on all returned study medication; 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 52 of 72                                            17 July 2015 
• Six bottles of CCX168 study medication will be dispensed to the subject, with dosing 
instructions; 
• The subject will be asked to take the dose of study medication, 3 x 10 mg CCX168 
capsules, while at the study center, unless the medication has already been taken that 
morning; the time of dosing will be recorded; 
• All adverse events will be recorded;  
• After all study procedures have been completed, the subject will be reminded to: 
− Come to the study center for the Day 85 study visit with their first morning urine 
sample; 
− Store the study medications in a cool and dry place according to label instructions for 
the duration of the study;  
− Take the CCX168 medication every morning and evening, approximately 12 hours 
after the morning dose;  
− Not to take CCX168 medication on the morning of Day 85; and 
− Continue taking their RAAS blocker(s) at a stable dose, and all their other 
concomitant medications as usual. 
6.10. 
Study Day 85/Early Termination Prior to Day 85 
The Study Day 85 visit may occur within ± a 2-day window of the scheduled date. During this 
visit, the following study procedures will be performed: 
• A physical examination (excluding genitourinary, ophthalmic, and female breast 
assessments) will be performed; body weight and body mass index will be determined; 
• Vital signs (temperature, blood pressure, heart rate) will be measured supine after at least 
3 minutes of rest; 
• Serum pregnancy test for women of childbearing potential; 
• Serum chemistry and hematology; an eGFR will be calculated; 
• Urinalysis, including pH, specific gravity, glucose, nitrite, ketones, bilirubin, 
urobilinogen, RBCs, and WBCs on a first morning urine sample collection;  
• Urinary protein, creatinine, albumin, MCP-1, EGF, and microscopic RBC count on a first 
morning urine sample collection;  
• A blood sample will be collected for IgA and C3 measurements; 
• Plasma samples will be collected for PD marker and PK assessment; the time of sample 
collection as well as the date and time of the last dose of CCX168 prior to sample 
collection will be recorded; 
• A urine sample will collected for PD marker assessment; 
• Any changes in concomitant medication use will be recorded; 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 53 of 72                                            17 July 2015 
• Study drug accountability will be performed on all returned study medication; 
• All adverse events will be recorded;  
• An optional renal biopsy could be performed after the 12-week treatment period; 
• After all study procedures have been completed, the subject will be reminded to: 
− Come to the study center for the Day 113 study visit with their first morning urine 
sample; and 
− Continue taking their RAAS blocker(s) at a stable dose, and all their other 
concomitant medications as usual. 
6.11. 
Study Day 113 
The Study Day 113 visit may occur within ± a 4-day window of the scheduled date. During this 
visit, the following study procedures will be performed: 
• A physical examination (excluding genitourinary, ophthalmic, and female breast 
assessments) will be performed; body weight and body mass index will be determined; 
• Vital signs (temperature, blood pressure, heart rate) will be measured supine after at least 
3 minutes of rest; 
• Serum pregnancy test for women of childbearing potential; 
• Serum chemistry and hematology; an eGFR will be calculated; 
• Urinalysis, including pH, specific gravity, glucose, nitrite, ketones, bilirubin, 
urobilinogen, RBCs, and WBCs on a first morning urine sample collection;  
• Urinary protein, creatinine, albumin, MCP-1, EGF, and microscopic RBC count on a first 
morning urine sample collection;  
• A blood sample will be collected for IgA and C3 measurements; 
• A plasma sample will be collected for PD marker assessment; 
• A urine sample will collected for PD marker assessment; 
• Any changes in concomitant medication use will be recorded; 
• All adverse events will be recorded;  
• After all study procedures have been completed, the subject will be reminded to: 
− Come to the study center for the Day 141 study visit with their first morning urine 
sample; and 
− Continue taking their RAAS blocker(s) at a stable dose, and all their other 
concomitant medications as usual. 
6.12. 
Study Day 141 
The Study Day 141 visit may occur within ± a 4-day window of the scheduled date. During this 
visit, the following study procedures will be performed: 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 54 of 72                                            17 July 2015 
• Vital signs (temperature, blood pressure, heart rate) will be measured supine after at least 
3 minutes of rest; 
• Serum chemistry and hematology; an eGFR will be calculated; 
• Urinalysis, including pH, specific gravity, glucose, nitrite, ketones, bilirubin, 
urobilinogen, RBCs, and WBCs on a first morning urine sample collection;  
• Urinary protein, creatinine, albumin, MCP-1, EGF, and microscopic RBC count on a first 
morning urine sample collection;  
• A blood sample will be collected for IgA and C3 measurements; 
• A plasma sample will be collected for PD marker assessment; 
• A urine sample will collected for PD marker assessment; 
• Any changes in concomitant medication use will be recorded; 
• All adverse events will be recorded;  
• After all study procedures have been completed, the subject will be reminded to: 
− Come to the study center for the Day 169 study visit with their first morning urine 
sample; and 
− Continue taking their RAAS blocker(s) at a stable dose, and all their other 
concomitant medications as usual. 
6.13. 
Study Day 169/Early Termination Prior to Day 169 
The Study Day 169 visit may occur within ± a 4-day window of the scheduled date. During this 
visit, the following study procedures will be performed: 
• A physical examination (excluding genitourinary, ophthalmic, and female breast 
assessments) will be performed; body weight and body mass index will be determined; 
• Vital signs (temperature, blood pressure, heart rate) will be measured supine after at least 
3 minutes of rest; 
• Serum pregnancy test for women of childbearing potential; 
• Serum chemistry and hematology; an eGFR will be calculated; 
• Urinalysis, including pH, specific gravity, glucose, nitrite, ketones, bilirubin, 
urobilinogen, RBCs, and WBCs on a first morning urine sample collection;  
• Urinary protein, creatinine, albumin, MCP-1, EGF, and microscopic RBC count on a first 
morning urine sample collection;  
• A blood sample will be collected for IgA and C3 measurements; 
• A plasma sample will be collected for PD marker assessment; 
• A urine sample will collected for PD marker assessment; 
• Any changes in concomitant medication use will be recorded; 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 55 of 72                                            17 July 2015 
• All adverse events will be recorded;  
• After all study procedures have been completed, the subject will be discharged from the 
study. The subject’s condition will be evaluated by the Investigator at the end of the 
clinical trial (Day 169) and appropriate SOC medical treatment will be provided to all 
subjects by their treating nephrologist. 
7. 
STUDY ASSESSMENTS 
7.1. 
Efficacy Assessments 
7.1.1. 
Urinary Protein:Creatinine and Albumin:Creatinine 
Proteinuria will be assessed by measuring the protein, albumin, and creatinine concentrations on 
first morning urinary samples, and calculating the urinary protein:creatinine ratio and urinary 
albumin:creatinine ratio. Results will be expressed as mg protein/g creatinine or mg albumin/g 
creatinine. This will be done by the central laboratory. 
7.1.2. 
Estimated Glomerular Filtration Rate 
Estimated glomerular filtration rate (eGFR) will be calculated at the study visits indicated in the 
Time and Events Table using the following MDRD equation: 
eGFR (mL/min/1.73 m2) = 175 x (serum creatinine in mg/dL)-1.154 x (Age)-0.203 x (0.742 if 
female) x (1.212 if African-American/Black) 
Cystatin C measurements may be used to calculate eGFR using the following equation: 
eGFRcys (mL/min/1.73 m2) = 127.7 x (cystatin C in mg/L)−1.17 x (Age)−0.13 x (0.91 if female) 
x (1.06 if African-American/Black) 
7.1.3. 
Other Urinary Assessments 
First morning urine samples will be analyzed for hematuria, when appropriate at the study visits 
indicated in the Time and Events Table. Microscopic review is triggered if a urinary dipstick test 
is positive for WBC, RBC, nitrite, or protein. When microscopy is performed, hematuria will be 
categorized as follows:  None, Occasional (Occ), 1 - 2, 3 - 5, 6 - 9, 10 - 15, 16 - 29, 30 - 49, 50 - 
75, and >75 RBCs per high power field. For the purpose of analyzing the change from baseline 
in urinary RBCs, the following values will be assigned for each category: 
None = 0.1, Occ = 0.5, 1 - 2 = 1, 3 - 5 = 3, 6 - 9 = 6, 10 - 15 = 10, 16 - 29 = 16, 30 - 49 = 30; 
50 - 75 = 50, >75 = 75.  
Urine MCP-1 and EGF levels will also be measured by the central laboratory in urine samples by 
specific ELISA at the study visits indicated in the Time and Events Table. Urine creatinine will 
be measured in the same urine samples. MCP-1 and EGF levels will be standardized to urine 
creatinine and expressed as pg MCP-1/mg creatinine and pg EGF/mg creatinine. Urinary 
EGF:MCP-1 ratios will be calculated from the creatinine-corrected values.  


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 56 of 72                                            17 July 2015 
7.1.4. 
Serum IgA and Plasma C3 
Serum samples will be collected for Immunoglobulin A and plasma for complement C3 
measurements by specific nephelometry assays by the central laboratory at the study visits 
indicated in the Time and Events Table. 
7.1.5. 
Plasma and Urinary Pharmacodynamic Markers 
Plasma and urine samples will be collected at the study visits indicated in the Time and Events 
Table. These samples will be stored at -70 °C until measurement. These samples may be used to 
measure galactose-deficient IgA1, complement factor H, C3a, C5a, properdin, and sC5b-9, 
cystatin C, other relevant cytokine, chemokine, inflammatory, and other complement markers.  
7.2. 
Safety Assessments 
7.2.1. 
Physical Examinations and Vital Signs 
A complete physical examination (including evaluation of general appearance/mental status, 
HEENT [head, eyes, ears, nose, throat], and the following body systems: dermatologic, 
cardiovascular, respiratory, gastrointestinal, musculoskeletal and neurologic) for safety 
assessment will be performed at Screening and Study Days 1, 29, 43, 57, 85, 113, and 169. 
Physical examination will include a neurological examination including speech, consciousness 
level, mood, cranial nerves, motor, coordination and gait, reflexes, and sensory systems. 
Findings must be recorded in the source documents.  
Any new or worsening findings upon physical examination need to be recorded as adverse 
events. 
Body weight will be measured at all visits where a physical examination is performed. Body 
mass index will be calculated based on height, measured at Screening, and each of the body 
weight assessments. 
Vital signs will be measured during Screening and on each scheduled study day as indicated in 
the Time and Events Table. Blood pressure, pulse rate, and body temperature will be measured.  
All assessments will be performed while the subject is in the supine position and after the subject 
has rested for at least three minutes. 
7.2.2. 
Clinical Safety Laboratory Assessments 
The following tests will be performed at the visits identified in the Time and Events Table. 
• Hematology:  hemoglobin, hematocrit, red blood cell (RBC) count, white blood cell 
(WBC) count with differential, platelet count, mean cell hemoglobin (MCH), mean cell 
hemoglobin concentration (MCHC), mean corpuscular volume. 
• Serum Chemistry:  liver panel (bilirubin, lactate dehydrogenase [LDH], SGOT/AST, 
SGPT/ALT), renal panel (BUN, creatinine), pancreatic enzymes (amylase and lipase), 
creatine phosphokinase (CPK), albumin, sodium, potassium, magnesium, bicarbonate, 
chloride, calcium, inorganic phosphorus, glucose, total proteins, alkaline phosphatase, 
cholesterol, uric acid. 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 57 of 72                                            17 July 2015 
• Urinalysis:  At the central laboratory, pH, specific gravity, glucose, nitrite, ketones, 
bilirubin, urobilinogen, RBC, and WBC tests. 
• Virology (measured only at Screening at the local laboratory): hepatitis B surface 
antigen, hepatitis C antibodies, HIV 1 and 2 antibodies. 
7.2.3. 
Reporting of Adverse Events 
An adverse event (AE) is defined as any untoward medical occurrence in a subject participating 
in a clinical trial who is administered an investigational product, at any dose; the adverse event 
does not necessarily have to have a causal relationship with this product. An adverse event could 
therefore be any unfavorable and/or unintended sign (including abnormal laboratory findings), 
symptom, or disease temporally associated with the use of an investigational product, whether or 
not considered related to the investigational product. This definition includes intercurrent 
illnesses or injuries, and exacerbation of pre-existing conditions. 
An unexpected adverse event is an adverse event that is not identified in nature, severity, or 
frequency in the current Clinical Investigator’s Brochure, or that is of greater severity than 
expected based on the information in the Clinical Investigator’s Brochure. 
All adverse events occurring in subjects who have been enrolled will be recorded on the CRF 
and will be reported in accordance with regulatory requirements. Adverse events reported prior 
to commencement of administration of study medication will be considered pre-treatment events. 
All adverse events will be monitored until resolution or, if the AE is determined to be chronic, 
until a cause is identified. If an adverse event remains unresolved at the conclusion of the study, 
a clinical assessment will be made by the Investigator and the Sponsor’s Medical Monitor 
whether continued follow-up of the adverse event is warranted. 
The severity of each adverse event will be determined by the investigator using the following 
scale: 
• Mild (Grade 1):  no limitation of usual activities. 
• Moderate (Grade 2):  some limitation of usual activities.  
• Severe (Grade 3):  inability to carry out usual activities. 
• Life-threatening (Grade 4):  an immediate risk of death. 
• Death (Grade 5) 
The relationship of CCX168 to an adverse event will be determined by the Investigator and 
Sponsor based on the following definitions: 
• Probably Not Related:  the adverse event was more likely explained by causes other than 
CCX168.  
• Possibly Related:  CCX168 administration and the adverse event occurrence were 
reasonably related in time, and the AE was explained equally well by causes other than 
CCX168 or was more likely explained by exposure to CCX168 than by other causes. 
A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose: 
• Results in death. 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 58 of 72                                            17 July 2015 
• Is life-threatening (i.e., the patient was, in the opinion of the Investigator, at immediate 
risk of death from the event as it occurred). 
• Requires or prolongs hospitalization. 
• Results in persistent or significant disability or incapacity. 
• Is a congenital anomaly or birth defect. 
• Is an important and significant medical event that, based on appropriate medical 
judgment, may jeopardize the patient and/or may require medical or surgical intervention 
to prevent one of the other outcomes defining serious.  
Elective surgery, already known during screening to occur in course of the study and elective 
hospitalizations for convenience of the subject which are clearly unrelated to any medical 
condition, and agreed between the investigator and the subject prior to randomization, will not 
have to be reported as SAEs.  
A suspected unexpected serious adverse reaction (SUSAR) is defined as an SAE that is 
considered at least possibly related to study drug (CCX168) and that is unexpected, i.e., not 
described in terms of nature, severity, or frequency in the current Investigator’s Brochure. 
Any pregnancies that occur in female subjects or partners of male study subjects must be 
reported within 24 hours of awareness as indicated in section 7.2.5. All pregnancies must be 
followed up until conclusion and the outcome of the pregnancy reported within 24 hours of 
awareness as indicated in section 7.2.5.  
7.2.4. 
Stopping Criteria 
Decreases in WBC counts (mostly neutrophil and lymphocyte counts) have been observed in 
previous clinical trials with CCX168 (see Investigator’s Brochure). In an ANCA-associated 
vasculitis study (CL002_168), subjects have also received cyclophosphamide, which is known to 
cause leukopenia. Therefore, the contribution of CCX168 to this effect on WBCs is unclear. In 
this study, CCX168 will not be given cytotoxic compounds such as cyclophosphamide. 
Therefore, the same extent of decrease in WBC counts is not anticipated. Nevertheless, WBC 
counts will be monitored regularly over the course of the study. When more than 4 subjects have 
been enrolled and dosed with CCX168, and if more than 25% of these subjects develop severe 
leukopenia, neutropenia, or lymphopenia, defined as WBC count < 2000/μL, neutrophil count 
<1000/μL, or lymphocyte count <500/μL, deemed possibly related to CCX168 use, the 
Sponsor will consider stopping the study. If any subject who receives CCX168 develops 
severe leukopenia, neutropenia, or lymphopenia, defined as WBC count < 2000/μL, 
neutrophil count <1000/μL, or lymphocyte count <500/μL, CCX168 use will be interrupted 
and will not be re-started until the WBC, neutrophil, or lymphocyte count is above the 
lower limit of normal. If leukopenia/neutropenia/lymphopenia recurs upon re-challenge, 
CCX168 use will be discontinued permanently in this subject. 
One serious unexpected suspected adverse reaction of elevated liver enzymes has been reported 
in study CL002_168 in ANCA-associated vasculitis. The study is still blinded as to treatment 
assignment. The subject also received concomitant cyclophosphamide, pantoprazole, and 
sulfamethoxazole plus trimethoprim, which all have documented evidence of hepatotoxicity. 
Nevertheless, hepatic enzymes and bilirubin will be monitored regularly over the course of the 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 59 of 72                                            17 July 2015 
study. The Sponsor will consider stopping the study if at least one subject develops severe 
liver injury believed to be caused by CCX168. Severe liver injury is based on Hy’s law 
(elevated aminotransferase of >3 x upper limit of normal [ULN], alkaline phosphatase <2 x 
ULN, and associated with an increase in total bilirubin ≥2 x ULN). If any subject who 
receives CCX168 develops hepatic aminotransferase or total bilirubin elevations of >3 x 
ULN, CCX168 use will be stopped in this subject.       
7.2.5. 
Reporting of Serious Adverse Events 
Any serious adverse event, whether or not considered study related, will be reported immediately 
(within 24 hours) to the Sponsor. Reporting is done by completing the SAE form electronically 
in the Electronic Data Capture (EDC) system. If it is not possible to access the EDC system, the 
Investigator will send an email to the Medical Monitor and Clinical Operations Manager 
notifying them of the SAE. 
Any medication or other therapeutic measures used to treat the event will be recorded in the EDC 
in addition to the outcome of the adverse event. The Sponsor will report all SUSARs to all 
applicable national health authorities, IRBs, and ethics committees in an expedited manner. 
7.3. 
Pharmacokinetic Assessments 
Concentrations of CCX168 (and potential metabolites) will be determined in plasma from 4-mL 
blood samples collected in K3EDTA tubes on Days 1, 8, 15, 29, 43, 57, and 85. The samples on 
Day 1 will be collected just prior to the morning dose on that day, and at 0.5, 1, 2, 3, 4, and 6 
hours following the morning dose. The date and time of the last dose prior to the sample 
collections on Days 8, 15, 29, 43, 57, and 85 will be recorded in the EDC. The blood samples 
will be mixed gently and kept on wet ice until centrifuged (within 30 minutes after collection) at 
approximately 2000 x g, for approximately 10 minutes. Resultant plasma needs to be split into 
three ~0.6-mL aliquots and transferred to three appropriately labeled polypropylene tubes and 
stored at approximately -70°C or below until analysis. If the site does not have access to a -70°C 
freezer, the samples must be put on dry ice and shipped to the central laboratory as expeditiously 
as possible, or stored at -20°C and shipped to the central laboratory according to instructions 
provided.  
Total plasma concentrations of CCX168 (and potential metabolites) will be determined using 
validated analytical methods. These plasma samples may also be used to measure cytokines, 
complement fragments, or other markers associated with IgAN. 
7.4. 
Study Completion and Withdrawal 
Day 169 will be the last Study Day for all subjects. Procedures for this day will be completed per 
the Time and Events Table. The subject’s condition will be evaluated by the Investigator at the 
end of the clinical trial and appropriate SOC medical treatment will be provided to all subjects as 
needed by their treating nephrologist. For early withdrawals (prior to Day 85), the procedures 
scheduled for Study Day 85 will be performed and recorded as an Early Termination visit. For 
withdrawals after Day 85, procedures for Day 169 will be performed. 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 60 of 72                                            17 July 2015 
7.5. 
Statistical Methods 
Statistical analysis of efficacy data will be performed using SAS® (SAS Institute, Cary, NC) 
software, based on a predefined Statistical Analysis Plan. Data analysis and writing of an 
Integrated Clinical and Statistical Report (ICSR) for all study data will be performed in 
accordance with applicable SOPs. 
7.6. 
Subject Populations 
For the purposes of data analysis, the ITT Population will include all subjects who are enrolled, 
have received at least one dose of study drug, and have at least one post baseline urinary PCR 
assessment. The safety population will include all subjects who are randomized and have 
received at least one dose of study drug. A per protocol (PP) population may also be defined if 
there are major protocol deviations that could affect study outcome. 
7.7. 
Safety Endpoints 
The primary safety endpoint is the subject incidence of adverse events. 
Other safety endpoints include: 
1. Change from baseline in all safety laboratory parameters; 
2. Change from baseline in vital signs. 
7.8. 
Efficacy Endpoints 
The primary efficacy endpoint is the change in slope of first morning urinary PCR from the 8-
week RAAS blocker run-in period to the 12-week CCX168 treatment period. 
Other efficacy endpoints include: 
1. The proportion of subjects achieving renal response, defined as an improvement in 
proteinuria based on a decrease from baseline to Day 85 in proteinuria to a level < 300 mg/g 
creatinine and maintaining estimated glomerular filtration rate (eGFR) within 15% of 
baseline; 
2. The proportion of subjects achieving a partial renal response, defined as an improvement in 
proteinuria based on a decrease from baseline to Day 85 in proteinuria to a level < 1 g/g 
creatinine and maintaining estimated glomerular filtration rate (eGFR) within 15% of 
baseline; 
3. Change in slope from the run-in period to the treatment period for urinary ACR, eGFR, 
urinary MCP-1:creatinine, urinary EGF:MCP-1, and urinary microscopic RBC counts; 
4. The percent change from baseline to Day 85 in urinary PCR and ACR; 
5. The change from baseline to Day 85 in eGFR; 
6. In patients with hematuria at baseline, the percent change from baseline in urinary RBC 
count; 
7. The percent change from baseline to Day 85 in urinary MCP-1:creatinine ratio; 
8. The percent change from baseline to Day 85 in serum IgA:plasma C3 ratio; 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 61 of 72                                            17 July 2015 
9. The percent change from baseline to Day 85 in urinary EGF:MCP-1 ratio;  
10. The percent change from baseline in plasma and urinary biomarkers, e.g., C3a, C5a, 
properdin, and sC5b-9.  
Changes from baseline in all efficacy measurements at time points other than Day 85 will also be 
assessed.  
7.9. 
Pharmacokinetic Endpoints 
Plasma samples will be collected on Days 1, 8, 15, 29, 43, 57, and 85 to determine the PK profile 
of CCX168 and potential metabolites. The following parameters will be determined on Day 1, 
where possible: 
Cmax  
Maximum plasma concentration 
tmax 
 
Time of maximum plasma concentration  
AUC0-6 
Area under the plasma concentration-time curve from Time 0 to Hour 6 on 
Day 1 
Cmin  
Trough level plasma concentrations at post-Day 1 visits 
7.10. 
Statistical Analysis Methodology 
A statistical analysis plan (SAP) with specific details of all the planned analyses will be 
generated. As the SAP may be updated based on the evaluation of the data distribution 
assumption, when differences exist between the SAP and the methods described in this section, 
the SAP takes the primacy. 
7.10.1. 
Titration and Run-In Period 
The following data collected during the titration (if applicable) and run-in periods will be listed 
by subject and summarized:  
• Blood pressure measurements (supine, after at least 3 minutes of rest); 
• RAAS blocker(s) type and dose titration detail; 
• Serum creatinine and eGFR measurements; 
• Urinary PCR and ACR measurements; 
• Urinary MCP-1:creatinine ratio, EGF:MCP-1 ratio, and urinary microscopic RBC count 
data; 
• Changes in concomitant medications, with particular attention to the dose(s) of RAAS 
blocker(s), and 
• Any pre-treatment adverse events reported.    
7.10.2. 
Baseline Characteristics and Subject Disposition 
All subject baseline characteristics and demographic data (age, sex, race, ethnicity, weight, 
height, body mass index, blood pressure, smoking status, viral test results, IgAN disease duration 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 62 of 72                                            17 July 2015 
(from time of first renal biopsy diagnosis), urinary PCR, urinary ACR, eGFR, hematuria, urinary 
MCP-1:creatinine ratio, physical examination abnormalities, medical history, previous (within 6 
months of screening) and concomitant medications (including IgAN medication use such as 
RAAS blocker(s)) at start of CCX168 dosing will be listed by study center and subject number, 
and will also be summarized. Baseline is defined as the last value prior to start of dosing with 
CCX168 (typically the Day 1 pre-dose value). For urinary PCR, baseline will be the geometric 
mean of the two measurements made in the Day -7 to -2 window plus the Day 1 (pre-dose) 
value. For the eGFR, urinary ACR, MCP-1:creatinine ratio, EGF:MCP-1 ratio, and microscopic 
RBC count, baseline will be the geometric mean of the one measurement made in the Day -7 
to -2 window plus the Day 1 (pre-dose) value. 
The number of patients screened, and the number of patients who entered, discontinued from, 
and completed each of the titration period, run-in period, treatment period, and follow-up period, 
along with the reason for discontinuation, will be presented.  
7.10.3. 
Safety Analyses 
Safety analyses will be performed on the Safety Population. The CCX168 treatment group will 
be summarized descriptively in terms of the subject incidence of adverse events. 
All safety data will be summarized descriptively. 
Adverse events will be coded using MedDRA and listed, including all available information of 
interest such as onset and resolution dates, study day of onset relative to first dosing day, 
severity, seriousness, causal relationship to study medication, action taken, and outcome. 
Adverse events will be flagged in the data listings as “pre-treatment” if these occur prior to the 
time of administration of the first dose of CCX168, “on-treatment” if these occur during the 
treatment period, or “post-treatment” if these occur after the last dose of CCX168. All “on-
treatment” and “post-treatment” adverse events will be considered “treatment-emergent” and will 
be summarized as appropriate. Symptoms or signs of IgAN will be considered adverse events if 
these increase in severity or frequency while a subject is on-study. Adverse events will be listed 
by subject. AEs will be summarized separately for maximum severity and relationship to study 
drug. If applicable, AEs leading to withdrawal and SAEs will be tabulated separately. 
Safety laboratory data will be listed by subject number and will be summarized. Actual 
laboratory values and change from baseline in laboratory values will be listed and summarized. 
Laboratory values outside the reference ranges will be flagged in the listings. Laboratory shift 
tables from baseline to subsequent study visits may also be generated for safety laboratory 
parameters, if appropriate. Vital signs data will be listed and summarized similarly.  
No inferential statistical analysis will be performed on adverse event or other safety data.   
7.10.4. 
Efficacy Analyses 
The primary efficacy endpoint is the change in slope of first morning urinary PCR from the 8-
week RAAS blocker run-in period to the 12-week CCX168 treatment period.  
For the primary efficacy endpoint analysis, the slope of the urinary PCR during the 8-week run-
in period, during the initial 4-week, as well as the full 12-week treatment period will be 
calculated for each subject. The mean slope for the 8-week run-in period will be compared to the 
mean slope for the initial 4-week, as well as the full 12-week treatment period to evaluate the 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 63 of 72                                            17 July 2015 
treatment effect of CCX168. If the slope for the first 4 weeks of the run-in period is steeper than 
the slope of the last 4 weeks of the run-in period, indicating that steady state has not been 
achieved over the first 4 weeks, the slope of the last 4 weeks of the run-in period may be used as 
the baseline slope, instead of the slope over the 8 weeks of the run-in period. This comparison 
will be performed by the random coefficients regression model with the test for slope-by-period 
(pre and on-treatment) interaction. 
Similar analyses will be performed for the urinary ACR, eGFR, urinary MCP-1:creatinine ratio, 
urinary EGF:MCP-1 ratio, and urinary microscopic RBC count. 
The proportion of subjects achieving renal response, defined as an improvement in urinary PCR 
based on a decrease from baseline to each subsequent time point in urinary PCR to a level < 300 
mg/g creatinine and maintaining estimated glomerular filtration rate (eGFR) within 15% of 
baseline, will be calculated and summarized. 
The same summary will be provided for subjects achieving partial renal response, i.e., a urinary 
PCR reduction to a level < 1 g/g creatinine while maintaining an eGFR within 15% of baseline. 
Summary statistics at each time point will be calculated for each of the efficacy endpoints. For 
categorical endpoints, numbers and percentages will be calculated. For continuous variables, 
numbers, means, medians, ranges, and standard deviations will be calculated. Geometric means 
will be calculated at each time point for urinary PCR, ACR, and MCP-1:creatinine, and other 
measurements that are not normally distributed. 
The 84-day follow-up period results for the endpoints listed above will also be summarized. 
Shift tables will be generated for urinary parameters such as urinary PCR, ACR, and hematuria 
for each measured time point. The categories of interest are < 300 mg/g, 301-1000 mg/g, ≥ 1001 
mg/g for PCR and ACR, and ≤ 5 RBCs/hpf, >5 but <30 RBCs/hpf, and ≥30 RBCs/hpf for 
urinary RBC count. 
The main efficacy analysis will be in the ITT population. Sensitivity analyses may also be done 
in the PP population.  
7.10.5. 
Pharmacokinetic Analysis 
Individual plasma concentrations of CCX168 and relevant metabolites will be listed, plotted, and 
summarized descriptively and graphically. Pharmacokinetic parameters will be calculated based 
on plasma CCX168 concentrations at the time of sample collection in relation to time of 
administration of the most recent dose of study medication. Plasma levels of significant 
metabolites may also be determined and PK parameters calculated. 
It is of interest to evaluate whether the PK profile of subjects with IgAN is similar to the profile 
in healthy volunteers. The relationship between PK parameters and renal function based on 
eGFR will also be evaluated. The data may also be used to evaluate the PK/PD relationship of 
CCX168 treatment. To this end, the change and/or percent change from baseline in urinary ACR, 
PCR, eGFR, urinary MCP-1:creatinine ratio, or other markers may be used as PD markers. 
7.11. 
Sample Size Justification 
The sample size for the study is based on the slope of the urinary ACR observed in a study in 
patients with ANCA-associated vasculitis while receiving CCX168 (CL002_168). The mean 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 64 of 72                                            17 July 2015 
slope was -1.32, with a standard deviation of 1.67 over 12 weeks, and -4.62, with a standard 
deviation of 4.77 over the initial 4-week treatment period with CCX168 in ANCA-associated 
vasculitis. Assuming a mean difference in pre-treatment and on-treatment slopes of 4.6, a sample 
size of 15 subjects will provide approximately 80% power and 20 subjects approximately 90% 
power to detect a difference in slopes using the paired t-test. 
7.12. 
Protocol Deviations 
Significant protocol deviations will be listed and summarized by category. The effect of 
significant protocol deviations on the safety and efficacy outcomes will be evaluated. If 
warranted, sensitivity analyses of select efficacy endpoints will be conducted excluding subjects 
and/or study visits with significant protocol deviations. 
8. 
STUDY COMPLETION AND TERMINATION 
8.1. 
Study Completion 
A subject has completed the study when s/he has completed the study procedures per protocol. 
8.2. 
Study Termination 
The end of study is defined as the last study visit of the last clinical trial subject. 
9. 
REGULATORY AND ADMINISTRATIVE REQUIREMENTS 
9.1. 
Investigator Responsibilities 
Prior to trial initiation, the Investigator will provide the Sponsor with a fully executed and signed 
FDA Form 1572 and a Financial Disclosure Form. Financial Disclosure Forms also will be 
completed for all Sub-Investigators listed on the Form 1572 who will be involved directly in the 
treatment or evaluation of research subjects in this trial.  
The study will be conducted in accordance with the Declaration of Helsinki (amended by the 
59th World Medical Association General Assembly, October 2008) and Good Clinical Practice 
(GCP) according to International Conference on Harmonisation (ICH) guidelines.  Specifically, 
the study is based on adequately performed laboratory and animal experimentation; the study 
will be conducted under a protocol reviewed by a properly constituted IRB/EC; the study will be 
conducted by scientifically and medically qualified persons; the benefits of the study are in 
proportion to the risks; the rights and welfare of the subjects will be respected; and each subject 
will give his/her informed consent before any protocol-specific tests or evaluations are 
performed. 
9.2. 
Institutional Review Board or Ethics Committee 
Prior to initiating the study, the Investigator will obtain written confirmation from the IRB/EC 
that the IRB/EC was properly constituted and met the definition of all United States Code of 
Federal Regulations Title 21, Section 312.3(b) and Part 56, and/or the applicable local, regional 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 65 of 72                                            17 July 2015 
or national Regulatory requirements. A copy of the confirmation will be provided to the Sponsor.  
The Principal Investigator will provide the IRB/EC with all appropriate materials, including the 
protocol and Informed Consent documents. The trial will not be initiated until IRB/EC approval 
of the protocol, the Informed Consent document, and all recruiting materials are obtained in 
writing by the Investigator and copies are received by the Sponsor. Appropriate reports on the 
progress of the study will be made to the IRB/EC and the Sponsor by the Principal Investigator 
in accordance with applicable governmental regulations and in agreement with the policy 
established by the Sponsor. 
9.3. 
Informed Consent 
A properly executed, written, and appropriately explained Informed Consent Form, in 
compliance with the Declaration of Helsinki, ICH GCP, and US Code of Federal Regulations for 
Protection of Human Subjects (21 CFR 50.25[a,b], CFR 50.27, and CFR Part 46, Subpart A), 
will be signed by each subject prior to entering the trial. Either the investigator or the 
investigator’s designee will obtain the consent of the study subject. The subject will be provided 
as much time as necessary to review the document, to inquire about details of the trial, and to 
decide whether or not to participate in the study. The informed consent will be signed and dated 
by the study subject and by the person who conducted the informed consent discussion. The 
Investigator will provide a copy of the signed Informed Consent Form to each subject and will 
maintain a copy in the subject’s record file. 
9.4. 
Protocol Modifications 
Only the Sponsor may modify the protocol. Amendments to the protocol will be made only after 
consultation and agreement between the Sponsor and the Principal Investigator. The only 
exception is when the Investigator considers that a subject’s safety would be compromised 
without immediate action. In this circumstance, immediate approval of the chairperson of the 
IRB/EC must be sought, and the Investigator should inform the Sponsor’s Medical Monitor and 
the full IRB/EC within five working days after the emergency occurred. All other amendments 
that have an impact on subject risk or the study objectives, and/or that require revision of the 
Informed Consent Form, must receive approval from the IRB/EC prior to their implementation, 
except when the changes involve only logistical or administrative aspects of the trial. The 
IRB/EC must be notified of changes that are made to study contact personnel, but IRB/EC 
review or approval of these changes is not required. If protocol amendments are substantial and 
are likely to have an impact on the safety of the trial subjects or to change the interpretation of 
the scientific documents in support of the conduct of the trial, or if they are otherwise significant, 
the sponsor shall notify the FDA and other applicable competent authorities of the reasons for, 
and content of, these amendments according to the European Directive “Detailed guidance on the 
request to the competent authorities for authorization of a clinical trial on a medical products for 
human use, the notification of substantial amendments and the declaration of the end of trial 
(CT-1)(2010/C 82/01)”.  
9.5. 
Regulatory Documentation 
All regulatory documentation including regulatory submissions, 1572 forms, and correspondence 
regarding this study will be kept by the Sponsor. The Sponsor will maintain all study 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 66 of 72                                            17 July 2015 
documentation according to their SOPs. Clinical trial related documents will be archived for at 
least 10 years according to national Swedish and EU regulations (LVFS 2003:3). 
9.6. 
Subject Identification Register 
The Investigator agrees to complete a subject identification register, which will be used for the 
purpose of long-term follow-up, if needed. This form will be treated as confidential, and will be 
filed by the Investigator in a secure locked place. Otherwise, all reports and communications 
relating to the study will identify participants by initials and assigned number only. 
9.7. 
Record Retention 
The Investigator must retain all study records required by the Sponsor and by the applicable 
regulations in a secure and safe facility. The Investigator must consult a Sponsor CRA before 
disposal of any study records, and must notify the Sponsor of any change in the location, 
disposition, or custody of the study files. The FDA requires retention of records for two years 
following the date a marketing application is approved, or for two years after the FDA is notified 
that the IND is discontinued if there is no marketing application. Records must be retained for a 
period at least as long as that specified by FDA regulations. Clinical trial related documents will 
be archived for at least 10 years according to national Swedish and EU regulations (LVFS 
2003:3). 
9.8. 
Case Report Form Completion 
Electronic Case Report Forms (CRFs) will be generated for each subject. The electronic system 
must comply with CFR 21 Part 11. 
It is the policy of the Sponsor that study data must be verifiable to the source data, which 
necessitates access to all original recordings, laboratory reports, and subjects’ records. The 
Investigator must therefore agree to allow access to subjects’ records, and source data must be 
made available for all study data. The subjects (or their legal representatives) must also allow 
access to the subjects’ medical records, and they will be informed of this requirement and will 
indicate their agreement when giving Informed Consent. Upon completion of the study, 
electronic copies of the CRFs will be provided to the investigators and should be included as part 
of his/her study files and retained as per FDA or local regulations. 
9.9. 
Monitoring 
At intervals during the study, as well as after the completion of subject enrollment, the study 
center will be monitored by a CRA for compliance, which will include ensuring that accurate and 
complete data are recorded on CRFs, and reviewing source documentation and drug 
accountability records. The study will be conducted according to the principles of GCP as 
accepted in the United States and according to CPMP/ICH/135/95. 
9.10. 
On-site Audits 
The Sponsor’s representatives will visit the study center prior to initiation of the study to review 
with the center personnel information regarding the investigational agent, protocol requirements, 
monitoring requirements, and reporting of serious adverse events. 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 67 of 72                                            17 July 2015 
In certain circumstances, a secondary audit may be conducted by members of a Quality 
Assurance group designated by the Sponsor. The Investigator will be informed if this is to take 
place and advised as to the nature of the audit. Representatives of the FDA and/or representatives 
of other regulatory authorities may also conduct an audit of the study. If informed of such an 
audit, the Investigator should notify the Sponsor immediately. 
9.11. 
Use of Information and Publication 
It is understood by the Investigator that the information generated in this study will be used by 
the Sponsor in connection with the development of the product and therefore may be disclosed to 
government agencies in various countries. To allow for the use of information derived from the 
study, it is understood that the Investigator is obliged to provide the Sponsor with complete test 
results, all study data, and access to all study records. 
The Sponsor recognizes the importance of communicating study data and will disclose or publish 
the results in a suitable form regardless of outcome. The Sponsor may elect to publish some or 
all of the results of this study in scientific journals, at seminars or conferences, and/or in other 
manner(s) it so chooses. Results from this study shall not be made available to any third party by 
the investigating team without the express permission of the Sponsor. 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 68 of 72                                            17 July 2015 
10. 
REFERENCES 
Abe K, Miyazaki M, Koji T, et al. 2001 Enhanced espression of complement C5a receptor 
mRNA in human diseased kidney assessed by in situ hybridization. Kidney Int 60:137-146. 
Cattran DC, Coppo R, Cook HT, et al. 2009 The Oxford classification of IgA nephropathy: 
rationale, clinicopathological correlations, and classification. Kidney Int 76:534–545; 
doi:10.1038/ki.2009.243. 
Gharavi AG, et al. Genome-wide association study identifies susceptibility loci for IgA 
nephropathy. Nat Genet 2011;43:321-327. 
KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl. 2012;2:209-217. 
Liu L, Zhang Y, Duan X, et al. 2013 C3a, C5a renal expression and their receptors are correlated 
to severity of IgA nephropathy. J Clin Immunol DOI 10.1007/s10875-013-9970-6. 
Miyazaki R, et al. Glomerular deposition and serum levels of complement control proteins in 
patients with IgA nephropathy. Clin Nephrol 1984;21:335–340. 
Pozzi C, Bolasco PG, Fogazzi GB, et al. 1999 Corticosteroids in IgA nephropathy: a randomised 
controlled trial. Lancet 353:883–887. 
Rauterberg EW, et al. Complement membrane attack (MAC) in idiopathic IgA 
glomerulonephritis. Kidney Int 1987;31:820–829. 
Roos A, et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is 
associated with more severe renal disease. J Am Soc Nephrol 2006;17:1724–1734. 
Schreiber A, Xiao H, Jennette JC, et al.  2009. C5a Receptor mediates neutrophil activation and 
ANCA-induced glomerulonephritis. J Am Soc Nephrol 20:289-298. 
Stangou M, et al. C5b-9 glomerular deposition and tubular alpha3beta1-integrin expression are 
implicated in the development of chronic lesions and predict renal function outcome in 
immunoglobulin A nephropathy. Scand J Urol Nephrol 2008;42:373–380. 
Suzuki K, et al. Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. 
Kidney Int. 2003;63:2286–2294. 
Xiao H, et al C5a Receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc 
Nephrol 2014;25:225-231. 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 69 of 72                                            17 July 2015 
11. 
APPENDICES 
11.1. 
Statement of Obligations of Sponsor, Monitor, and Clinical 
Investigator 
Sponsor and Monitor 
If the Sponsor is not familiar with the Study Site, the Sponsor or its designated representative, 
will: 
A. Conduct a prestudy visit to: 
1. Establish the acceptability of the facility, the recruitment potential and the standard of patient 
care at this site, and record this in a written report. 
2. Discuss the proposed clinical trial with the Investigator, review the CRF requirements, and 
supply the Investigator Brochure and the draft protocol for review and approval. 
3. Discuss with the Investigator FDA and other regulatory requirements with respect to 
Informed Consent, competent authority (CA) and institutional review board (IRB)/ethics 
committee (EC) approval of the trial, the protocol, protocol amendments, and Informed 
Consent changes. 
B. Conduct periodic site visits to: 
1. Assure adherence to the protocol. 
2. Review CRFs and medical records for accuracy and completeness of information. 
3. Examine pharmacy records for documentation of quantity and date of receipt of 
investigational supplies, dispensation and accountability data for administration to each 
subject, loss of materials, contamination, and unused supplies. 
4. Record and report observations on the progress of the trial and continued acceptability of the 
facilities in a Site Visit Report. 
 
5. Review Investigator files for required documents, e.g., protocols, protocol amendments, CA 
and IRB/EC approvals (protocols, amendments, Informed Consent, etc.), IRB/EC charter and 
membership, and communications between the IRB/EC and the Investigator.  
Clinical Investigator 
A. IRB/EC 
The Investigator must assure the monitor that the IRB/EC: 
1. Meets FDA regulations as defined in 21 CFR Part 56 and other applicable ICH and GCP 
requirements. 
2. Has authority delegated by the parent institution and found in IRB/EC by-laws, operation 
guidelines, or charter to approve or disapprove clinical trials and protocols, including 
Informed Consent Forms and other documents (protocol amendments, information to be 
supplied to subjects concerning Informed Consent, etc.). 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 70 of 72                                            17 July 2015 
3. Complies with proper personnel makeup of an IRB/EC and maintains an active up-to-date 
roster of all IRB/EC members participating in the meetings. 
4. Convenes meetings using acceptable rules of order for making decisions, recording such 
decisions, and implementing them. 
5. Files contain (a) documentation of its decisions such as are found in IRB/EC minutes and 
correspondence, (b) written guidelines or by-laws governing IRB/EC functions, (c) protocols, 
(d) protocol information to be supplied to the subject, (e) correspondence between the 
IRB/EC and the Investigator (Informed Consent Form changes, protocol amendments, etc.). 
B. Informed Consent of Human Subjects. 
The Principal Investigator must assure the monitor that the Informed Consent Form: 
1. Meets FDA regulations as defined in 21 CFR Part 50 Informed Consent, and other applicable 
ICH and GCP requirements. 
2. Has been approved by the IRB/EC, including, when required, information to be given to the 
subject regarding the trial in which s/he is enrolled. 
a. The Informed Consent Form includes the Basic Elements and any Additional Elements 
necessary. 
b. The subject and a study center representative sign the Informed Consent Form and the 
subject is given a copy. 
C. Storage and Dispensing of Study Supplies. 
The Investigator (or pharmacist or pharmacy technician) must demonstrate to the monitor that: 
1. Adequate and accurate written records show receipt and disposition of all study supplies, 
including dates, serial or lot numbers, quantities received, and each quantity dispensed, 
administered, or used, with identification of each subject. 
2. Purpose and reasons are given in written records for study material disposal, e.g., the amount 
contaminated, broken, or lost, and the quantity returned to the Sponsor. 
D. Case Report Forms. 
The Investigator must assure the monitor that: 
1. Case report forms, when completed, accurately reflect the medical records on each subject. 
2. Case report forms and medical records will be accessible to the monitor or FDA and other 
Regulatory inspectors during site visits. 
E. Files and Records. 
The Investigator must assure the quality, integrity, and content of his or her files that will be 
inspected by the monitor and regulatory inspectors.  The files must contain, at a minimum: 
1. Correspondence between the IRB/EC and the Investigator. 
2. The following documents: 
a. IRB/EC-approved protocols. 
b. IRB/EC-approved protocol amendments. 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 71 of 72                                            17 July 2015 
c. IRB/EC-approved Informed Consent Form and information supplied to the subject. 
d. IRB/EC charter, membership, and qualifications. 
3. Clinical supplies: 
a. Record of receipt, date and quantity, and batch or lot number. 
b. Disposition dates and quantity administered to each subject. 
c. Inventory records. 
The FDA requires retention of records for two years following the date a marketing application 
is approved, or for two years after the FDA is notified that the IND is discontinued if there is no 
marketing application. Records must be retained for a period at least as long as that specified by 
FDA regulations. Clinical trial related documents will be archived for at least 10 years according 
to national Swedish and EU regulations (LVFS 2003:3). 


ChemoCentryx, Inc.                            CONFIDENTIAL                                Protocol CL005_168 
CCX168 
                                                      
Amendment 3.0 
                                                                   Page 72 of 72                                            17 July 2015 
11.2. 
Informed Consent Form  
In seeking Informed Consent, the following information shall be provided to each subject: 
1. A statement that the study involves research, an explanation of the purposes of the research 
and the expected duration of the subject's participation, a description of the procedures to be 
followed, and identification of any procedures which are experimental. 
2. A description of any reasonably foreseeable risks or discomforts to the subject. 
3. A description of any benefits to the subject or to others that may reasonably be expected from 
the research. 
4. A disclosure of appropriate alternative procedures or courses of treatment, if any, that might 
be advantageous to the subject. 
5. A statement describing the extent, if any, to which confidentiality of records identifying the 
subject will be maintained and that notes the possibility that the Food and Drug 
Administration or other Regulatory agency may inspect the records. 
6. For research involving more than minimal risk, an explanation as to whether any 
compensation and as to whether any medical treatments are available if injury occurs and, if 
so, what they consist of, or where further information may be obtained. 
7. An explanation of whom to contact for answers to pertinent questions about the research and 
research subjects' rights, and whom to contact in the event of a research related injury to the 
subject. 
8. A statement that participation is voluntary, that refusal to participate will involve no penalty 
or loss of benefits to which the subject is otherwise entitled, and that the subject may 
discontinue participation at any time without penalty or loss of benefits to which the subject 
is otherwise entitled. 
ADDITIONAL ELEMENTS OF INFORMED CONSENT 
1. A statement that the particular treatment or procedure may involve risks to the subject (or to 
the embryo or fetus if the subject is or may become pregnant) which are currently 
unforeseeable. 
2. Anticipated circumstances under which the subject’s participation may be terminated by the 
Investigator without regard to the subject’s consent. 
3. Any additional costs to the subject that may result from participation in the research. 
4. The consequences of a subject’s decision to withdraw from the research and procedures for 
orderly termination of participation by the subject. 
5. A statement that significant new findings developed during the course of the research which 
may relate to the subject’s willingness to continue participation will be provided to the 
subject. 
6. The approximate number of subjects involved in the study. 
  

SAP_001.pdf: 






C h e  m o  C e ntr y x, I n c.   
 
St atisti c al   A n al ysis  Pl a n  
Pr ot o c ol   C L 0 0 5- 1 6 8  
 
3   O ct o b er  2 0 1 6  
 
C o nfi d e nti al   
3  
T  A  B  L  E   O F   C  O  N  T  E  N  T S   
S e cti o n  
P a g e  
1.      
A  B  B  R  E  VI  A  TI  O  N S   ..................................................................................................................................... 6  
2.      
R  E  VI SI  O  N   HI S  T  O  R  Y   ................................................................................................................................  7 
3.      
I nt r o d ucti o n  .................................................................................................................................................  7 
4.      
St u d y   O bj e cti v es  ..........................................................................................................................................  7 
4. 1.      
P ri  m a r y   O bj e cti v es  .......................................................................................................................  7 
4. 2.      
S e c o n d a r y   O bj e cti v es ....................................................................................................................  7 
5.      
S  T  U  D  Y   D  E SI  G  N  .........................................................................................................................................  8 
5. 1.      
G e n e r al   D es c ri pti o n   ......................................................................................................................  8 
5. 2.      
St u d y   T r e at  m e nt  ...........................................................................................................................  8 
5. 3.      
R a n  d o  mi z ati o n    M et h o d ol o g y  .......................................................................................................  8 
5. 4.      
St o p pi n g   R ul e s  a n d   U n bli n di n g  ...................................................................................................  8 
5. 5.      
St u d y  S c h e  m a  ................................................................................................................................  9 
5. 6.      
St u d y  P r o c e d u r es  ..........................................................................................................................  9 
S c h e d ul e  of   E v e nts  ................................................................................................................................................... 1 0  
6.      
D efi niti o ns   .................................................................................................................................................. 1 2  
7.      
Effi c a c y  a n d  S af et y   V a ri a bl es   .................................................................................................................. 1 3  
7. 1.      
P ri  m a r y   Effi c a c y   E n d p oi nt  ........................................................................................................ 1 3  
7. 2.      
Ot h e r   Effi c a c y   E n d p oi nts   ........................................................................................................... 1 3  
7. 3.      
S af et y   V a ri a bl es  .......................................................................................................................... 1 3  
8.      
A  N  A  L  Y SI S  P  O P  U  L  A  TI  O  N S   ................................................................................................................... 1 3  
9.      
D  A  T  A   R  E  VI  E   W   A  N  D  P  R  E S  E  N  T  A  TI  O  N   .............................................................................................. 1 4  
9. 1.      
D at a  S c r e e ni n g   ............................................................................................................................ 1 4  
9. 2.      
P r ot o c ol   D e vi ati o ns  ..................................................................................................................... 1 4  
9. 3.      
D at a  P r es e nt ati o n   ........................................................................................................................ 1 4  
1 0.      
S  T A  TI S  TI  C  A  L    M  E  T  H  O  D S   ..................................................................................................................... 1 5  
1 0. 1.      S a  m pl e  Si z e  J ustifi c ati o n  ............................................................................................................ 1 5  
1 0. 2.      G e n e r al  St atisti c al    M et h o ds  a n d   D at a   H a n dli n g   ...................................................................... 1 5  
1 0. 2. 1.      G e n er al   M et h o ds   ......................................................................................................... 1 5  
1 0. 2. 2.      C o  m p ut i n g  E n vir o n  m e nt ............................................................................................. 1 6  
1 0. 2. 3.      Gr o u pi n g  of  S u bj e cts   .................................................................................................. 1 6  


C h e  m o  C e ntr y x, I n c.   
 
St atisti c al   A n al ysis  Pl a n  
Pr ot o c ol   C L 0 0 5- 1 6 8  
 
3   O ct o b er  2 0 1 6  
 
C o nfi d e nti al   
4  
S e cti o n  
P a g e  
1 0. 2. 4.      D efi niti o n  of   B as eli n e   ................................................................................................. 1 6  
1 0. 2. 5.      M et h o ds  of  P o oli n g   D at a    ............................................................................................ 1 6  
1 0. 2. 6.      A dj ust  m e nts f or   C o v ari at e s   ......................................................................................... 1 6  
1 0. 2. 7.      M ulti pl e   C o  m p aris o ns/  M ulti pli cit y   ............................................................................. 1 6  
1 0. 2. 8.      S u b p o p ul ati o ns ............................................................................................................ 1 6  
1 0. 2. 9.      Wit h dr a  w als,   Dr o p o uts,  L oss t o  F oll o  w   -u p  ................................................................ 1 6  
1 0. 2. 1 0.      Missi n g,   U n us e d,  a n d  S p uri o us   D at a    .......................................................................... 1 6  
1 0. 2. 1 1.      Visit    Wi n d o  ws   ............................................................................................................ 1 6  
1 0. 3.      I nt e ri  m   A n al ys e s  ......................................................................................................................... 1 6  
1 0. 4.      S u bj e ct   Dis p o siti o n  ..................................................................................................................... 1 6  
1 0 . 5.     D e  m o g r a p hi c  a n d   B as eli n e   C h a r a ct e risti cs   .............................................................................. 1 7  
1 0. 6.      Tit r ati o n  a n d   R u n  -I n  P e ri o ds .................................................................................................... 1 7  
1 0. 7.      Effi c a c y   E v al u ati o n   ..................................................................................................................... 1 7  
1 0. 7. 1.      C h a n g e i n  sl o p e  of first   m or ni n g  uri n ar y  P  C  R ( pr ot ei n: cr e ati ni n e r ati o) 
fr o  m t h e  8-w e e k   R  A  A S  bl o c k er r u n  -i n  p eri o d t o t h e  1 2-w e e k tr e at  m e nt 
p eri o d  .......................................................................................................................... 1 7  
1 0. 7. 2.      Pr o p orti o n  of s u bj e cts  a c hi e vi n g r e n al r es p o ns e  ......................................................... 1 8  
1 0. 7. 3.      Pr o p orti o n  of s u bj e cts  a c hi e vi n g  p arti al r e n al r es p o ns e  .............................................. 1 8  
1 0. 7. 4.      C h a n g e i n  sl o p e fr o  m t h e r u n  -i n  p eri o d t o t h e tr e at  m e nt  p eri o d f or ............................ 1 8  
1 0. 7. 5.      P er c e nt  c h a n g e fr o  m  b as eli n e t o   D a y  8 5 i n  ................................................................. 1 8  
1 0. 7. 6.      C h a n g e fr o  m  b as eli n e t o   D a y  8 5 i n  e  G F  R   .................................................................. 1 8  
1 0. 7. 7.      I n  p ati e nts   wit h  h e  m at uri a  at  b as eli n e, t h e  p er c e nt  c h a n g e fr o  m  b as eli n e 
i n  uri n ar y   R  B  C  c o u nt .................................................................................................. 1 8  
1 0. 7. 8.      P er c e nt  c h a n g e fr o  m  b as eli n e t o   D a y  8 5 i n  uri n ar y   M  C P -1: cr e ati ni n e 
r ati o;   P er c e nt  c h a n g e fr o  m  b a s eli n e t o   D a y  8 5 i n s er u  m I g  A: pl as  m a   C 3 
r ati o ;  P er c e nt  c h a n g e fr o  m  b a s eli n e t o   D a y  8 5 i n  uri n ar y  E  G F:  M  C P-1 
r ati o ............................................................................................................................. 1 9  
1 0. 7. 9.      S hift i n   Uri n ar y  P  C  R,   A  C  R,  a n d  h e  m at uri a  ................................................................ 1 9  
1 0. 7. 1 0.      P er c e nt  c h a n g e fr o  m  b as eli n e i n  pl as  m a  a n d  uri n ar y  bi o  m ar k ers,  e. g., 
C 3 a,   C 5 a,  pr o p er di n,  a n d s  C 5 b  - 9 ................................................................................ 1 9  
1 0. 8.      S af et y   A n al ys es  ............................................................................................................................ 1 9  
1 0. 8. 1.      Dr u g  E x p os ur e   ............................................................................................................ 1 9  
1 0. 8. 2.      A d v ers e  E v e nts   ........................................................................................................... 1 9  
1 0. 8. 3.      L a b or at or y   D at a  .......................................................................................................... 2 0  


C h e  m o  C e ntr y x, I n c.   
 
St atisti c al   A n al ysis  Pl a n  
Pr ot o c ol   C L 0 0 5- 1 6 8  
 
3   O ct o b er  2 0 1 6  
 
C o nfi d e nti al   
5  
S e cti o n  
P a g e  
1 0. 8. 4.      Vit al  Si g ns   .................................................................................................................. 2 0  
1 0. 8. 5.      P h ysi c al  e x a  mi n ati o n  .................................................................................................. 2 0  
1 0. 8. 6.      C o n c o  mit a nt   M e di c ati o ns   ........................................................................................... 2 0  
1 1.      
C  H  A  N  G  E S   T  O  P  L  A  N  N  E  D   A  N  A  L  Y S  E S   ................................................................................................ 2 0  
1 2.      
R ef e r e n c es   .................................................................................................................................................. 2 0  
 
 
 
 


C h e  m o  C e ntr y x, I n c.   
 
St atisti c al   A n al ysis  Pl a n  
Pr ot o c ol   C L 0 0 5- 1 6 8  
 
3   O ct o b er  2 0 1 6  
 
C o nfi d e nti al   
6  
1.      
A  B  B  R  E  VI  A  TI  O  N S   
A b b r e vi ati o n   
D efi niti o n   
A E   
A d v ers e  e v e nts   
A T  C   
A n at o  mi c al  T h er a p e uti c   C h e  mi c al   
b .i.d . 
t  wi c e  a  d a y 
B  MI   
B o d y   m ass i n d e x   
C F  B   
C h a n g e  Fr o  m   B as eli n e   
C T  C  A E   
C o  m  m o n  T er  mi n ol o g y   Crit eri a f or   A d v ers e  E v e nts   
E  C  G  
El e ctr o c ar di o gr a  m  
e  C  R F  
El e ctr o ni c  c as e r e p ort f or  m  
E  G F  
e pi d er  m al  gr o  wt h  f a ct or 
e  G F  R  
Esti  m at e d  gl o  m er ul ar filtr ati o n r at e  
F  D  A  
F o o d  a n d   Dr u g   A d  mi nistr ati o n  
G  C P   
G o o d   Cli ni c al  Pr a cti c e   
I  C  H 
I nt er n ati o n al   C o nf er e n c e  o n   H ar  m o nis ati o n 
I g  A  N 
I g  A  n e p hr o p at h y 
I T T 
I nt e nt-t o-tr e at 
M  C P  -1  
M o n o c yt e  c h e  m o attr a ct a nt  pr ot ei n   -1   
M e d  D  R  A   
M e di c al   Di cti o n ar y f or   R e g ul at or y   A cti viti es   
mI T T   
M o difi e d i nt e nt  -t o-tr e at 
P  C  R  
Uri n ar y  pr ot ei n :  cr e ati ni n e r ati o   
P  D  
P h ar  m a c o d y n a  mi cs  
P E  
P h ysi c al  E x a  mi n ati o n  
P  K  
P h ar  m a c o ki n eti c s 
p P  
P er  pr ot o c ol   
P T  
Pr ef err e d  T er  m   
R  A  A S   
R e ni n  -a n gi ot e nsi n -al d ost er o n e s yst e  m   
S  A E  
S eri o us  a d v ers e  e v e nt  
S  A P  
St atisti c al  a n al ysis  pl a n  
SI  
I nt er n ati o n al  S yst e  m  of   U nits 
S  O  C  
S yst e  m   Or g a n   Cl ass  
T E  A E  
Tr e at  m e nt -e  m er g e nt  a d v ers e  e v e nt  
T E S  A E  
Tr e at  m e nt -e  m er g e nt s eri o us  a d v ers e  e v e nt  
W  H  O  D  D    
W   orl d   H e alt h   Or g a ni z ati o n  Dr u g   Di cti o n ar y   


C h e  m o  C e ntr y x, I n c.   
 
St atisti c al   A n al ysis  Pl a n  
Pr ot o c ol   C L 0 0 5- 1 6 8  
 
3   O ct o b er  2 0 1 6  
 
C o nfi d e nti al   
7  
2.      
R  E  VI SI  O  N   HI S  T  O  R  Y   
T his is  v ersi o n  0. 2  of t h e  S  A P.  
 
3.      
I  N  T  R  O  D  U  C  TI  O  N 
T his  st atisti c al  a n al ysis  pl a n ( S  A P) is  b as e d  o n t h e  cli ni c al  st u d y  pr ot o c ol   C L 0 0 5  _ 1 6 8,   A  m e n d  m e nt  3. 0, 
d at e d  1 7 J ul y  2 0 1 5  a n d its  ass o ci at e d  el e ctr o ni c  c as e r e p ort f or  ms ( e  C  R F).  
T his  d o c u  m e nt  d es cri b es t h e r ul es  a n d  c o n v e nti o ns t o  b e  us e d i n t h e  a n al ysis  a n d  pr es e nt ati o n  of  effi c a c y 
a n d  s af et y  d at a  as  pl a n n e d  f or  t h e  cli ni c al  pr ot o c ol.  It  d es cri b es,  i n  d et ail,  t h e  d at a  a n d  v ari a bl es  t o  b e 
s u  m  m ari z e d  a n d  a n al y z e d, i n cl u di n g s p e cifi c ati o ns  of t h e  a n al yti c al   m et h o ds t o  b e  p erf or  m e d. 
T his  S  A P  d o es  n ot  c o v er t h e  st atisti c al   m et h o ds f or  dr u g  c o n c e ntr ati o n,  p h ar  m a c o ki n eti c  p ar a  m et ers ( P  K) 
a n d  p h ar  m a c o ki n eti c/ p h ar  m a c o d y n a  mi cs ( P  K/ P  D)  a n al ysis.  T h es e  a n al ys es   will  b e  d es cri b e d i n  a s e p ar at e 
pl a n. 
 
4.      
S  T  U  D  Y  O  B J  E  C  TI  V  E S    
4. 1.      
P ri  m a r y   O bj e cti v es  
T h e  pri  m ar y  s af et y  o bj e cti v e  of t his  st u d y is t o  e v al u at e t h e  s af et y  a n d t ol er a bilit y  of   C  C  X 1 6 8 i n  s u bj e cts 
wit h I g  A  N  o n  b a c k gr o u n d s u p p orti v e t h er a p y   wit h  a   m a xi  m all y t ol er at e d  d os e  of   R  A  A S  bl o c k a d e.  
T h e  pri  m ar y  effi c a c y  o bj e cti v e  is  t o  e v al u at e  t h e  effi c a c y  of    C  C  X 1 6 8  b as e d  o n  a n  i  m pr o v e  m e nt  i n 
pr ot ei n uri a.  
4. 2.      
S e c o n d a r y   O bj e cti v es   
T h e s e c o n d ar y  o bj e cti v es  of t his st u d y i n cl u d e  ass ess  m e nt  of:   
1.    C h a n g e i n  al b u  mi n uri a   wit h   C  C  X 1 6 8 tr e at  m e nt;  
2.    C h a n g e i n r e n al f u n cti o n  b as e d  o n  e  G F  R   wit h   C  C  X 1 6 8 tr e at  m e nt;  
3.    C h a n g e i n  h e  m at uri a   wit h   C  C  X 1 6 8 tr e at  m e nt;  
4.    C h a n g e  i n  r e n al  i nfl a  m  m at or y  a cti vit y  b as e d  o n  uri n ar y    m o n o c yt e  c h e  m o attr a ct a nt  pr ot ei n  -1 
(  M  C P 1): cr e ati ni n e r ati o  a n d  uri n ar y  e pi d er  m al  gr o  wt h f a ct or ( E  G F):  M  C P -1 r ati o   wit h   C  C  X 1 6 8 
tr e at  m e nt;  
5.    C h a n g e i n s er u  m I g  A: pl as  m a   C 3 r ati o   wit h   C  C  X 1 6 8 tr e at  m e nt;  
6.    C h a n g es  i n  p h ar  m a c o d y n a  mi c    m ar k ers  i n  pl as  m a  a n d  uri n e   wit h   C  C  X 1 6 8  tr e at  m e nt,  e. g.,   C 3 a, 
C 5 a,  pr o  p er di n,  a n d s  C 5 b - 9;  
7.    E v al u ati o n  of t h e  p h ar  m a c o ki n eti c  pr ofil e  of   C  C  X 1 6 8 i n s u bj e cts   wit h I g  A  N.  
 
 
 


C h e  m o  C e ntr y x, I n c.   
 
St atisti c al   A n al ysis  Pl a n  
Pr ot o c ol   C L 0 0 5- 1 6 8  
 
3   O ct o b er  2 0 1 6  
 
C o nfi d e nti al   
8  
5.      
S  T  U  D  Y   D  E SI  G  N  
5. 1.      
G e n e r al   D es c ri pti o n   
T his is  a n  o p e n -l a b el,  si n gl e  ar  m  st u d y t o t est t h e s af et y, t ol er a bilit y,  a n d  effi c a c y  of   C  C  X 1 6 8 i n r e d u ci n g 
pr ot ei n uri a i n  p ati e nts   wit h I g  A  N  a n d  p ersist e nt  pr ot ei n uri a  d es pit e  s u p p orti v e t h er a p y   wit h  a   m a xi  m all y 
t ol er at e d   R  A  A S  bl o c k er.   
T h e  st u d y  i n cl u d es  a  ≤ 1 4  d a ys  s cr e e ni n g  p eri o d,  a  ≤ 4   w e e ks  of   R  A  A S  d os e  titr ati o n  p eri o d,  a  ≤ 7  d a ys 
uri n ar y   P  C  R  a n d  e  G F  R  eli gi bilit y  c o nfir  m ati o n  p eri o d,   a n  8    w e e ks  r u n -i n  p eri o d,  a n d  a  1 2    w e e ks 
tr e at  m e nt  p eri o d, f oll o  w e d  b y  a  1 2   w e e ks  of f oll o  w- u p  p eri o d.  
P ati e nts   w h o   m e et t h e i n cl usi o n  crit eri a  i n cl u di n g  
•      bi o ps y- pr o v e n I g  A  N   
•      pr ot ei n uri a  >  1  g/ g  cr e ati ni n e ( b y first   m or ni n g  uri n ar y  P  C  R )  
a n d  n o n e  of t h e  e x cl usi o n  crit eri a   will  b e  e nr oll e d f or  bl o o d  pr ess ur e/  R  A  A S  bl o c k a d e titr ati o n  a n d r u n -i n 
p eri o d.  P ati e nts’   R  A  A S  bl o c k e r(s)  d os e   will  b e titr at e d t o  a   m a xi  m all y t ol er at e d  d os e (  M T  D) t o  a c hi e v e  a 
st a bl e  bl o o d  pr ess ur e t ar g et  of  < 1 2 5/ 7 5   m  m  H g  ( S  B P/  D  B P).  P ati e nts   will  b e   m ai nt ai n e d  o n t h e st a bl e  d os e 
of  t h e    R  A  A S  bl o c k er(s)  f or  t h e  r u n -i n,  tr e at  m e nt  a n d  f oll o  w-u p  p eri o ds.    D uri n g  t h e  r u n -i n  p eri o d, 
p ati e nts’  uri n ar y  pr ot ei n:  cr e ati ni n e  r ati o   will  b e  c oll e ct e d  a n d t h e  sl o p e  o v er ti  m e   will  b e  c al c ul at e d t o 
f or  m t h e  b as eli n e f or t h e  pri  m ar y  e n d p oi nt  a n al ysis. I n t h e tr e at  m e nt  p eri o d,  p ati e nts   will r e c ei v e   C  C  X 1 6 8 
b.i. d.   T h e  s c h e d ul e   of  d at a  c oll e cti o n  is  f o u n d  i n  St u d y    Di a gr a  m  a n d   Ti  m e  a n d   E v e nts   T a bl e   i n  t h e 
s e cti o ns  b el o  w. 
5. 2.      
St u d y   T r e at  m e nt  
C  C  X 1 6 8,  3  0  m g,   will  b e  a d  mi nist er e d  b  .i. d.  d uri n g t h e tr e at  m e nt  p eri o d. 
5. 3.      
R a n d o  mi z ati o n    M et h o d ol o g y   
T h er e is  o nl y  o n e tr e at  m e nt  gr o u p i n t h e st u d y.   N o r a n d o  mi z ati o n   will  b e  p erf or  m e d.  
5. 4.      
St o p pi n g   R ul es  a n d   U n bli n di n g  
T o s af e g u ar d t h e s u bj e ct’s   w ell -b ei n g, t h e tri al st o p pi n g  crit eri a  ar e s et  u p  as f oll o  ws.  
•      If  > 2 5  %  of  t h e  p ati e nts  (  N > 4)  h a v e  d e v el o p e d    C T  C  A E  ( v 4. 0 3)  st u d y  dr u g-r el at e d    Gr a d e  3 + 
l e u k o p e ni a, n e utr o p e ni a,  or l y  m p h o p e ni a  d e e  m e d  p ossi bl y  r el at e d  t o   C  C  X 1 6 8  us e , t h e tri al   will 
b e st o p p e d. 
•      T h e  S p o ns or   will  c o nsi d er  st o p pi n g t h e  st u d y if  at l e ast  o n e  s u bj e ct  d e v el o ps  s e v er e li v er i nj ur y 
b eli e v e d   t o   b e   c a us e d   b y    C  C  X 1 6 8.   S e v er e   li v er   i nj ur y   is   b as e d   o n   H y’s   l a  w   ( el e v at e d 
a  mi n otr a nsf er as e  of  > 3  x  u p p er  li  mit  of  n or  m al  [  U L  N],  al k ali n e  p h os p h at as e  < 2  x    U L  N,  a n d 
ass o ci at e d   wit h  a n  i n cr e as e  i n  t ot al  bilir u bi n  ≥ 2  x   U L  N).  If  a n y  s u bj e ct   w h o  r e c ei v es   C  C  X 1 6 8 
d e v el o ps  h e p ati c  a  mi n otr a nsf er as e  or t ot al  bilir u bi n  e l e v ati o ns  of  > 3  x   U L  N,   C  C  X 1 6 8  us e   will  b e 
st o p p e d i n t his s u bj e ct.. 
 


C h e  m o  C e ntr y x, I n c.   
 
St atisti c al   A n al ysis  Pl a n  
Pr ot o c ol   C L 0 0 5- 1 6 8  
 
3   O ct o b er  2 0 1 6  
 
C o nfi d e nti al   
9  
5. 5.      
St u d y  S c h e  m a  
 
 
 
5. 6.      
St u d y  P r o c e d u r es  
T h e s c h e d ul e  of  e v e nts,  as  o utli n e d i n t h e st u d y  pr ot o c ol, is  pr o vi d e d  b el o  w. 
 


C h e  m o  C e ntr y x, I n c.   
 
St atisti c al   A n al ysis  Pl a n  
Pr ot o c ol   C L 0 0 5- 1 6 8  
 
3   O ct o b er  2 0 1 6  
 
C o nfi d e nti al   
1 0  
S  C  H  E  D  U  L  E   O F   E  V  E  N  T S  
 
St u d y   D a y
1 
 
S c r e e ni n g 2 
Tit r ati o n       
R u n  -i n 
T r e at  m e nt   
F oll o  w -u p  
     ≤  1 4  d a ys      ≤  2 8  d a ys      -6 3      -3 5      -7 t o  -2  
1
3 
8      1 5      2 9      4 3      5 7       8 5      1 1 3      1 4 1      1 6 9  
I nf or  m e d  c o ns e nt 
X   
     
     
     
     
     
     
     
     
     
     
     
     
     
 
D e  m o gr a p hi cs,   m e di c al  hist or y,  pri or 
m e di c ati o ns   
X   
     
     
     
     
     
     
     
     
     
     
     
     
     
 
P h ysi c al  e x a  mi n ati o n
4  
X   
     
     
     
     
X 5     
     
     X  
X       X  
X  
X       
     
X  
Bl o o d   pr ess ur e
6 
X       
X       
X       
X       
X  ,   X     
X       X       X       X       X       X       X       
X       
X       
X   
R  A  A S  bl o c k er  d os e titr ati o n
7 
     
(  X)     
     
     
     
     
     
     
     
     
     
     
     
     
 
R  A  A S  bl o c k er st a bl e  d osi n g  at   M T  D   
 
     
X   →       →        
→        
→        →        →        →        →        →        →        →        →        →    
Ot h er  vit al si g ns
8  
X   
     
     
     
     
X 5     X       X       X       X       X       X       
X       
X       
X   
S er u  m  pr e g n a n c y t e st f or   w o  m e n  of 
c hil d b e ari n g  p ot e nti al  
X   
 
     
 
X  
 
     
     X       X       X       X       
X   
 
X   
HI  V,   H  B  V,   H  C  V t esti n g   
X   
     
     
     
     
     
     
     
     
     
     
     
     
     
 
S er u  m  c h e  mistr y
9,  h e  m at ol o g y 
X   
     
     
     
     
X 5     X       X       X       X       X       X       
X       
X       
X   
S er u  m  cr e ati ni n e ( n ot f ull  c h e  mistr y)  
 
     
X       
X       
X       
     
     
     
     
     
     
     
     
     
 
Uri n al ysis
1 0 
X   
     
     
     
     
X 5     X       X       X       X       X       X       
X       
X       
X   
Uri n e  pr ot ei n  a n d  cr e ati ni n e  a ss a ys   
X   
     
X       
X       
X  ,   X     
X 5     X       X       X            X       X       
X       
X       
X   
R e n al  bi o ps y
1 1 
X   
     
     
     
     
     
     
     
     
     
     
X       
     
     
 
Uri n e  al b u  mi n,   M  C P  -1,  E  G F,  a n d 
mi cr os c o pi c   R  B  C  c o u nt   
 
     
X       
X       
X       
X 5     X       X       X            X       X       
X       
X       
X   
S er u  m I g  A  a n d  pl as  m a   C 3 s a  m pl es  
 
     
     
     
     
X 5     
     
     X            X       X       
X       
X       
X   
C  C  X 1 6 8  dis p e nsi n g    
 
     
     
     
     
X 5     X       X       X       X       X       
     
     
     
 
C  C  X 1 6 8  d osi n g  3 0   m g  b.i. d.   
 
     
     
     
     
X   →       →        →        →        →        →        →  X        
     
     
 
C  C  X 1 6 8  a c c o u nt a bilit y   
 
     
     
     
     
     
X       X       X       X       X       X       
     
     
 
P  D  pl as  m a  s a  m pl e  c oll e cti o n
1 3 
 
     
     
     
     
X 5     X       X       X            X       X       
X       
X       
X   
P  D  uri n e s a  m pl e  c oll e cti o n  
 
     
     
     
     
X 5     X       X       X            X       X       
X       
X       
X   
P  K  pl as  m a  s a  m pl e  c oll e cti o n
1 3 
 
     
     
     
     
X 5     X       X       X       X       X       X       
     
     
 
C o n c o  mit a nt   m e di c ati o ns   
X       
X       
X       
X       
X  ,   X     
X 5     X       X       X       X       X       X       
X       
X       
X   
A d v ers e  e v e nt  ass ess  m e nt   
 
X       
X       
X       
X  ,   X     
X 5     X       X       X       X       X       X       
X       
X       
X   
1 Visit   D a ys  1,  8,  a n d  1 5   m ust  o c c ur  o n t h e s c h e d ul e d st u d y  d a ys.   Visit   D a ys  2 9,  4 3,  5 7,  a n d  8 5   m a y  o c c ur   wit hi n  a  +/  -  2-d a y   wi n d o  w  of t h e s c h e d ul e d  visit.   Visit   D a ys 
1 1 3,  1 4 1,  a n d  1 6 9   m a y  o c c ur   wit hi n  a  +/ -  4-d a y   wi n d o  w  of t h e s c h e d ul e d  visit.  
2 S cr e e ni n g   m ust  o c c ur   wit hi n  a  p eri o d  n ot t o  e x c e e d  1 4  d a ys.  


C h e  m o  C e ntr y x, I n c.   
 
St atisti c al   A n al ysis  Pl a n  
Pr ot o c ol   C L 0 0 5- 1 6 8  
 
3   O ct o b er  2 0 1 6  
 
C o nfi d e nti al   
1 1  
3 St art  of  d osi n g   wit h   C  C  X 1 6 8.  
4 P h ysi c al  e x a  mi n ati o n   will i n cl u d e  b o d y   w ei g ht   m e a s ur e  m e nt;   H ei g ht   will  o nl y  b e   m e a s ur e d  at  S cr e e ni n g.  
5 T h es e  pr o c e d ur es   m ust  b e  d o n e   B E F  O  R E t a ki n g t h e first  d os e  of st u d y   m e di c ati o n.   
6 Bl o o d   pr ess ur e  n e e ds t o  b e   m e as ur e d i n t h e s u pi n e  p ositi o n  aft er  3   mi n ut e s  of r est.  
7 F o ur -w e e k  d os e titr ati o n  p eri o d  o nl y  n e e d e d f or  p ati e nts   w h o  ar e  n ot  o n  a   m a xi  m u  m t ol er at e d  d os e  of  a   R  A  A S  bl o c k er,  or st a bl e  d os e   of t  w o   R  A  A S  bl o c k ers.  
8 Ass ess  m e nt  of  h e art r at e  a n d  b o d y t e  m p er at ur e   
9 S er u  m  c h e  mistr y i n cl u di n g  cr e ati ni n e   m e a s ur e  m e nts  
1 0 S u bj e cts   will  b e  as k e d t o  v oi d t h eir  bl a d d ers  c o  m pl et el y,  a n d  a r e pr es e nt ati v e  cl e a n  c at c h,   mi dstr e a  m  uri n e s a  m pl e   will  b e  c oll e ct e d.   Uri n al ysis i n cl u d e s  p  H, s p e cifi c 
gr a vit y,  gl u c os e,  nitrit e,  k et o n es,  bilir u bi n,  ur o bili n o g e n,   R  B  Cs,  a n d    W  B  Cs.  
1 1 R e n al  bi o ps y is  a n  o pti o n al  pr o c e d ur e f or t his st u d y,  e x c e pt if  n e c e ss ar y f or  eli gi bilit y  a ss e ss  m e nt.   
1 2 Bl o o d s a  m pl es   will  b e  p ut i n   w et i c e i  m  m e di at el y  aft er  c oll e cti o n,  c e ntrif u g e d i n  a r efri g er at e d  c e ntrif u g e  a n d  pl as  m a  p ut  at   -7 0  °  C.   
1 3P  K  bl o o d s a  m pl e ( 4   m L)   will  b e  c oll e ct e d  pri or t o t h e   m or ni n g  d os e  o n   D a y  1  a n d  at  0. 5,  1,  2,  3,  4,  a n d  6  h o urs f oll o  wi n g  d os i n g. 
 


C h e  m o  C e ntr y x, I n c.   
 
St atisti c al   A n al ysis  Pl a n  
Pr ot o c ol   C L 0 0 5- 1 6 8  
 
3   O ct o b er  2 0 1 6  
 
C o nfi d e nti al   
1 2  
6.      
D  E FI  NI  TI  O  N S   
T a bl e   1 .   T er  mi n ol o g y  a n d   D efi niti o n  
T e r  mi n ol o g y       
D efi niti o n   
A g e   
A g e is  c al c ul at e d  as t h e  n u  m b er  of f ull  y e ars  si n c e  d at e  of  birt h  at t h e ti  m e  of 
si g ni n g t h e I nf or  m e d   C o ns e nt  F or  m (I C F).  
St u d y   Dr u g 
C  C  X 1 6 8   
St u d y   D a y 
T h e  n u  m b er  of  d a ys  r el ati v e t o t h e  v er y  first  d a y  w h e n t h e  s u bj e ct r e c ei v es  a 
d os e  of  t h e  st u d y  dr u g.  F or  visits  pri or  t o  t h e  first  d os e  of  t h e  st u d y  dr u g, 
St u d y   D a y is  c al c ul at e d  as   Visit   D at e    mi n us t h e first  d os e  d at e.  F or  visits  aft er 
t h e  first  d os e,   St u d y    D a y  is  c al c ul at e d  as    Visit    D at e   mi n us t h e  first   d os e 
d at e  pl us  1. 
S cr e e n e d  
S u bj e ct   w h o  h as si g n e d i nf or  m e d  c o ns e nt.  
E nr oll e d  
S u bj e ct   w h o  h as  e nt er e d t h e   R  A  A S  d os e titr ati o n/r u n -i n  p eri o d 
Tr e at e d  
S u bj e ct   w h o  h as r e c ei v e d  a  d os e  of t h e st u d y  dr u g. 
Tr e at  m e nt  P eri o d      
Fr o  m t h e first  d os e t o t h e l ast  d os e, i n cl usi v e,  of t h e st u d y  dr u g 
F oll o  w- u p  P eri o d     
Aft er t h e l ast  d os e,  e x cl usi v e,  of t h e st u d y  dr u g 
C o  m pl et er f or t h e 
tr e at  m e nt 
S u bj e ct   w h o  h as  c o  m pl et e d  t h e  1 2   w e e ks  of t h e tr e at  m e nt  p eri o d   wit h   D a y  8 5 
ass ess  m e nt.  
C o  m pl et er f or t h e st u d y      S u bj e ct   w h o  h as  c o  m pl et e d  t h e  1 2   w e e ks  of t h e tr e at  m e nt  p eri o d  a n d f oll o  w-
u p  p eri o d. 
B as eli n e   
G e n er all y,  b  as eli n e is  d efi n e d  as t h e  n o n -missi n g  v al u e  c oll e ct e d   m ost  r e c e nt 
t o  a n d  b ef or e t h e ti  m e  of t h e  v er y first  d os e  of t h e  st u d y  dr u g u nl ess  s p e cifi e d 
ot h er  wis e . F or  uri n ar y  P  C  R,  b as eli n e   will  b e  t h e  g e o  m etri c   m e a n  of  t h e t  w o 
m e as ur e  m e nts    m a d e  i n  t h e   D a y    -7  t o   -2    wi n d o  w  pl us  t h e    D a y  1  ( pr e - d os e) 
v al u e.   F or  t h e   e  G F  R,   uri n ar y    A  C  R,    M  C P -1: cr e ati ni n e  r ati o,    E  G F:  M  C P -1 
r ati o,  a n d   mi cr os c o pi c   R  B  C  c o u nt,  b as eli n e   will  b e t h e  ge o  m etri c   m e a n  of t h e 
o n e   m e as ur e  m e nt   m a d e i n t h e   D a y  -7 t o  2   wi n d o  w  pl us t h e   D a y  1 ( pr e - d os e) 
v al u e.  
Pr e -tr e at  m e nt   A d v ers e 
E v e nt  
A d v ers e  e v e nt  st arti n g/  w ors e ni n g  pri or  t o  t h e  ti  m e  of  t h e  first  d os e  of  t h e 
st u d y  dr u g  a d  mi nistr ati o n. 
T r e at  m e nt E  m er g e nt 
A d v  ers e  E v e nt  
A d v ers e  e v e nt  st arti n g/  w ors e ni n g  b et  w e e n t h e first  a n d l ast  d os e  of t h e  st u d y 
dr u g  a d  mi nistr ati o n. 
P ost -tr e at  m e nt   A d v ers e 
E v e nt  
A d v ers e  e v e nt st arti n g/  w ors e ni n g  aft er t h e l ast  d os e  of t h e st u d y  dr u g. 
Pri or   M e di c ati o n      
M e di c ati o n  o n t h e  Pri or/  C o n c o  mit a nt    M e di c ati o n   C  R F   wit h  st art  d at e  pri or t o 
St u d y   D a y  1. 
C o n c o  mit a nt 
M e di c ati o n   
M e di c ati o n  c oll e ct e d  o n t h e  Pri or/  C o n c o  mit a nt   M e di c ati o n   C  R F   wit h  e n d  d at e 
o n/ aft er  St u d y   D a y  1, i n cl u di n g   missi n g  e n d  d at e  or   m e di c ati o n  o n g oi n g. 
 
 
 


C h e  m o  C e ntr y x, I n c.   
 
St atisti c al   A n al ysis  Pl a n  
Pr ot o c ol   C L 0 0 5- 1 6 8  
 
3   O ct o b er  2 0 1 6  
 
C o nfi d e nti al   
1 3  
7.      
E F FI  C  A  C  Y   A  N  D  S  A F  E  T  Y   V  A  RI  A  B  L  E S    
All  effi c a c y  v ari a bl es  ar e  d eri v e d fr o  m l a b or at or y  bl o o d  a n d  uri n e s a  m pl es,  u nl ess i n di c at e d  ot h er  wis e.   
7. 1.      
P ri  m a r y   Effi c a c y   E n d p oi nt  
•      C h a n g e i n  sl o p e  of first   m or ni n g  uri n ar y  P  C  R ( pr ot ei n: cr e ati ni n e   r ati o) fr o  m t h e  8-w e e k   R  A  A S 
bl o c k er r u n -i n  p eri o d t o t h e  1 2-  w e e k tr e at  m e nt  p eri o d. 
7. 2.      
Ot h e r   Effi c a c y   E n d p oi nts   
1.    Pr o p orti o n  of  s u bj e cts  a c hi e vi n g  r e n al  r es p o ns e,  d efi n e d  as  a n  i  m pr o v e  m e nt  i n  pr ot ei n uri a 
b as e d  o n  a  d e cr e as e fr o  m  b as eli n e t o   D a y  8 5 i n  pr ot ei n uri a t o  a l e v el  < 3 0 0   m g/ g  cr e ati ni n e 
a n d   m ai nt ai ni n g  esti  m at e d  gl o  m er ul ar filtr ati o n r at e ( e  G F  R)   wit hi n  1 5  %  of  b as eli n e  
2.    Pr o p orti o n  of  s u bj e cts  a c hi e vi n g  a  p arti al  r e n al  r es p o ns e,  d efi n e d  as  a n  i  m pr o v e  m e nt  i n 
pr ot ei n uri a  b as e d  o n  a  d e cr e as e  fr o  m  b as eli n e  t o    D a y  8 5  i n  pr ot ei n uri a  t o  a  l e v el  < 1  g/ g 
cr e ati ni n e  a n d   m ai nt ai ni n g  e  G F  R   wit hi n  1 5  %  of  b as eli n e   
3.    C h a n g e i n sl o p e fr o  m t h e r u n-  i n  p eri o d t o t h e tr e at  m e nt  p eri o d f or  
a.      
uri n ar y   A  C  R,   
b.      
e  G F  R,   
c.      
uri n ar y   M  C P -1: cr e ati ni n e  r ati o,  
d.      
uri n ar y  E  G F:  M  C P - 1 r ati o,  a n d  
e.      
uri n ar y   m i cr os c o pi c   R  B  C  c o u nts  
4.    P er c e nt  c h a n g e fr o  m  b as eli n e t o   D a y  8 5 i n  
a.      
uri n ar y  P  C  R  a n d  
b.      
uri n ar y   A  C  R   
5.    C h a n g e fr o  m  b as eli n e   (  C F  B) t o   D a y  8 5 i n  e  G F  R  
6.    I n  p ati e nts    wit h  h e  m at uri a  at  b as eli n e,  t h e  p er c e nt  c h a n g e  fr o  m  b as eli n e  i n  uri n ar y   R  B  C 
c o u nt  
7.    P er c e nt  c h a n g e fr o  m   b as eli n e t o   D a y  8 5 i n  uri n ar y   M  C P- 1: cr e ati ni n e r ati o  
8.    P er c e nt  c h a n g e fr o  m  b as eli n e t o   D a y  8 5 i n s er u  m I g  A: pl as  m a   C 3 r ati o  
9.    P er c e nt  c h a n g e fr o  m  b as eli n e t o   D a y  8 5 i n  uri n ar y  E  G F:  M  C P - 1 r ati o  
1 0.  P er c e nt  c h a n g e  fr o  m  b as eli n e i n  pl as  m a  a n d  uri n ar y  bi o  m ar k ers,  e. g.,   C 3 a,   C 5 a,  pr o p er di n, 
a n d s  C 5 b- 9 ; if  p erf or  m e d, r es ults fr o  m t h es e  a n al ys es   will  b e  pr es e nt e d i n  a s e p ar at e r e p ort  
7. 3.      
S af et y   V a ri a bl es  
T h e  pri  m ar y s af et y  e n d p oi nt is t h e s u bj e ct i n ci d e n c e  of  a d v ers e  e v e nts.  
Ot h er s af et y  e n d p oi nts i n cl u d e:   
•     C  h a n g es fr o  m  b as eli n e i n  all s af et y l a b or at or y  p ar a  m et ers;  
•     C h a n g  es fr o  m  b as eli n e i n  vit al si g ns.  
 
8.      
A  N  A  L  Y SI S   P  O P  U  L  A  TI  O  N S  
T h e f oll o  wi n g  s u bj e ct  p o p ul ati o ns will  b e   e v al u at e d  a n d  us e d f or  pr es e nt ati o n  a n d  a n al ysis  of t h e  d at a:  
•      S af et y   P o p ul ati o n i n cl u d es  of  all s u bj e cts   w h o  h a v e r e c ei v e d  at l e ast  o n e  d os e  of st u d y  dr u g. 


C h e  m o  C e ntr y x, I n c.   
 
St atisti c al   A n al ysis  Pl a n  
Pr ot o c ol   C L 0 0 5- 1 6 8  
 
3   O ct o b er  2 0 1 6  
 
C o nfi d e nti al   
1 4  
•      M o difi e d  I nt e nt   -t o-T r e at  m e nt  (  mI  T  T)     P o p ul ati o n i n cl u d es all  s u bj e cts   w h o  h a v e  r e c ei v e d  at 
l e ast  o n e  d os e  of st u d y  dr u g,  a n d  h a v e  at l e ast  o ne  p ost  b as eli n e  uri n ar y  P  C  R  ass ess  m e nt .   
•      P e r -P r ot o c ol ( p P)  P o p ul ati o n  i n cl u d es all    MI T T  s u bj e cts   w h o  h a v e  c o  m pli e d   wit h t h e  pr ot o c ol 
f or  t h e  st u d y  dr u g  a d  mi nistr ati o n,  h a v e  b e e n  o n  st a bl e    R  A  A S  d os e,  a n d  n ot  t a k e n  pr ot o c ol-
pr o hi bit e d  c o n c o  mit a nt   m e di c ati o n s. 
T h e   S af et y   p o p ul ati o n     will   b e   us e d   f or   t h e   s u  m  m ari es   of   dis p ositi o n,   d e  m o gr a p hi cs,   b as eli n e 
c h ar a ct eristi cs,   m e di c al  hist or y,  a n d  pri or/ c o n c o  mit a nt   m e di c ati o ns.   A d diti o n all y, t h e  S af et y  p o p ul ati o n 
will  b e  us e d f or t h e s u  m  m ari es  of  a d v ers e  e v e nts, l a b or a  t or y t ests,  E  C  G,  a n d  vit al si g ns. 
T h e   mI T T  a n d  p P  p o p ul ati o ns   will  b e  us e d f or t h e s u  m  m ari es  of t h e  effi c a c y  e n d p oi nts. 
 
9.      
D  A  T  A   R  E  VI  E   W   A  N  D  P  R  E S  E  N  T  A  TI  O  N   
9. 1.      
D at a  S c r e e ni n g   
I n  a d diti o n t o t h e r o uti n e  d at a r e vi e  w f or i n di vi d u al s u bj e cts,  all  e  C  R F  d at a   will  b e  p eri o di c all y r e vi e  w e d 
f or  c o nsist e n c y  a n d  a c c ur a c y  a cr oss s u bj e cts.  T h e  p eri o di c  d at a r e vi e  w   m a y i n v ol v e  a d  h o c  pr o gr a  m  mi n g 
t o  g e n er at e  e dit  c h e c ks.    W h e n  a v ail a bl e, t a bl es, fi g ur es,  a n d listi n gs ( T F L)   m a y  b e  us e d t o i d e ntif y  d at a 
iss u es  pri or t o t h e d at a b as e l o c k.    
9. 2.      
P r ot o c ol   D e vi ati o ns  
All  pr ot o c ol  d e vi ati o ns   will  b e  cl assifi e d  as   m aj or  or   mi n or  b as e d  o n t h e f oll o  wi n g  g ui d eli n es: 
•      M aj or  pr ot o c ol  d e vi ati o ns  ar e t h os e t h at  vi   ol at e   G o o d   Cli ni c al  Pr a cti c e  (  G  C P)  g ui d eli n es  (I C  H 
E 6 )  a n d  i  m p a ct  t h e  a bilit y  t o  a n al y z e  t h e  d at a  c oll e ct e d.   E x a  m pl es    m a y  i n cl u d e  b ut  ar e  n ot 
li  mit e d t o:  f ail ur e t o  a d  mi nist er t h e i nf or  m e d  c o ns e nt  pri or t o i niti ati n g  st u d y  pr o c e d ur es;  n o n-
c o  m pli a n c e    wit h  t a ki n g  st u d y    m e di c ati o n  (l ess  t h a n  7 5  %  of    m e di c ati o n  t a k e n  b as e d  o n  st u d y 
r e c or ds  or   l o  w   pl as  m a    C  C  X 1 6 8   c o n c e ntr ati o ns   i n di c ati n g   n o n -c o  m pli a n c e );   vi ol ati o ns   of 
i n cl usi o n  a n d/ or  e x cl usi o n  crit eri a t h at  c o ul d  aff e ct t h e  effi c a c y r es ults. 
•      Mi n or   d e vi ati o ns     m a y     i n cl u d e   b ut   ar e   n ot   li  mit e d   t o:   o ut- of-wi n d o  w   visits;   s c h e d ul e d 
ass ess  m e nts  o  mitt e d  or  p erf or  m e d i n i  m pr o p er s e q u e n c e.   
Pr ot o c ol  d e vi ati o ns   will  b e  c at e g ori z e d f or  d at a s u  m  m ar y   p ur p os e.   
9. 3.      
D at a  P r es e nt ati o n   
T h e f oll o  wi n g r ul es  d es cri b e r e p orti n g  c o n v e nti o ns f or t h e st u d y. 
•      R e p ort  o ut p ut   will  b e  pr o vi d e d  as   Ri c h  T e xt  F or  m at (  R T F)  or  P ort a bl e   D o c u  m e nt  F or  m at ( P  D F) 
d o c u  m e nts  g e n er at e d  usi n g  S  A S. 
•      F o nt  –  C o uri er   N e  w  or  S  A S  f o nt   wit h   mi ni  m u  m  of  9  p oi nt  f o nt  si z e  f or t a bl es  a n d  7  p oi nt  f or 
listi n gs. 
•      M ar gi ns    –  Mi ni  m  u  m  of  3/ 4 ”  b o u n d  e d g e   m ar gi n  a n d  3/ 8 ”  ot h er   m ar gi ns  o n  8. 5 ” x 1 1 ”  p a p er  as 
p er t h e  F  D  A  g ui d a n c e f or  e- s u b  missi o n. 
•      C o nti n u o us    d at a     will    b e   s u  m  m ari z e d    usi n g    n   ( n u  m b er    of   s u bj e cts     wit h    n o n  -missi n g 
o bs er v ati o ns),   m e a n,   m e di a n,  st a n d ar d  d e vi ati o n  ( S T D),    mi ni  m u  m  v  al u e,  a n d   m a xi  m u  m  v al u e . 
G e o  m etri c   m e a ns   a n d  g e o  m etri c   m e a n  r ati os  (  Visit:  B as eli n e)  will  als o  b e  pr o vi d e d  f or  uri n ar y 
P  C  R,    A  C  R,    R  B  C  c o u nt,    M  C P -1: cr e ati ni n e,   E  G F:  M  C P -1  r ati o ,  E  G F:  M  C P -1  r ati o ,  a n d  s er u  m 
I g  A: pl as  m a   C 3 r ati o. C o nfi d e n c e i nt er v als   will  als o  b e  pr o vi d e d f or  effi c a c y  p ar a  m et ers.   


C h e  m o  C e ntr y x, I n c.   
 
St atisti c al   A n al ysis  Pl a n  
Pr ot o c ol   C L 0 0 5- 1 6 8  
 
3   O ct o b er  2 0 1 6  
 
C o nfi d e nti al   
1 5  
•      C at e g ori c al  d at a   will  b e s u  m  m ari z e d  usi n g t h e fr e q u e n c y  c o u nt  a n d  p er c e nt a g e ( n,   %)  of s u bj e cts 
i n  e a c h  c at e g or y.    C o nfi d e n c e  i nt er v al  f or  t h e  p er c e nt a g e    will  b e  c al c ul at e d  f or  t h e  effi c a c y 
v ari a bl es.   
•      N u  m b er  of  s u bj e cts   wi  t h  n o n-missi n g  v al u es  or  n u  m b er  of  s u bj e cts   wit h   missi n g  v al u es ( e g,   N ot 
D o n e)   will  b e  pr es e nt e d,   w h er e  a p pr o pri at e.  S u bj e cts   wit h   missi n g  v al u es   will  n ot  c o ntri b ut e t o 
t h e  d e n o  mi n at or  of  p er c e nt a g e  c al c ul ati o ns.  
•      C o u nts  of  z er o i n  a n y  c at e g or y   will  b e  pr es e nt e d   wit h o ut  p er c e nt a g e. 
•      Pr e cisi o n  of s u  m  m ar y st atisti cs:  
o     S a  m pl e si z e ( n,   N)  a n d  n u  m b er  of   missi n g r es p o ns es (if  dis pl a y e d)  –  I nt e g er. 
o     M e a n,  c o nfi d e n c e i nt er v al   –  O n e  a d diti o n al  d e ci  m al  pl a c e t h a n r e p ort e d/ c oll e ct e d  . 
o     St a n d ar d  d e vi ati o n  –  T  w o  a d diti o n a l  d e ci  m al  pl a c es t h a n r e p ort e d/ c oll e ct e d. 
o     M e di a n,  ot h er  p er c e ntil e,    mi ni  m u  m,    m a xi  m u  m    –   S a  m e  n u  m b er  of  d e ci  m al  pl a c es  as 
r e p ort e d/ c oll e ct e d. 
o     R ati os   –  t  w o  d e ci  m al  pl a c es. 
o     P er c e nt a g es  –  o n e  d e ci  m al  pl a c e  g e n er all y,  or t  w o  d e ci  m al  pl a c es f or  < 0. 1  % . 
•      D at a  listi n gs    will  i n cl u d e  p erti n e nt  s u bj e ct  i nf or  m ati o n,  e g,  tr e at  m e nt,  a g e/ g e n d er/r a c e,  st u d y 
d a y.  T h e s e will  b e  s ort e d i n t h e  or d er  of  s u bj e ct I  D,  ass ess  m e nt  d at e/ti  m e  a n d  ass ess  m e nt (i n t h e 
or d er  c oll e ct e d  o n   C  R F,  u nl ess s p e cifi e d  ot h er  wis e) .  
•      D at es   wi  ll  b e  pr es e nt e d i n t h e I S  O-8 6 0 1 f or  m at   Y  Y  Y  Y -M  M  -D  D.  Ti  m es   will  b e  dis pl a y e d i n  2 4  -
h o ur  cl o c k f or  m at. 
•      N u  m b eri n g f or t a bl es, fi g ur es  a n d listi n gs   will f oll o  w I  C  H  E 3   G ui d eli n es. 
 
1 0.      
S  T  A  TI S  TI  C  A  L    M  E  T  H  O  D S  
1 0. 1.      
S a  m pl e  Si z e  J ustifi c ati o n 
T h e  s a  m pl e  si z e  f or t h e  st u d y is  b a s e d  o n t h e  sl o p e  of t h e  uri n ar y   A  C  R  o bs er v e d i n  a  st u d y i n  p ati e nts 
wit h   A  N  C  A  -ass o ci at e d  v as c ulitis   w hil e  r e c ei vi n g   C  C  X 1 6 8.   T h e   m e a n  sl o p e   w as  -1. 3 2,   wit h  a  st a n d ar d 
d e vi ati o n  of  1. 6 7  o v er  1 2   w e e ks,  a n d  -4. 6 2,   wit h  a  st a n d ar d  d e vi ati o n  of  4. 7 7  o v er t h e i ni ti al  4   w e e ks  of 
t h e  tr e at  m e nt    wit h    C  C  X 1 6 8  i n    A  N  C  A-ass o ci at e d   v as c ulitis.    Ass u  mi n g   a    m e a n   diff er e n c e  i n   pr e -
tr e at  m e nt  a n d  o n-tr e at  m e nt  sl o p es  of  4. 6,  a  s a  m pl e  si z e  of  1 5  s u bj e cts   will  pr o vi d e  a p pr o xi  m at el y  8 0  % 
p o  w er  a n d  2 0 s u bj e cts  a p pr o xi  m at el y  9 0  %  p o  w er t o  d et e ct  a  diff er e n c e i n sl o p es.   
1 0. 2.      
G e n e r al   St atisti c al    M et h o ds  a n d   D at a   H a n dli n g  
1 0. 2. 1.      
G e n er al   M et h o ds 
U nl ess  s p e cifi e d  ot h er  wis e,  all  s u  m  m ar y t a bl es   will  b e  pr es e nt e d  b y  visit fr o  m  b as eli n e t o   e n d  of  st u d y  
(  D a y 1 6 9).   
S u  m  m ar y   st atisti cs    will   b e   pr es e nt e d,   as    w e ll   as  2- si d e d   9 5  %   c o nfi d e n c e   i nt er v als   o n   s el e ct e d 
p ar a  m et ers ,  as  d es cri b e d i n t h e s e cti o ns  b el o  w. All  d at a   will  b e i n cl u d e d i n t h e s u bj e ct  d at a listi n g.   


C h e  m o  C e ntr y x, I n c.   
 
St atisti c al   A n al ysis  Pl a n  
Pr ot o c ol   C L 0 0 5- 1 6 8  
 
3   O ct o b er  2 0 1 6  
 
C o nfi d e nti al   
1 6  
1 0. 2. 2.      
C o  m p uti n g  E n vir o n  m e nt 
All  st atisti c al    s u  m  m ari es  a n d  a n al ys es    will  b e  p erf or  m e d  usi n g   S  A S  s oft  w ar e   v 9. 4   or  l at er,  u nl ess 
ot h er  wis e  n ot e d.   A d v ers e  e v e nts   will  b e  c o d e d  usi n g    M e d  D  R  A  v ersi o n  1 7. 1 .   C o n c o  mit a nt   m e di c ati o ns 
will  b e  c o d e d  usi n g    W orl d   H e alt h   Or g a ni z ati o n   Dr u g   Di cti o n ar y (   W  H  O  D  D)   v ersi o n  M ar c h  2 0 1 2.  
1 0. 2. 3.      
Gr o u pi n g  of  S u bj e cts 
T his is  a si n gl e  ar  m st u d y.   Al l s u bj e cts   will  b e  pr es e nt e d  a n d s u  m  m ari z e d i n t h e s a  m e tr e at  m e nt  gr o u p.   
1 0. 2. 4.      
D efi niti o n   of   B as eli n e  
F or  all  a n al ys es,  b as eli n e   will  b e  d efi n e d  as t h e   m ost r e c e nt   m e as ur e  m e nt  pri or t o t h e  d at e  a n d ti  m e  of t h e 
first  a d  mi nistr ati o n  of  C  C  X  1 6 8 . B  as eli n e  c a n  b e  o n t h e  s a  m e  d a y  as t h e  first  d os e  of  st u d y   m e di c ati o n, 
b ut  pri or t o  a d  mi nistr ati o n  of  st u d y  dr u g  (t y pi c all y t h e   D a y  1  pr e-d os e  v al u e) . F or  uri n ar y  P  C  R,  b as eli n e 
will  b e t h e  g e o  m etri c   m e a n  (  G  M)  of t h e t  w o   m e as ur e  m e nts   m a d e i n t h e   D a y   -7 t o  -2   wi n d o  w  pl u s t h e 
D a y  1  ( pr e  -d os e)  v al u e.  F or  t h e  e  G F  R,  uri n ar y    A  C  R,    M  C P -1: cr e ati ni n e  r ati o,   E  G F:  M  C P -1  r ati o,  a n d 
mi cr os c o pi c   R  B  C  c o u nt,  b as eli n e   will  b e t h e  g e o  m etri c   m e a n  of t h e  o n e   m e as ur e  m e nt   m a d e i n t h e   D a y   -
7 t o - 2   wi n d o  w  pl us t h e   D a y  1 ( pr e- d os e)  v al u e.  
1 0. 2. 5.      
M et h o ds   of  P o oli n g   D at a  
N o  p o oli n g  of  d at a   wit h   ot h er st u d i es is  pl a n n e d. 
1 0. 2. 6.      
A dj ust  m e nts f or   C o v ari at es 
N ot  a p pli c a bl e.   
1 0. 2. 7.      
M ulti pl e   C o  m p aris o ns/  M ulti pli cit y   
N ot  a p pli c a bl e.   
1 0. 2. 8.      
S u b p o p ul ati o ns 
N ot e  a p pli c a bl e.   
1 0. 2. 9.      
Wit h dr a  w als,   Dr o p o uts,  L oss t o  F oll o  w- u p 
S u bj e cts   w h o   wit h dr e  w   fr om  t h e  st u d y    will  b e  i n cl u d e d  i n  t h e  d at a  listi n g  a n d  s u  m  m ar y  t a bl es   w h er e 
a p pli c a bl e . 
1 0. 2. 1 0.      Missi n g,   U n us e d,  a n d  S p uri o us   D at a 
N o i  m p ut ati o n   will  b e  c arri e d  o ut   f or missi n g  d at a  p oi nts.   
1 0. 2. 1 1.      Visit    Wi n d o  ws 
N o  visit   wi n d o  w   will  b e  us e d.   All  d at a   will  b e s u  m  m ari z e d   b y t h e  e v al u ati o n  visit r e c or d e d  o n t h e  e  C  R F. 
I n  d at a listi n gs,  all  d at es   will  b e  pr es e nt e d  al o n g   wit h t h e st u d y  d a y r el ati v e t o t h e  d a y  of t h e first  d os e  of 
t h e st u d y  dr u g. 
1 0. 3.      
I nt e ri  m   A n al ys es 
T his is  a n  u n bli n d e d si n gl e  ar  m st u d y.   N o f or  m al i nt eri  m  a n al ysi s   will  b e p erf or  m e d . 
1 0. 4.      
S u bj e ct   Dis p ositi o n  
T h e  n u  m b er  of  s u bj e cts   w h o  h a v e   si g ne d  t h e  i nf or  m e d  c o ns e nt, w h o  e nt er e d  t h e  titr ati o n  p eri o d,   w h o 
e nt er e d t h e r u n -i n  p eri o d,   w h o r e c ei v e d  st u d y  dr u g, w h o   c o  m pl et e d  t h e 1 2- w e e k tr e at  m e nt  p eri o d  of t h e 
st u d y,  w h o  dis  c o nti n u e d t h e  1 2 -w e e k  p eri o d  e arl y (  wit h r e as o ns f or  dis c o nti n u ati o n),   w h o  c o  m pl et e d t h e 


C h e  m o  C e ntr y x, I n c.   
 
St atisti c al   A n al ysis  Pl a n  
Pr ot o c ol   C L 0 0 5- 1 6 8  
 
3   O ct o b er  2 0 1 6  
 
C o nfi d e nti al   
1 7  
1 2- w e e k  f oll o  w  -u p  p eri o d,    w h o  dis c o nti n u e d  t h e  1 2 -w e e k  f oll o  w  -u p  p eri o d  e arl y  (  wit h  r e as o ns  f or 
dis c o nti n u ati o n),  will  b e t a b ul at e d.     
A  b y  -s u bj e ct  d at a   listi n g  of  st u d y  c o  m pl eti o n  i nf or  m ati o n,  i n cl u di n g  t h e  r e as o n  f or  pr e  m at ur e  st u d y 
wit h dr a  w al, if  a p pli c a bl e,   will  b e  pr e  s e nt e d. If  dis c o nti n u ati o n is  d u e t o  a n   A E, t h e   A E   will  b e  s p e cifi e d. 
M aj or  a n d    mi n or  pr ot o c ol  d e vi ati o ns    will  b e  i n cl u d e d  i n  t h e  s u bj e ct  d at a  list   i n g.  S u bj e cts    wit h    m aj or 
pr ot o c ol  d e vi ati o ns  aff e cti n g  effi c a c y  e v al u ati o n   will  b e  e x cl u d e d fr o  m t h e  p P  p o p ul ati o n. 
1 0. 5.      
D e  m o g r a p hi c  a n d   B as eli n e   C h a r a ct e risti cs   
D e  m o gr a p hi cs  ( a g e,  s e x,  r a c e,  a n d  et h ni cit y)  as   w ell  as  h ei g ht  ( c  m),   w ei g ht  ( k g),  a n d   B  MI  at  b as eli  n e 
will  b e  s u  m  m ari z e d  f or   t h e s af et y  p o p ul ati o n  usi n g  d es cri pti v e  st atisti cs.  All  d  e  m o gr a p hi c  d at a   will  b e 
pr o vi d e d i n  a  d at a listi n g.  
I g  A  N  dis ea s e  d ur ati o n,  c al c ul at e d  fr o  m  ti  m e  of  first  r e n al  bi o ps y  di a g n osis  t o  St u d y    D a y  1,    will  b e 
s u  m  m ari z e d   wit h d es cri pti v e st atisti cs.  
1 0. 6.      
Tit r ati o n  a n d   R u n  -I n  P e ri o ds 
T h e  f oll o  wi n g  d at a  c oll e ct e d  d uri n g  t h e  titr ati o n  (if  a p pli c a bl e)  a n d  r u n  -i n  p eri o ds    will  b e  list e d  b y 
s u bj e ct  a n d s u  m  m ari z e d:  
•     Bl o o d  pr ess ur e   m e as ur e  m e nts (s u pi n e,  aft er  at l e ast  3   mi n ut es  of r est);   
•     R  A  A S  bl o c k er(s) t y p e  a n d  d os e titr ati o n  d et ail;   
•     S er u  m  cr e ati ni n e  a n d  e  G F  R   m e as ur e  m e nts;  
•     Uri n ar y  P  C  R  a n d   A  C  R   m e as ur e  m e nts;   
•     Uri n ar y   M  C P  -1: cr e ati ni n e r ati o,  E  G F:  M  C P - 1 r ati o,  a n d  uri n ar y   mi cr os c o pi c   R  B  C  c o u nt  d at a; 
•     C h a n g es   i n   c o n c o  mit a nt     m e di c ati o ns,     wit h   p art  i c ul ar   att e nti o n   t o   t h e   d os e(s)   of    R  A  A S 
bl o c k er(s),  a n d  
•     A n y  pr e-  tr e at  m e nt  a d v ers e  e v e nts r e p ort e d. 
1 0. 7.      
Effi c a c y   E v al u ati o n 
1 0. 7. 1.      
C h a n g e i n sl o p e  of first   m or ni n g  uri n ar y  P  C  R ( pr ot ei n: cr e ati ni n e r ati o) fr o  m t h e  8-  w e e k 
R  A  A S  bl o c k er r u n  -i n  p eri o d t o t h e  1 2-w e e k tr e at  m e  nt  p eri o d 
Sl o p e   will  b e  c al c ul at e d f or  e a c h s u bj e ct  usi n g t h e ti  m e  p oi nts  as f oll o  ws.  
Ti  m e       Wi n d o  w     f or 
Sl o p e   C al c ul ati o n  
Ti  m e  P oi nts   U s e d f or  Sl o p e  C al c ul ati o n   
C orr es p o n di n g      Ti  m e      V al u e 
Us e d f or   R e gr e ssi o n *   
W e e ks    -8 t o  -5      
D a y   -6 3  a n d   D a y  -3 5  
-6 3  a n d  -3 5  
W e e ks    -4 t o  -1      
D a y   -3 5,   D a y  -7 t o  0 2,  a n d   D a y  1  
-3 5,  -5 ,  a n d  0 
W e e ks    -8 t o  -1      
D a y   -6 3,   D a y  -3 5,   D a y  -7 t o  0 2,  a n d   D a y  1  
-6 3,  -3 5,  -5 ,  a n d  0 
W e e ks  1 t o  4        
D a y  1,   D a y  8,   D a y  1 5,  a n d   D a y  2 9   
0,  7,  1 4,  2 8  
W e e ks  1 t o  1 2        
D a y  1,   D a y  8,   D a y  1 5,   D a y  2 9,   D a y  5 7,  a n  d   D a y  8 5      
0,  7,  1 4,  2 8,  5 6,  a n d  8 5  
*  F or   Ti  m e  P oi nt   D a y  -7  t o  -2,  ti  m e  v al u e  of  -5   will  b e  us e d.  F or  St u d y   D a y  o n/ aft er  t h e  first  d os e,  o n e  d a y  is 
s u btr a ct e d t o r et ur n t h e  v al u e t o  c o nti n u o us  s c al e s u c h t h at   D a y  0 is  d a y  of first  d os e.  
F or t h e  pri  m ar y  effi c a c y  e n d p oi nt  a n al ysis, t h e sl o p e  of t h e  uri n ar y  P  C  R  d uri n g t h e  8 -w e e k r u n  -i n  p eri o d, 
d uri n g t h e i niti al  4 -w e e k   tr e at  m e nt  p erio d ,  as   w ell  as t h e f ull  1 2-w e e k tr e at  m e nt  p eri o d   will  b e  c al c ul at e d 
f or  e a c h s u bj e ct.  T h e   m e a n sl o p e f or t h e  8-w e e k r u n  -i n  p eri o d   will  b e  c o  m p ar e d t o t h e   m e a n sl o p e f or t h e 
i niti al  4-w e e k,  as   w ell  as t h e f ull  1 2  -w e e k tr e at  m e nt  p eri o d t o  e v al u at e t h e tr e at  m e n  t  eff e ct  of   C  C  X 1 6 8. 


C h e  m o  C e ntr y x, I n c.   
 
St atisti c al   A n al ysis  Pl a n  
Pr ot o c ol   C L 0 0 5- 1 6 8  
 
3   O ct o b er  2 0 1 6  
 
C o nfi d e nti al   
1 8  
If t h e  sl o p e f or t h e first  4   w e e ks  of t h e r u n-i n  p eri o d is  st e e p er t h a n t h e  sl o p e  of t h e l ast  4   w e e ks  of t h e 
r u n-i n  p eri o d, i n di c ati n g t h at  st e a d y  st at e  h as  n ot  b e e n  a c hi e v e d  o v er t h e first  4   w e e ks, t h e  sl o p e  of t h e 
l ast  4   w e e ks  of t h e r u n-i n  p eri o d will   b e  us e d  as t h e  b as eli n e  sl o p e, i nst e a d  of t h e sl o p e  o v er t h e  8   w e e ks 
of t h e r u n-i n  p eri o d.  T his  c o  m p aris o n   will  b e  p erf or  m e d  b y t h e  p air e d t -t est.  T h e  9 5  %  c o nfi d e n c e i nt er v al 
f or t h e  diff er e n c e i n t h e   m e a n sl o p es   will  b e  pr es e nt e d. 
1 0. 7. 2.      
Pr o p o rti o n  of s u bj e cts  a c hi e vi n g r e n al r es p o ns e 
R e n al  r es p o ns e  is  d efi n e d  as   ( 1)  a  d e cr e as e  i n  pr ot ei n uri a  fr o  m  b as eli n e  t o   D a y  8 5  t o  a  l e v el  of  < 3 0 0 
m g/ g  cr e ati ni n e   a n d ( 2 )   m ai nt ai ni n g t h e D a y  8 5   esti  m at e d  gl o  m er ul ar filtr ati o n r at e ( e  G F  R)   wit hi n  1 5  % 
of  b as eli n e.   T h e  n u  m b er   (  %)  of  s u bj e cts  a c hi e vi n g  r e n al  r es p o ns e    will  b e  c al c ul at e d  a n d  pr es e nt e d.  
S u bj e cts   w h o  dis c o nti n u e d  pri or t o    W e e k  1 2   will  b e  c o u nt e d  as  n o n-r es p o n d ers. 
1 0. 7. 3.      
Pr o p orti o n  of s u bj e cts  a c hi e vi n g  p arti al r e n al r es p o ns e  
P arti al r e n al r es p o ns e is  d efi n e d  as ( 1)  a  d e cr e as e i n  pr ot ei n uri a fr o  m  b as eli n e t o   D a y  8 5 t o  a l e v el  of  < 1 
g/ g   cr e ati ni n e  a n d  ( 2 )    m ai nt ai ni n g  t h e   esti  m at e d   gl o  m er ul ar  filtr ati o n  r at e  ( e  G F  R)    wit hi n   1 5  %   of 
b as eli n e.  T h e  n u  m b er  (  %)  of  s u bj e cts  a c hi e vi n g  p arti al r e n al  r es p o ns e   will  b e  c al c ul at e d  a n d  pr es e nt e d. 
S u bj e cts   w h o  dis c o nti n u e d  pri or t o    W e e k  1 2   will  b e  c o u nt e d  as  n o n-r es p o n d ers. 
1 0. 7. 4.      
C h a n g e i n sl o p e fr o  m t h e r u n-  i n  p eri o d t o t h e tr e at  m e nt  p eri o d f or 
a.      
uri n ar y   A  C  R,   
b.      
e  G F  R,  
c.      
uri n ar y   M  C P - 1: cr e ati ni n e,  
d.      
uri n ar y  E  G F:  M  C P - 1,  a n d  
e.      
uri n ar y   mi cr os c o pi c   R  B  C  c o u nts  
T h es e  v ari a bl es   will  b e s u  m  m ari z e d si  mil arl y t o t h e  pri  m ar y  effi c a c y  v ari a bl e.  
1 0. 7. 5.      
P er c e nt  c h a n g e fr o  m  b as eli n e t o   D a y  8 5 i n  
a.      
uri n ar y  P  C  R  a n d  
b.      
uri n ar y   A  C  R   
Uri n ar y  P  C  R  a n d   A  C  R   will  b e  s u  m  m ari z e d   wit h  g e o  m etri c   m e a n,   m e di a n,   mi ni  m u  m,  a n d   m a xi  m u  m   at 
e a c h  visit . P er c e nt  c h a n g e  fr o  m  b as eli n e   will  b e  b as e d  o n t h e  g e o  m etri c   m e a n  r ati os  of   Visit:  B as eli n e . 
T h e  9 5  %  c o nfi d e n c e i nt er v al f or t h e  g e o  m etri c   m e a n r ati os  will  b e  pr es e nt e d.   
1 0. 7. 6.      
C h a n g e fr o  m  b as eli n e t o   D a y  8 5 i n  e  G F  R  
Esti  m at e d    G F  R  a n d  its  c h a n g e  fr o  m   b as eli n e    will   b e  s u  m  m ari z e d    wit h  arit h  m eti c    m e a n,  st a n d ar d 
d e vi ati o n,  S E  M,   m e di a n,    mi ni  m u  m,  a n d    m a xi  m u  m  at  e a c h    visit .   T h e  9 5  %  c o nfi d e n c e  i nt er v al  f or  t h e 
c h a n g e   will  b e  pr es e nt e d.  
1 0. 7. 7.      
I n  p ati e nts   wit h  h e  m at uri a  at  b as eli n e, t h e  p er c e nt  c h a n g e fr o  m  b as eli n e i n  uri n ar y   R  B  C 
c o u nt  
F or t h e  p ur p os e  of  a n al ysis,  uri n ar y   R  B  C  c o u nt   will  b e r e c o d e d  as f oll o  ws.   N o n e  =  0. 1,   O c c  =  0. 5,  1   - 2 
=  1,  3 -  5  =  3,  6 -  9  =  6,  1 0 -  1 5  =  1 0,  1 6 -  2 9  =  1 6,  3 0 -  4 9  =  3 0;  5 0 -  7 5  =  5 0,  > 7 5  =  7 5.  
T h e   m et h o d  of s u  m  m ar y  d es cri b e d i n  S e cti o n  1 0. 6. 5  a p pli es  h er e. 


C h e  m o  C e ntr y x, I n c.   
 
St atisti c al   A n al ysis  Pl a n  
Pr ot o c ol   C L 0 0 5- 1 6 8  
 
3   O ct o b er  2 0 1 6  
 
C o nfi d e nti al   
1 9  
1 0. 7. 8.      
P er c e nt  c h a n g e fr o  m  b as eli n e t o   D a y  8 5 i n  uri n ar y   M  C P -1: cr e ati ni n e r ati o ;  
P er c e nt  c h a n g e fr o  m  b as eli n e t o   D a y  8 5 i n s er u  m I g  A: pl as  m a   C 3 r ati o ; 
P er c e nt  c h a n g e fr o  m  b as eli n e t o   D a y  8 5 i n  uri n ar y  E  G F:  M  C P - 1 r ati o  
T h e   m et h o d  of s u  m  m ar y  d es cri b e d i n  S e cti o n  1 0. 6. 5  a p pli es  h er e. 
1 0. 7. 9.      
S hift i n   Uri n ar y  P  C  R,   A  C  R,  a n d  h e  m at uri a 
S hift t a bl es   will  b e  cr e at e d f or  uri n ar y  p ar a  m et ers,  s u c h  as  uri n ar y  P  C  R,   A  C  R,  a n d r e d  bl o o d  c ells, fr o  m 
b as eli n e t o  e a c h  visit .   T h e  c at e g ori es  of i nt er est  ar e  < 3 0 0   m g/ g,  3 0 1- 1 0 0 0   m g/ g,  ≥ 1 0 0 0  m g/ g  f or  P  C  R 
a n d   A  C  R,  a n d  ≤ 5   R  B  Cs/ h pf,  > 5 t o  < 3 0   R  B  Cs/ h pf,  a n d  ≥ 3 0   R  B  Cs/ h pf f or  uri n ar y   R  B  C  c o u nt.  
1 0. 7. 1 0.      P er c e nt  c h a n g e fr o  m  b as eli n e i n  pl as  m a  a n d  uri n ar y  bi o  m ar k ers,  e. g.,   C 3 a,   C 5 a,  pr o p er di n, 
a n d s  C 5 b- 9  
If  c o n d u ct e d, t h e r es ults   will  b e  pr es e nt e d i n  a s e p ar at e r e p ort.  
1 0. 8.      
S af et y   A n al ys es  
S af et y  a n al ys es   will  b e  c o n d u ct e d  usi n g t h e  S af et y  P o p ul ati o n.   
1 0. 8. 1.      
Dr u g  E x p os ur e 
St u d y  dr u g  c o  m pli a n c e   will  b e  c al c ul at e d f or  e a c h  p ati e nt  b y  di vi di n g t h e t ot al  n u  m b er  of  c a ps ul es  t a k e n 
( n u  m b er  dis p e ns e d  –  n u  m b er r et ur n e d)  b y t h e t ot al  n u  m b er  pr es cri b e d.   D ur ati o n  of  s u bj e ct  o n   C  C  X 1 6 8 
will  b e  c al c ul at e d  as t h e ti  m e i nt er v al  (  w e e ks)  b et  w e e n  first  a n d l ast  d os e  of t h e  st u d y  dr u g  , i n cl usi v e. 
T h e t ot al  n u  m b er  of  c a ps ul es  pr es cri b e d is  c a l c ul at e d  as  6  c a ps ul es/ d a y  x  n u  m b er  of  d a ys i n t h e  d ur ati o n. 
T h e   %  c o  m pli a n c e  a n d  d ur ati o n  of  e x p os ur e   will  b e s u  m  m ari z e d   wit h  d es cri pti v e st atisti cs.  
1 0. 8. 2.      
A d v ers e  E v e nts   
A d v ers e  e v e nts   will  b e  c o d e d  usi n g   M e d  D  R  A    a n d  dis pl a y e d i n t a bl es  usi n g M e d  D  R  A   S  O  C  a n d  P T.    
T r e at  m e nt  e  m er g e nt  a d v ers e  e v e nt ( T E  A E) will  b e  s u  m  m ari z e d  usi n g   a  s u bj e ct i n ci d e n c e t a bl e.  I n  t h e 
t a bl e,  t h e  n u  m b er  a n d  p er c e nt  (  %)  ar e  c al c ul at e d  b as e d  o n  t h e  n u  m b er  of  u ni q u e  s u bj e cts   wit hi n  e a c h 
c at e g or y ( e g,  P T).   A s u bj e ct r e p orti n g   m ulti pl e  e v e nts  of t h e s a  m e  c at e g or y   will  b e  c o u nt e d  o nl y  o n c e f or 
t h e c at e g or y.  F or  s u  m  m ar y  p ur p os e,   A E  r el ati o ns hi p  t o  t h e  st u d y  dr u g   will  b e  gr o u p e d  i nt o  “ p ossi bl y  
r el at e d”  or  “ pr o b a bl y  n ot  r el at e d ”.  F or  s u bj e cts   wit h    m or e  t h a n  o n e  e v e nt  c o d e d  t o  t h e  s a  m e  P T,  t h e 
s u bj e cts   will  b e  c o u nt e d f or t h e  c at e g ori es   wit h t h e  str o n g est r el ati o ns hi p  a n d t h e  gr e at est  s e v erit y.  O n  -
tr e at  m e nt  T E  A Es  a n d  p ost-tr e at  m e nt  T E  A Es   will  b e s u  m  m ari z e d s e p ar at el y. 
A  n   A E  o v er vi e  w  t a bl e  s u  m  m ari zi n g t h e  n u  m b er (  %)  s u bj e cts   m e eti n g  e a c h  of t h e f oll o  wi n g  crit eri a   will 
b e  pr es e nt e d ,   w h er e  a p pr o pri at e.   
•      Tr e at  m e nt -e  m er g e nt   A E ( T E  A E)  
•      P ossi bl y r el at e d  T E  A E  
•      T E  A E l e a di n g t o st u d y  dr u g  dis c o nti n u ati o n 
•      C T  C  A E   Gr a d e  3 +  T E  A E   
•      Tr e at  m e nt -e  m er g e nt s eri o us   A E ( T E S  A E)  
•      R el at e d  T E S  A E   
•      T E  A Es   wit h  o ut c o  m e  of  d e at h 
A d diti o n all y, t h e f oll o  wi n g s u bj e ct i n ci d e n c e t a bl es   will  b e  pr es e nt e d.    


C h e  m o  C e ntr y x, I n c.   
 
St atisti c al   A n al ysis  Pl a n  
Pr ot o c ol   C L 0 0 5- 1 6 8  
 
3   O ct o b er  2 0 1 6  
 
C o nfi d e nti al   
2 0  
•      T E  A Es   b y  P T s ort e d  b y t h e  d e cr e asi n g  or d er  of s u bj e ct i n ci d e n c e  
•      T E  A Es  b y  S  O  C  a n d  P T s ort e d  b y t h e  al p h a b eti c  or d er  of t h e  S  O  C  a n d  P T  
•      T E  A Es  b y  S  O  C  a n d  P T,  gr o u p e d  b y r el ati o ns hi p t o  st u d y  dr u g (  p ossi bl y  r el at e d  or pr o b a bl y  n ot 
r el at e d)  
•      T E  A Es  b y  S  O  C  a n d  P T,  gr o u p e d  b y   C T  C A E   gr a d e   
D at a listi n gs   will  b e  pr o vi d e d f or  s u bj e cts   w h o  di e  d  o n  st u d y,  e x p eri e n c e d  S  A Es,  or  h a d   A E s l e a di n g t o 
st u d y  dr u g  dis c o nti n u ati o n. 
A s u bj e ct  d at a listi n g   will  b e  pr o vi d e d f or  all  a d v ers e  e v e nts. I n cl u d e d i n t h e listi n g  ar e t h e r e p or  t e d t er  m, 
P T,  S  O  C,  T E  A E fl a g, st u d y  d a y  a n d st u d y  p eri o d ( pr e -tr e at  m e nt,  o n-tr e at  m e nt,  a n d  p ost-tr e at  m e nt) w h e n 
A E st arts,  d ur ati o n, r el ati o ns hi p, s e v erit y,  a cti o n t a k e n,  o ut c o  m e,  a n d s eri o us n ess  c at e g or y. 
1 0. 8. 3.      
L a b or at or y   D at a  
All  l a b or at or y  r e p orti n g  u nits   will  b e  c o n v ert e d  t o  I nt er n ati o n al  S yst e  m  of   U nits   ( SI)  u nits  b ef or e  a n y 
c al c ul ati o ns.    T h e   a ct u al   v al u e   a n d   c h a n g e  fr o  m   b as eli n e  t o  s c h e d ul e d   p ost   b as eli n e   visit    will   b e 
s u  m  m ari z e d  f or  h e  m at ol o g y  a n d  c h e  mistr y.    A d diti o n all y,   s u bj e ct  i n ci d e n c es   of   s hift  fr o  m   b as eli n e 
cl assifi c ati o n  (  wit h r es p e ct t o t h e  n or  m al r a n g e) t o t h e  p ost-b as eli n e  cl assifi c ati o n  will  b e  pr es e nt e d  as  a 
s hift t a bl e.  T h e s u  m  m ar y  a n d s hift t a bl es   will  b e  pr es e nt e d f or  all  visits .  
All  l a b or at or y  d at a    will  b e    i n cl u d e d  i n  t h e  b y-s u bj e ct  a n d  visit   listi n gs.  Fl a gs  f or  l a b or at or y  v al u es 
o utsi d e  of  n or  m al li  mit ( L  a n d   H)   will  b e  a p pli e d i n t h e listi n gs.  
1 0. 8. 4.      
Vit al  Si g ns   
Vit al  si g ns  ( b o d y  t e  m p er at ur e,  h e art  r at e,  r es pir ati o n  r at e,  s yst oli c  bl o o d  pr ess ur e,  a n d  di ast oli c  bl  o o d 
pr ess ur e),  a n d  t h eir  c h a n g es  fr o  m  b as eli n e   will  b e  s u  m  m ari z e d  b y  visit.   A  s u bj e ct  d at a  listi n g   will  b e 
pr o vi d e d. 
1 0. 8. 5.      
P h ysi c al  e x a  mi n ati o n  
All  p h ysi c al  e x a  mi n ati o n fi n di n gs   will  b e  pr es e nt e d i n  a  d at a listi n g.   
1 0. 8. 6.      
C o n c o  mit a nt   M e di c ati o ns   
Pri or  or  c o n c o  mit a nt   m e di c ati o ns   will  b e  c o d e d  usi n g t h e  W  H  O  D  D   . S u bj e ct i n ci d e n c es  of t h e  pri or  a n d 
c o n c o  mit a nt   m e di c ati o ns   will  b e t a b ul at e d  b y   A n at o  mi c  T h er a p e uti c  C h e  mi c al  cl ass  ifi c ati o n (  A T  C3 )  a n d 
P T . 
T h e  us e  of  c o n c o  mit a nt   m e di c ati o ns   will  b e i n cl u d e d i n  a  b y- s u bj e ct d at a  listi n g. 
T h e t ot al  d ail y  d os e  of   R  A  A S  bl o c k ers  at  st art  of   C  C  X 1 6 8  d osi n g   will  b e  s u  m  m ari z e d  b y t h e  Pr ef err e d 
T er  m.  
 
1 1.      
C  H  A  N  G  E S   T  O  P  L  A  N  N  E  D   A  N  A  L  Y S  E S   
N o n e. 
1 2.      
R  E F  E  R  E  N  C  E S   
N o n e. 
 
 


C h e  m o  C e ntr y x, I n c.   
 
St atisti c al   A n al ysis  Pl a n  
Pr ot o c ol   C L 0 0 5- 1 6 8  
 
3   O ct o b er  2 0 1 6  
 
C o nfi d e nti al   
2 1  
A P P E  N  DI  X   A   
List  of  T a bl es ,  Listi n gs,  a n d  Fi g ur es 
 
N  U   M  B  E  R       TI  T  L  E   
P  O P  U  L  A  TI  O  N  
 
T a bl es  
1 4. 1. 1 . 1      
Dis p ositi o n    
MI T T    
1 4. 1. 1. 2      
Dis p ositi o n    
S af et y   
1 4. 1. 2. 1      
S u bj e ct   D e  m o gr a p hi c s  
MI T T    
1 4. 1. 2. 2      
S u bj e ct   D e  m o gr a p hi c s  
S af et y   
1 4. 1. 3       
B as eli n e I g  A   N e p hr o p at h y   D ur ati o n    
S af et y   
1 4. 1. 4. 1      
St u d y   Dr u g  E x p os ur e   
MI T T    
1 4. 1. 4. 2      
St u d y   Dr u g  E x p os ur e   
S af et y   
1 4. 1. 5      
Pri or   M e di c ati o ns  b y    W  H  O  D  D   A n at o  mi c  T h er a p e uti c   C h e  mi c al   Cl assifi c ati o n 
a n d  Pr ef err e d  T er  m   
S af et y   
1 4. 1. 6       
C o n c o  mit a nt   M e di c ati o ns  b y    W  H  O  D  D   A n at o  mi c  T h er a p e uti c   C h e  mi c al 
Cl assifi c ati o n  a n d  Pr ef err e d  T er  m    
S af et y   
1 4. 2. 1. 1       
C h a n g e fr o  m   B as eli n e i n   Sl o p e  of   Uri n ar y  Pr ot ei n t o   Cr e ati ni n e   R ati o ( P  C  R)       
MI T T    
1 4. 2. 1. 2       
C h a n g e fr o  m   B as eli n e i n   Sl o p e  of   Uri n ar y  Pr ot ei n t o   Cr e ati ni n e   R ati o ( P  C  R)       
P P   
1 4. 2. 2. 1       
S u bj e cts   A c hi e vi n g   R e n al   R es p o ns e  
MI T T    
1 4. 2. 2. 2       
S u bj e cts   A c hi e vi n g  R e n al   R es p o ns e   
P P   
1 4. 2. 3       
C h a n g e fr o  m   B as eli n e i n   Sl o p e  of   Uri n ar y   Al b u  mi n t o   Cr e ati ni n e   R ati o n 
(  A  C  R)  
MI T T    
1 4. 2. 4       
C h a n g e fr o  m   B as eli n e i n   Sl o p e  of   Uri n ar y  Esti  m at e d   Gl o  m er ul ar  Filtr ati o n 
R at e ( e  G F  R)   
MI T T    
1 4. 2. 5       
C h a n g e fr o  m   B as eli n e i n   Sl o p e  of   Uri n ar y   M  C P -1 t o   Cr e ati ni n e   R ati o       
MI T T    
1 4. 2. 6       
C h a n g e fr o  m   B as eli n e i n   Sl o p e  of   Uri n ar y  E pi d er  m al   Gr o  wt h  F a ct or ( E  G F) t o 
M  C P  -1   R ati o   
MI T T    
1 4. 2. 7      
C h a n g e fr o  m   B as eli n e i n   Sl o p e  of   Uri n ar y   Mi cr os c o pi c   R e d   Bl o o d   C ell (  R  B  C) 
C o u nts   
MI T T    
1 4. 2. 8      
P er c e nt   C h a n g e fr o  m   B as eli n e i n   Uri n ar y  Pr ot ei n t o   Cr e ati ni n e   R ati o  
MI T T    
1 4. 2. 9      
P er c e nt   C h a n g e fr o  m   B as eli n e i n   Uri n ar y   Al b u  mi n   Cr e ati ni n e   R ati o  
MI T T    
1 4. 2. 1 0      
P er c e nt   C h a n g e fr o  m   B as eli n e i n   Uri n ar y   R  B  C   C o u nt  
MI T T    
1 4. 2. 1 1       
C h a n g e fr o  m   B as eli n e i n  e  G F  R   
MI T T    
1 4. 2 . 1 2     
P er c e nt   C h a n g e fr o  m   B as eli n e i n   Uri n ar y   M  C P -1 t o   Cr e ati ni n e   R ati o  
MI T T   
1 4. 2 . 1 3     
P er c e nt   C h a n g e fr o  m   B as eli n e i n  S er u  m I g  A t o  Pl as  m a   C 3   R ati o  
MI T T   
1 4. 2 . 1 4     
P er c e nt   C h a n g e fr o  m   B as eli n e i n   Uri n ar y  E  G F t o   M  C P -1   R ati o  
MI T T   
1 4. 2 . 1 5     
S hift i n  Uri n ar y  P  C  R fr o  m   B as eli n e t o   Visit   
MI T T   
1 4. 2 . 16      
S hift i n   Uri n ar y   A  C  R fr o  m   B as eli n e t o   Visit  
MI T T   
1 4. 2 . 17      
S hift i n   Uri n ar y   R  B  C fr o  m   B a s eli n e t o   Visit  
MI T T   
1 4. 3. 1. 1 . 1     O v er all  S u  m  m ar y  of  Tr e at  m e nt  -E  m er g e nt   A d v ers e  E v e nts  
S af et y  
1 4. 3. 1. 1. 2      O v er all  S u  m  m ar y   of  Tr e at  m e nt -E  m er g e nt  a n d  P ost  Tr e at  m e nt   A d v ers e  E v e nts      S af et y  
1 4. 3. 1. 2. 1       Tr e at  m e nt -E  m er g e nt   A d v ers e  E v e nts  b y   M e d  D  R  A  Pr ef err e d  T er  m i n t h e   Or d er 
of   D e cr e asi n g  Fr e q u e n ci e s ( S af et y  P o p ul ati o n)  
S af et y  
1 4. 3. 1. 2. 2       Tr e at  m e nt -E  m er g e nt  a n d  P ost  Tr e at  m e nt  A d v ers e  E v e nts  b y    M e d  D  R  A 
Pr ef err e d  T er  m i n t h e   Or d er  of   D e cr e asi n g  Fr e q u e n ci e s ( S af et y  P o p ul ati o n)  
S af et y  
1 4. 3. 1. 3. 1       Tr e at  m e nt -E  m er g e nt   A d v ers e  E v e nts  b y   M e d  D  R  A  S yst e  m   Or g a n   Cl ass  a n d 
Pr ef err e d  T er  m i n t h e   Al p h a b eti c al   Or d er ( S af et y  P o p ul ati o n)  
S af et y  
1 4. 3. 1. 3. 2       Tr e at  m e nt -E  m er g e nt  a n d  P ost  Tr e at  m e nt   A d v ers e  E v e nts  b y    M e d  D  R  A  S yst e  m 
Or g a n   Cl ass  a n d  Pr ef err e d  T er  m i n t h e   Al p h a b eti c al   Or d er ( S af et y  P o p ul ati o n)   
S af et y  
1 4. 3. 1. 4. 1       Tr e at  m e nt -E  m er g e nt   A d v ers e  E v e nts  b y   M e d  D  R  A  S yst e  m   Or g a n   Cl ass  a n d 
Pr ef err e d  T er  m,   Gr o u p e d  b y   R el ati o ns hi p t o  St u d y   Dr u g   
S af et y  


C h e  m o  C e ntr y x, I n c.   
 
St atisti c al   A n al ysis  Pl a n  
Pr ot o c ol   C L 0 0 5- 1 6 8  
 
3   O ct o b er  2 0 1 6  
 
C o nfi d e nti al   
2 2  
1 4. 3. 1. 4. 2       Tr e at  m e nt -E  m er g e nt  a n d  P ost  Tr e at  m e nt   A d v ers e  E v e nts  b y    M e d  D  R  A  S yst e  m 
Or g a n   Cl ass  a n d  Pr ef err e d  T er  m,   Gr o u p e d  b y   R  el ati o ns hi p t o  St u d y   Dr u g   
S af et y  
1 4. 3. 1. 5. 1       Tr e at  m e nt -E  m er g e nt   A d v ers e  E v e nts  b y   M e d  D  R  A  S yst e  m   Or g a n   Cl ass  a n d 
Pr ef err e d  T er  m,   Gr o u p e d  b y t h e    W orst  S e v erit y   
S af et y  
1 4. 3. 1. 5. 2       Tr e at  m e nt -E  m er g e nt  a n d  P ost  Tr e at  m e nt   A d v ers e  E v e nts  b y    M e d  D  R  A  S yst e  m 
Or g a n   Cl ass  a n d  Pr ef err e d  T er  m,   Gr o u p e d  b y t h e    W orst  S e v erit y    
S af et y  
1 4. 3. 2. 1 a       S hift i n   H e  m at ol o g y  T est   R e s ults fr o  m   B as eli n e t o   D a y  8   
S af et y  
1 4. 3. 2. 1 b       S hift i n   H e  m at ol o g y  T est   R e s ults fr o  m   B as eli n e t o   D a y  1 5   
S af et y  
1 4. 3. 2. 1 c       S hift i n   H e  m at ol o g y  T est   R e s ults fr o  m   B as eli n e t o   D a y  2 9   
S af et y  
1 4. 3. 2. 1 d       S hift i n   H e  m at ol o g y  T est   R e s ults fr o  m   B as eli n e t o   D a y  4 3  
S af et y  
1 4. 3. 2. 1 e       S hift i n   H e  m at ol o g y  T est   R e s ults fr o  m   B as eli n e t o   D a y  5 7  
S af et y  
1 4. 3. 2. 1f       
S hift i n   H e  m at ol o g y  T est   R e s ults fr o  m   B as eli n e t o   D a y  8 5  
S af et y  
1 4. 3. 2. 1 g       S hift i n   H e  m at ol o g y  T est   R e s ults fr o  m   B as eli n e t o   D a y  1 1 3  
S af et y  
1 4. 3. 2. 1 h       S hift i n   H e  m at ol o g y  T est   R e s ults fr o  m   B as eli n e t o   D a y  1 4 1  
S af et y  
1 4. 3. 2. 1i       
S hift i n   H e  m at ol o g y  T est   R e s ults fr o  m   B as eli n e t o   D a y  1 6 9  
S af et y  
1 4. 3. 2. 2 a       S hift i n  S er u  m   C h e  mistr y  T est   R es ults fr o  m   B as eli n e t o   D a y  8   
S af et y  
1 4. 3. 2. 2 b       S hift i n  S er u  m   C h e  mistr y  T est   R es ults fr o  m   B as eli n e t o   D a y  1 5   
S af et y  
1 4. 3. 2. 2 c       S hift i n  S er u  m   C h e  mistr y  T est   R es ults fr o  m   B as eli n e t o   D a y  2 9   
S af et y  
1 4. 3. 2. 2 d       S hift i n  S er u  m   C h e  mistr y  T est   R es ults fr o  m   B as eli n e t o   D a y  4 3  
S af et y  
1 4. 3. 2. 2 e       S hift i n  S er u  m   C h e  mistr y  T est   R es ults fr o  m   B as eli n e t o   D a y  5 7  
S af et y  
1 4. 3. 2. 2f       
S hift i n  S er u  m   C h e  mistr y  T est   R es ults fr o  m   B as eli n e t o   D a y  8 5  
S af et y  
1 4. 3. 2. 2 g       S hift i n  S er u  m   C h e  mistr y  T est   R es ults fr o  m   B as eli n e t o   D a y  1 1 3  
S af et y  
1 4. 3. 2. 2 h       S hift i n  S er u  m   C h e  mistr y  T est   R es ults fr o  m   B as eli n e t o   D a y  1 4 1  
S af et y  
1 4. 3. 2. 2i       
S hift i n  S er u  m  C h e  mistr y  T est   R es ults fr o  m   B as eli n e t o   D a y  1 6 9   
S af et y  
1 4. 3. 2. 3 a       S hift i n   Uri n al ysis  T est   R es ults fr o  m   B as eli n e t o   D a y  8   
S af et y  
1 4. 3. 2. 3 b       S hift i n   Uri n al ysis  T est   R es ults fr o  m   B as eli n e t o   D a y  1 5   
S af et y  
1 4. 3. 2. 3 c       S hift i n   Uri n al ysis  T est   R es ults fr o  m   B as eli n e t o   D a y  2 9   
S af et y  
1 4. 3. 2. 3 d       S hift i n   Uri n al ysis  T est   R es ults fr o  m   B as eli n e t o   D a y  4 3  
S af et y  
1 4. 3. 2. 3 e       S hift i n   Uri n al ysis  T est   R es ults fr o  m   B as eli n e t o   D a y  5 7  
S af et y  
1 4. 3. 2. 3f       
S hift i n   Uri n al ysis  T est   R e s ults fr o  m   B as eli n e t o   D a y  8 5  
S af et y  
1 4. 3. 2. 3 g       S hift i n   Uri n al ysis  T est   R es ults fr o  m   B as eli n e t o   D a y  1 1 3  
S af et y  
1 4. 3. 2. 3 h       S hift i n   Uri n al ysis  T est   R es ults fr o  m   B as eli n e t o   D a y  1 4 1  
S af et y  
1 4. 3. 2. 3i       
S hift i n   Uri n al ysis  T est   R es ults fr o  m   B as eli n e t o   D a y  1 6 9  
S af et y  
1 4. 3. 2. 4 a       S hift i n   Uri n e   C h e  mistr y  T est   R es ults fr o  m   B as eli n e t o   D a y  8   
S af et y  
1 4. 3. 2. 4 b       S hift i n   Uri n e   C h e  mistr y  T est   R es ults fr o  m   B as eli n e t o   D a y  1 5   
S af et y  
1 4. 3. 2. 4 c       S hift i n   Uri n e   C h e  mistr y  T est   R es ults fr o  m   B as eli n e t o   D a y  2 9   
S af et y  
1 4. 3. 2. 4 d       S hift i n   Uri n e   C h e  mistr y  T est   R es ults fr o  m   B as eli n e t o   D a y  4 3  
S af et y  
1 4. 3. 2. 4 e       S hift i n   Uri n e   C h e  mistr y  T est   R es ults fr o  m   B as eli n e t o   D a y  5 7  
S af et y  
1 4. 3. 2. 4f       
S hift i n   Uri n e   C h e  mistr y  T est   R es ults fr o  m   B as eli n e t o   D a y  8 5  
S af et y  
1 4. 3. 2. 4 g       S hift i n   Uri n e   C h e  mistr y  T est   R es ults fr o  m   B as eli n e t o   D a y  1 1 3  
S af et y  
1 4. 3. 2. 4 h       S hift i n   Uri n e   C h e  mistr y  T est   R es ults fr o  m   B as eli n e t o   D a y  1 4 1  
S af et y  
1 4. 3. 2. 4i       
S hift i n   Uri n e   C h e  mistr y  T est   R es ults fr o  m   B as eli n e t o   D a y  1 6 9  
S af et y  
1 4. 3. 2. 5       
S u  m  m ar y  of   H e  m at ol o g y  T est   R es ults   
S af et y  
1 4. 3. 2. 6       
S u  m  m ar y  of  S er u  m   C h e  mistr y  T est   R es ults   
S af et y  
1 4. 3. 2. 7       
S u  m  m ar y  of   Uri n al ysis  T est   R es ults   
S af et y  
1 4. 3. 2. 8      
S u  m  m ar y  of   Uri n e   C h e  mistr y  T est   R es ults  
S af et y  
1 4. 3. 3       
S u  m  m ar y  of   Vit al  Si g ns  
S af et y  
 
Listi n gs  
1 6. 2. 1. 1      
S u bj e ct   Dis p ositi o n   
S af et y   
1 6. 2. 1. 2      
S u bj e ct   D e  m o gr a p hi c s  
S af et y   
1 6. 2. 1. 3      
S cr e e ni n g   R e n al   Bi o ps y  
S af et y  
1 6. 2. 1. 4      
M e di c al   Hist or y   
S af et y  


C h e  m o  C e ntr y x, I n c.   
 
St atisti c al   A n al ysis  Pl a n  
Pr ot o c ol   C L 0 0 5- 1 6 8  
 
3   O ct o b er  2 0 1 6  
 
C o nfi d e nti al   
2 3  
1 6. 2. 1. 5      
Pri or  a n d   C o n c o  mit a nt   M e di c ati o ns   
S af et y  
1 6. 2. 1. 6      
St u d y   Dr u g  E x p os ur e   
S af et y  
1 6. 2. 2. 1      
Uri n e   C h e  mistr y   
S af et y  
1 6. 2. 2. 2      
Sl o p e  of   Uri n ar y  Pr ot ei n:  Cr e ati ni n e   R ati o  
S af et y  
1 6. 2. 2. 3      
Effi c a c y  P ar a  m et ers  at   D a y  8 4   C o  m p ar e d t o   B as eli n e  
S af et y  
1 6. 2. 2. 4      
Sl o p e  of   Uri n ar y   Al b u  mi n:  Cr e ati ni n e   R ati o  
S af et y  
1 6. 2. 2. 5      
Sl o p e  of  e  G F  R  
S af et y  
1 6. 2. 2. 6      
Sl o p e  of   Uri n ar y   M  C P -1:  Cr e ati ni n e   R ati o  
S af et y  
1 6. 2. 2. 7      
Sl o p e  of   Uri n ar y  E  G F:  M  C P -1   R ati o  
S af et y  
1 6. 2. 2. 8      
Sl o p e  of   Uri n ar y   Mi cr os c o pi c   R  B  C   C o u nts  
S af et y  
1 6. 2. 3. 1      
All   A d v ers e  E v e nts   
S af et y  
1 6. 2. 3. 2. 1      L a b or at or y   R es ults:   H e  m at ol o g y  
S af et y  
1 6. 2. 3. 2. 2      L a b or at or y   R es ults:  S er u  m   C h e  mistr y  
S af et y  
1 6. 2. 3. 2. 3      L a b or at or y   R es ults:   Uri n al ysis  
S af et y  
1 6. 2. 3. 3      
Vit al  Si g ns   
S af et y  
1 6. 2. 3. 4      
P h ysi c al  E x a  mi n ati o ns  
S af et y  
 
 
 
Fi g ur es      
 
 
1. 1 a      
S p a g h etti  Pl ot  of  u P  C  R  o v er  Ti  m e  S u p eri  m p os e d   wit h   M e a n  u P  C  R  
MI T T   
1. 1 b      
S p a g h etti  Pl ot  of  u P  C  R  o v er  Ti  m e  S u p eri  m p os e d   wit h   M e a n  u P  C  R  
P P  
1. 2 a      
S p a g h etti  Pl ot  of  u P  C  R  o v er  Ti  m e  S u p eri  m p os e d   wit h   R e gr essi o n  Li n es      
MI T T   
1. 2 b      
S p a g h etti  Pl ot  of  u P  C  R  o v er  Ti  m e  S u p eri  m p os e d   wit h   R e gr essi o n  Li n es      
P P  
2. 1 a      
B ar   C h art  of  Sl o p es   D uri n g    W e e k   -8 t o  -5,  -4 t o  -1,  1 t o  4,  a n d  1 t o  1 2      
MI T T   
2. 1 b      
B ar   C h art  of  Sl o p es   D uri n g    W e e k   -8 t o  -5,  -4 t o  -1,  1 t o  4,  a n d  1 t o  1 2      
P P